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AIM AND OUTLINE OF THE THESIS 
Aim of the thesis 
This thesis was performed under the supervision of Professor Didier Betbeder, head of the 
laboratory of Nanomedicine. This laboratory is part of the group of Therapeutic Innovation 
Targeting Inflammation of the INSERM unit LIRIC-UMR 995 of the University of Lille, 
France.  
The work was a part of the project UniVacFlu, financed by the European Union Seventh 
Framework Programme FP7/2007/2013, part of the People Programme, Marie Skłodowska-
Curie Actions. This International Training Network focuses on the development of a mucosal 
universal Influenza vaccine.  
The UniVacFlu project is coordinated by Professor Nils Lycke from the University of 
Gothenburg. The aim of this project is to develop a universal influenza vaccine. UniVac Flu 
project used the adjuvanted and targeted the conserved antigen M2 as a construction: CTA1-
3M2e-DD. This antigen contains three parts: the non-toxic cholera toxin subunit A as the 
vaccine adjuvant, the extracellular portion M2e as the universal flu antigen, and the dimer of 
the D fragment of the staphylococcal protein A for targeting B cells. Therefore, to optimize the 
mucosal vaccine efficacy we combined CTA1-3M2e-DD with the nanoparticle technology. 
This vaccine was evaluated for the induction of protective immunity after intranasal 
administration and we addressed the protection from influenza virus transmission (the process 
by which influenza viruses spread between mice) with Pr. Peter Staeheli and co-workers, from 
the University of Freiburg.  
We also investigated the oral administration of the nanoparticle vaccine in collaboration with 
Maria Rescigno et al., form the European Institute of Oncology in Milan. The immune response 
of antigen loaded nanoparticle through intradermal vaccination was investigated by Linda 
Klavinskis and co-workers, from the University of King’s college London.  
In our laboratory, we compared different nanocarriers to find the best candidate for intranasal influenza 
vaccine. Overall, the aim of this thesis is the evaluation of different nanocarriers used as nasal 
delivery system to search a suitable vehicle for the nasal vaccine. 
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Outline of the thesis 
 
This thesis is organized in four principal chapters: 
The PART I is a general introduction about nanomedicine and influenza vaccine. This chapter 
is arranged in two main sections:  
- The first section focuses on nanomedicines and their applications. This section contains 
a review, which discusses different nanotechnology approaches to improve the efficacy 
of the mucosal vaccine.  
 
Publication 1: “Nanotechnology solutions for mucosal vaccine”. MQ. Le, R. 
Carpentier, D.   Betbeder (submitted). 
 
- In the second section, the main features of Influenza virus and vaccines are described. 
The PART II presents the results on the nanoparticles evaluation for nasal vaccine:  
- In the first part, we present an article to evaluate the best type of nanoparticles captured 
by mucosa cells in vivo and in vitro. 
 
Publication 2: “Residence time and uptake of porous and cationic maltodextrin-
based nanoparticles in the nasal mucosa: comparison with anionic and cationic 
nanoparticles.” MQ. Le, R. Carpentier, I. Lantier, C. Ducournau, I. Dimier-Poisson, 
D. Betbeder. International Journal of Pharmaceutics (accepted).  
 
- In the second part, the results about the evaluation of the 5 nanoparticles as nasal protein 
delivery system was reported. 
 
Publication 3: “Porous and cationic maltodextrin nanoparticles are more efficient 
vectors for protein delivery into nasal mucosal cells than cationic or anionic 
nanoparticles”. MQ. Le, R. Carpentier, I. Lantier, C. Ducournau, I. Dimier-Poisson, 
D. Betbeder. International Journal of Pharmaceutics (revision). 
 
- In the third part, we present the study about the inhibition of H3N2 influenza virus 
transmission using our intranasal influenza vaccine delivered by NP. 
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Publication 4: “Porous and cationic maltodextrin nanoparticles carrying CTA1-
DD adjuvant induce protection from virus infection and transmission”. MQ. Le, 
L. Ye, V. Bernasconi, R. Carpentier, NY. Lycke, P. Staeheli, D. Betbeder (submitted). 
 
The PART III is a general discussion concerning the obtained results and the application of the 
nanoparticles in vaccinology. 
The PART IV draws out the conclusion and the future perspectives of this work. 
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ABSTRACT  
 
Nasal administration has great advantage for stimulating the immune system, such as 
stimulating local and systemic protective immunity. However, delivery systems and adjuvants 
are often necessary to improve the efficacy of the intranasal vaccine. We applied nanoparticle 
technology to deliver a universal influenza vaccine via the nasal route in a European FP7 
project called UniVacFlu.  
We evaluated different nanoparticles to search the best nanocarrier for an intranasal vaccine. 
Here we compared 5 types of nanoparticles with different surface charges (anionic or cationic) 
and various inner compositions as potential vectors: cationic and anionic liposomes, cationic 
and anionic PLGA (Poly Lactic co-Glycolic Acid) nanoparticles and zwitterionic maltodextrin 
nanoparticles (cationic surface with an anionic lipid core: NPL). We first quantified their nasal 
residence time after nasal administration in mice using in vivo live imaging and NPL showed 
the longest residence time. In vitro endocytosis on mucosal cells (airway epithelial cells, 
macrophages and dendritic cells) using labeled nanoparticles were performed by flow 
cytometry and confocal microscopy. Among the 5 nanoparticles, NPL were taken up to the 
greatest extent by the 3 different cell lines and the endocytosis mechanisms of NPL were 
characterized. In order to compare different nanoparticles as vaccine carriers, antigen loading 
and cell delivery were evaluated. In this study, we compared the loading and delivery of 
labeling ovalbumin with airway mucosa cells (airway epithelial cells, macrophages and 
dendritic cells) by flow cytometry. Our data showed that NPL were the best candidate that can 
payload with highest amount of protein and eventually the most efficient cellular protein 
delivery capacity. Taken together, our study revealed that among 5 nanoparticles, NPL were 
the best nanocarrier that own longer nasal residence time, efficiently uptake and deliver protein 
into airway epithelium. NPL were then selected as nanocarrier for the UniVac Flu project. 
The flu antigens CTA1-3M2e-DD and HA were formulated with NPL. The CTA1-3M2e-DD 
is an adjuvanted antigen composed of the A1 subunit of cholera toxin and a conserved epitope 
of influenza A virus (M2e), as well as the dimer of the synthetic analogue of Staphylococcus 
aureus protein A (DD) used to target B cells. To improve antigenic effect, recombinant HA 
from H1N1 was combined with CTA1-3M2e-DD. These formulations were evaluated in mice 
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by the UniVacFlu consortium. We observed that CTA1-3M2e-DD and HA loaded into NPL 
could be a promising universal intranasal influenza vaccine. 
 
Keywords: nanoparticles, intranasal vaccine delivery, influenza, mucoadhesive 
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RÉSUMÉ  
  
  
L'administration nasale a un grand avantage pour stimuler l'immunité protectrice locale et 
systémique. Cependant, des systèmes d'administration et des adjuvants sont souvent 
nécessaires pour améliorer l'efficacité du vaccin intranasal. Nous avons appliqué la technologie 
des nanoparticules en tant que système universel de délivrance de vaccins contre la grippe dans 
le projet européen FP7 appelé UniVacFlu.  
Nous avons évalué différentes nanoparticules (NP) pour rechercher le meilleur nanovecteur. 
Pour cela, nous avons comparé 5 types de nanoparticules avec différentes charges de surface 
(anioniques ou cationiques) et diverses compositions internes comme vecteurs potentiels: des 
liposomes cationiques ou anioniques, des NP de PLGA cationique ou anionique (poly acide 
lactique co-glycolique) et une NP cationique composée de maltodextrine fonctionnalisée par 
un agent cationisant avec un cœur de lipides anioniques (NPL). Nous avons d'abord quantifié 
leur temps de résidence nasale après l'administration nasale chez la souris en utilisant l'imagerie 
in vivo et les NPL ont montré le plus long temps de résidence. L'endocytose in vitro sur des 
cellules muqueuses (cellules épithéliales des voies respiratoires, macrophages et cellules 
dendritiques) en utilisant des nanoparticules marquées a été réalisée par cytométrie de flux et 
microscopie confocale. Parmi les 5 nanoparticules, les NPL ont été majoritairement captées 
par 3 lignées cellulaires différentes représentatives d’un épithélium respiratoire et les 
mécanismes d'endocytose ont été caractérisés. Afin d’évaluer le meilleur vecteur  en tant que 
véhicules, le chargement d'antigènes et la délivrance intracellulaire ont été évalués dans des 
cellules de la muqueuse des voies respiratoires (cellules épithéliales des voies aériennes, 
macrophages et cellules dendritiques) par cytométrie de flux. Nous montrons que les NPL sont 
les meilleurs candidats capables de délivrer la plus grande quantité de protéines dans les 
cellules. Pris ensemble, notre étude a révélé que parmi 5 nanoparticules, la NPL était le meilleur 
nanovecteur en termes de temps de résidence nasale, d'endocytose par les cellules et de 
délivrance de protéines dans l'épithélium des voies respiratoires. Les NPL ont donc été 
sélectionnées comme nanovecteurs pour le projet UniVac Flu.  
Les antigènes de la grippe CTA1-3M2e-DD et HA ont été formulés avec les NPL. Le CTA1-
3M2e-DD est un antigène chimérique adjuvanté et ciblé. Il est composé de la sous-unité A1 de 
la toxine du choléra et un épitope conservé du virus grippal A (M2e), ainsi que le dimère de 
l'analogue synthétique de la protéine A de Staphylococcus aureus (DD) utilisé comme agent 
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de ciblage des lyphocytes B. Pour améliorer l'effet antigénique, l’HA recombinant de H1N1 a 
été combinée avec CTA1-3M2e-DD. Ces formulations ont été évaluées chez la souris par le 
consortium UniVacFlu. Les résultats ont montré que CTA1-3M2e-DD et HA chargé dans les 
NPL formeraient un vaccin intranasal prometteur contre la grippe.  
Ce travail de thèse montre que les NPL sont des nanovecteurs d’intérêt pour le vaccin nasal.  
  
Mots - clés : nanoparticules, délivrance, administration intranasale, vaccin, grippe 
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RÉSUMÉ DE LA THÈSE 
  
Préambule  
Ce travail a été réalisé sous la direction du Professeur Betbeder au sein de l'équipe 
Nanomédecine de l'unité Inserm LIRIC-U995 de l'Université de Lille. Nous avons évalué 
différentes nanoparticules comme un système d'apport de protéines dans la muqueuse nasale. 
Ces études sont importantes pour développer un nouveau système de délivrance nano-
technologique pour une application dans le domaine du vaccin, et plus particulièrement pour 
le développement d'un vaccin universel contre la grippe administré par les voies muqueuses. 
Ce travail fait partie d'un consortium européen appelé UniVacFlu. Le projet UniVacFlu a été 
financé par le septième programme-cadre de l'Union européenne FP7 / 2007/2013. Le 
consortium UniVacFlu est coordonné par le professeur Lycke de l'Université de Göteborg et 
est composé de plusieurs partenaires: l’Université de Gand, l’Université de Fribourg, l’Institut 
européen d'oncologie de Milan et le Kings College de Londres. Notre rôle au sein du 
consortium UniVacFlu est (i) de comparer différentes nanoparticules pour définir le meilleur 
nanovecteur pour un vaccin nasal contre la grippe, (ii) de préparer et de caractériser les 
formulations vaccinales (nanoparticules et antigènes), et (iii) de fournir des formulations à nos 
partenaires.  
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 Introduction  
  
  
La vaccination est l'un des moyens les plus efficaces pour contrôler les maladies infectieuses 
telles que la grippe. Actuellement, il existe deux formulations du vaccin antigrippal: le vaccin 
antigrippal inactivé et le vaccin antigrippal vivant atténué. Le plus grand défi pour le vaccin 
antigrippal est la variabilité élevée et l'évolution rapide du virus qui résulte d'une adaptation 
constante du vaccin pour correspondre aux souches circulantes. Un autre obstacle pour un 
vaccin efficace est le délai nécessaire pour la fabrication du vaccin et l’approbation par les 
autorités réglementaires. En outre, les groupes à haut risque, tels que les personnes âgées ou 
les personnes immunodéprimées peuvent ne pas répondre de manière optimale à la vaccination 
en raison d’une fonction immunitaire diminuée. Les limites mentionnées mettent en évidence 
la nécessité de technologies innovantes et un système de délivrance d’antigènes, servant de 
plateforme vaccinale, pourrait améliorer la production et la disponibilité des vaccines, tout en 
induisant de manière durable une immunité protectrice. Différentes voies d’administration et 
différentes stratégies de vaccination pourraient améliorer la réponse immunitaire des vaccins 
traditionnels. En outre, les vaccins ciblant des régions conservés, universelles, du virus 
entraînent une immunité plus large et plus durable. Ces vaccinations «universelles» sont donc 
vivement souhaitables (Kunisaki and Janoff 2009).  
Le projet UniVacFlu a pour but le développement d’un vaccin intranasal universel contre la 
grippe basé sur l'épitope grippal conservé M2e. En outre, pour vaincre la potentielle faible 
immunogénicité de l’antigène M2e, un adjuvant innovant (CTA1-DD), a été fusionnée à 3 
répétitions M2e en tandem, pour donner la protéine de fusion antigénique adjuvantée : CTA1-
3M2e-DD. CTA1 correspond à la toxine cholérique détoxifiée. CTA1 est lié à la région C-
terminale d'un dimère du fragment D de la protéine A de Staphylococcus aureus (DD). DD lie 
les fragments Fc et Fab des immunoglobulines présentes sur les cellules B permettant ainsi la 
liaison du complexe CTA1-DD aux cellules (Lycke 2004a). En outre, afin de créer une réponse 
antigénique plus large, CTA1-3M2e-DD a été associée avec l’HA recombinant de H1N1.  
Les nanoparticules (NP) sont des transporteurs conçus pour prolonger le temps de résidence 
intranasale des antigènes et les protéger contre la dégradation. Selon cette idée, le vaccin 
universel contre la grippe sera une combinaison nanotechnologique de NP, de CTA1-3M2e-
DD et d’HA administrée par voie nasale. Différents nanovecteurs ont été étudiés dans notre 
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laboratoire pour sélectionner le système approprié pour le développement de la grippe 
intranasale.  
De nombreuses études récentes ont montré que les nanoparticules améliorent significativement 
l'administration de candidats vaccins dans la muqueuse nasale  (Bernocchi, Carpentier, and 
Betbeder 2017). Cependant, une meilleure compréhension de l'interaction des nanoparticules 
avec les cellules muqueuses sont essentielles pour l'administration de médicaments ainsi que 
pour les applications vaccinales.  
Par conséquent, étudier comment les caractéristiques physicochimiques des nanomatériaux 
influencent leurs interactions avec les cellules sont essentielles pour obtenir des applications 
cliniques efficaces. Les interactions des NP avec les cellules dépendent du matériau, de la taille, 
de la forme (Blanco, Shen, and Ferrari 2015), de la charge de surface et de la chimie de surface 
des NP. Par ailleurs, la physiologie cellulaire (état de différenciation, taux de prolifération, 
morphologie ...) et le type cellulaire, ainsi que leurs interactions avec milieux physiologiques 
(sels, protéines, agglomérats ...), influencent aussi les mécanismes d’interaction des 
nanoparticules avec des cellules. En outre, les NP sont utilisées comme système de délivrance 
pour le vaccin nasal, pour améliorer la délivrance de l'antigène aux cellules immunitaires tout 
en limitant la clairance muqueuse. D'autres avantages comprennent leur capacité à protéger des 
antigènes contre la dégradation enzymatique et le transport à travers la barrière muqueuse. 
Cependant, alors que de nombreux systèmes de délivrance nanoparticulaires sont décrits, 
aucune comparaison objective, dans des conditions équivalentes de dose, de modèle… n'a été 
faite; il est donc difficile de déterminer le vecteur idéal.  
Dans cette étude de thèse, nous avons étudié l'effet de la composition et de la charge de surface 
des nanoparticules sur leurs interactions avec les cellules de la muqueuse nasale, en comparant 
des liposomes anioniques et cationiques, des nanoparticules anioniques et cationiques d'acide 
co-glycolique poly-lactique (PLGA NP) et les NPL zwitterionique (nanoparticules poreuses à 
base de maltodextrine avec un cœur composé lipide anionique). Dans cette étude, nous avons 
déterminé l'influence de la charge et de la composition interne de ces 5 types de nanoparticules 
sur le temps de résidence nasale in vivo et leur absorption in vitro par les cellules de la 
muqueuse respiratoire. Dans cette comparaison, différentes propriétés telles que le chargement 
d'antigènes et la délivrance intracellulaire doivent être évaluées dans des cellules épithéliales 
des voies respiratoires, macrophages et cellules dendritiques.  
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BUT DE LA THESE 
  
Afin de sélectionner le nanovecteur approprié pour délivrer le vaccin intranasal contre la 
grippe, nous avons comparé différentes nanoparticules utilisées pour l'application de vaccins. 
Ces nanoparticules ont été synthétisées et comparées en termes d'interaction avec la muqueuse 
nasale in vivo et in vitro et d'efficacité de chargement et de délivrance d’antigènes dans les  
cellules.  
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Résultats et discussion  
  
De nombreuses études ont montré les avantages de l'utilisation des nanoparticules en tant que 
système de délivrance intranasal de vaccin : capacité à protéger les antigènes contre la 
dégradation enzymatique, amélioration de la délivrance intracellulaire, extension du temps de 
résidence dans la cavité nasale. Cependant, une meilleure compréhension de l'interaction des 
nanoparticules avec les cellules muqueuses est essentielle pour l'administration de 
médicaments ainsi que pour les applications de vaccins.  
Nous avons étudié l'effet de la charge de surface et de la composition des nanoparticules sur 
leurs interactions avec les cellules de la muqueuse nasale sur  5 types de nanoparticules 
cationiques et anioniques. L’étude du temps de résidence nasale in vivo de ces 5 types de 
nanoparticules a montré que les PLGA NP et les NPL ont le temps de résidence le plus long. 
Ceci est en accord avec les expériences précédentes qui ont décrit une interaction plus forte 
entre les composés cationiques et la muqueuse des voies aériennes que les composés anioniques 
ou neutres (Marasini, Skwarczynski, and Toth 2017). En effet, l’augmentation du temps de 
résidence peut être attribuée aux fortes interactions électrostatiques entre les nanoparticules 
cationiques et les fractions sialiques et les acides anioniques des glycosaminoglycanes portés 
par les mucines à la surface des cellules des voies respiratoires. De façon inattendue, les 
liposomes cationiques ont montré un comportement complètement différent, même s'ils 
possédaient une charge positive de surface similaire aux PLGA NP cationiques et aux NPL.  
Dans cette étude, les NPL montrent le temps de résidence nasale le plus long et en quantité plus 
importante comparé aux 4 autres nanoparticules. Ceci pourrait être dû à la présence de lipides 
anioniques dans le noyau de ces nanoparticules (Paillard et al. 2010). Dans une autre étude, 
nous avons constaté que les NPL augmentaient le temps de résidence nasale d'une protéine 
encapsulée et que ces NPL ont été observées dans la première couche de la muqueuse nasale 
après administration nasale (Bernocchi et al. 2016). Selon cette conclusion, nous avions émis 
l'hypothèse que NPL pourraient être plus efficacement absorbées par les cellules sous-jacentes 
à la couche de mucus. Afin de confirmer cela, nous avons étudié l’endocytose cellulaire des 5 
types de nanoparticules dans des lignées cellulaires représentatives de la muqueuse des voies 
respiratoires (Kiyono and Fukuyama 2004) par cytométrie en flux et microscopie confocale. 
Fait intéressant, alors que les NPL ont montré une endocytose initiale rapide (dans les 2 
premières heures), les autres types de nanoparticules étaient progressivement captées pendant 
24h. Comme prévu, les nanoparticules anioniques étaient endocytosées dans une moindre 
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mesure par rapport aux cationiques (Le Broc-Ryckewaert et al. 2013). Ces résultats étaient 
confirmés dans les 3 lignées cellulaires en utilisant une autre sonde fluorescente: Rhodamine 
DHPE (Dihexadécanoyl-sn- glycéro-3-phosphoéthanolamine). L’efficacité relativement faible 
de l'endocytose des liposomes par rapport aux PLGA NP et aux NPL pourrait être attribuable 
à leur stabilité in vitro et in vivo. Cependant, nous avons confirmé leur stabilité colloïdale.  
Comprendre les mécanismes d'endocytose des nanoparticules est donc vital pour développer 
des applications thérapeutiques efficaces. En pratique, les voies d'endocytose des 5 
nanoparticules pourraient être médiées par des mécanismes non-phagocytaires, la taille de 
toutes les nanoparticules est inférieure à 1µm.  En raison de l'endocytose relativement faible 
des liposomes et PLGA NP par rapport aux NPL, nous avons concentré notre étude sur 
mécanismes d'endocytose de ces NPL. Nous avons observé un profil similaire pour toutes les 
lignées cellulaires: l’inhibition des voies dépendantes des clathrines, des cavéolines et de la 
micropinocytose a diminué l’endocytose des NPL. La dynamine est impliquée dans de 
nombreuses voies d'endocytose, y compris les voies dépendantes des clathrines et des 
cavéolines, et favorise la scission de vésicules d'endocytose intracellulaires (Sahay, Alakhova, 
and Kabanov 2010). L'inhibition des mécanismes dépendants de la dynamine a confirmé que 
les clathrines et les cavéolines étaient impliquées dans l'endocytose des NPL. Nos résultats 
suggèrent que l'endocytose des NPL était une combinaison de plusieurs voies. Dans une étude 
la voie de la clathrine s'est révélée être la principale voie d'absorption cellulaire des 
nanoparticules de chitosan dans les cellules Caco-2 (Ma and Lim 2003). D'autres expériences 
ont suggéré que la voie de la clathrine et la macropinocytose étaient impliquées dans 
l'absorption de nanoparticuoles de  cholestéryl-pullulane (CHP) (Jiang et al. 2013). Nous avons 
constaté que les NPL entraient dans les cellules épithéliales, les macrophages et les cellules 
dendritiques via une combinaison de plusieurs voies. Ce comportement pourrait être due à la 
composition et la structure poreuse de ces nanoparticules, ce qui permet aux NPL d’exposer à 
la fois les charges cationiques (polysaccharides) et anioniques (lipides), permettant ainsi de 
fortes interactions avec les composants de la membrane cellulaire.  
L’étude du temps de résidence nasale et de l'endocytose de 5 NP a montré que les NPL étaient 
le meilleur candidat pour délivrer des antigènes dans les cellules épithéliales des voies 
respiratoires en raison de son long temps de résidence et de ses capacités d’endocytose. Selon 
ces résultats prometteurs, nous avons continué à comparer ces 5 nanoparticules différentes en 
termes de capacité d’association et de délivrance intracellulaire de protéines. Le but de cette 
étude est de déterminer le meilleur système de délivrance pour les vaccins administrés par voie 
nasale.  
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En conséquence, nous avons comparé l'efficacité de la charge protéique des 5 types de NP. 
Seul le NPL a montré 100% de charge en protéines à des rapports massiques de 1/10 et 3/10 
(OVA / NP). Les PLGA NP et les liposomes n'ont pas atteint ce niveau de chargement de 
protéines, comme attendu (Colletier et al. 2002). Ceci est probablement dû à la structure des 
nanoparticules: les NPL sont poreuses et la surface d'interaction avec les protéines est plus 
grande que les nanoparticules non poreuses comme le PLGA NP et les liposomes où les 
interactions protéiques sont limitées à la surface des nanoparticules. Avec les liposomes, nous 
avons observé une augmentation de la taille et une diminution du potentiel zêta qui s'approchait 
du potentiel zêta de la protéine libre, démontrant clairement une association de l'OVA avec ces 
NP à leur surface. Cette association a atteint la saturation puisque l'augmentation du rapport 
OVA / NP a conduit à une diminution de l'efficacité d’association. Pour augmenter la charge 
protéique, l'OVA aurait pu être piégé dans les liposomes comme décrit précédemment mais 
l'efficacité de chargement reste faible (Watson, Endsley, and Huang 2012) et les efforts pour 
augmenter l'efficacité de la charge protéique conduisent à une hétérogénéité de taille 
incompatible avec les applications pharmaceutiques (Xu, Khan, and Burgess 2011). Avec les 
PLGA NP, nous n'avons pas observé de grandes modifications de la taille et du potentiel zêta 
lorsqu'ils sont associés à des protéines. Cependant, les nanoparticules de PLGA sont des 
particules sphériques (Sanna et al. 2012) et il est probable que les protéines interagissent 
uniquement avec la surface des nanoparticules. De plus, l'insertion d'une protéine au cours de 
la synthèse de PLGA NP pourrait dénaturer sa forme native (van de Weert, Hennink, and 
Jiskoot 2000) et donc son immunogénicité ou sa fonction. Par conséquent, la méthode de post-
chargement est le processus préféré pour associer des protéines aux PLGA NP.  
Nous avons ensuite évalué la délivrance de protéines dans 3 lignées cellulaires représentatives 
du tissu muqueux des voies respiratoires: les cellules épithéliales, les cellules dendritiques et 
les macrophages. Pour garder la cohérence, la même quantité de nanovecteurs a été utilisée 
tout au long de la comparaison. Dans ces lignées cellulaires, les 5 types de nanoparticules ont 
délivré la protéine OVA. Cependant, le NPL étaient beaucoup plus efficaces à cet égard que 
les 4 autres types de nanoparticules testés. La différence est apparue dans les 30 premières 
minutes pour les cellules épithéliales et dendritiques et après seulement 2h dans les 
macrophages. Cela implique que l'utilisation de NPL pour la délivrance de protéines ne 
nécessitera pas un temps d'exposition trop long du nanovecteur avec des cellules ou des tissus. 
(Bernocchi et al. 2016). 
La cinétique de la délivrance protéique par les 5 types de nanoparticules a varié entre les types 
cellulaires, et notamment les macrophages. Dans ces cellules, on ne peut pas exclure que la 
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phagocytose et la pinocytose non-spécifiques se produisent en combinaison avec l'endocytose, 
conduisant à une libération constante et non saturée de la protéine sur 24 heures. Ceci est 
soutenu par la délivrance de protéines par les PLGA et les liposomes qui étaient très similaires 
à l'endocytose de la protéine seule (augmentation de 1,5 fois).  
A notre connaissance, il s'agit de la première étude qui compare plusieurs types de nanocarriers 
actuellement pour la délivrance de protéines dans les voies respiratoires. Nous avons 
précédemment montré que l'administration intranasale d'un extrait total de Toxoplasma.gondii 
chargé dans NPL a fourni une protection contre un challenge oral de ce parasite (Dimier-
Poisson et al. 2015) et que NPL augmentent également le temps de résidence nasal de protéines 
(Bernocchi et al. 2016). Ces données soulignent le potentiel de NPL en tant que nanovecteur 
pour la délivrance de vaccins administrés par voie nasale.  
Nous avons décidé d'utiliser les NPL comme nanosystème de libération d’un vaccin intranasal 
contre la grippe. Les antigènes de la grippe CTA1-3M2e-DD et HA ont été formulés avec NPL. 
La construction de l'antigène CTA1-3M2e-DD a été préparée par l’association de l'adjuvant 
muqueux CTA1-DD et du domaine M2e, un épitope conservé de la grippe. La protéine de 
fusion CTA1-3M2e-DD combine donc un adjuvant et un antigène conservé de grippe A pour 
générer un vaccin anti-grippal universel.  
Différents antigènes(Ag) de la grippe ont été combinés aux NPL pour préparer la formulation 
à des rapports de 1/5 (m/m). Le CTA1-3M2e-DD, l’hémagglutinine (HA) ou l’adjuvant CTA1-
DD ont été chargés dans ces NPL. L'analyse des formulations 1/5(m/m) a montré une 
augmentation de la taille des formulations, ce qui signifie que certaines formulations NPL-Ag 
ont été partiellement agglomérées.  
Lorsque l'antigène a été incubé aux NPL, nous avons obtenu seulement une légère diminution 
de la charge positive des nanoparticules montrant que CTA1-3M2e-DD a été chargé avec 
succès dans la NPL. Un résultat similaire a été obtenu avec le chargement de deux antigènes 
différents dans les NPL.  
Afin d'évaluer si un antigène était libre, nous avons analysé la formulation par électrophorèse 
en gel de polyacrylamide en conditions non- dénaturantes (PAGE natif). Au rapport 1/5, les 
protéines CTA1-3M2e-DD et CTA1-DD étaient totalement liées au NPL alors que seulement 
70% de l’HA était associé. Ces résultats peuvent être attribués à l'utilisation de détergents 
utilisés pour solubiliser l’HA. Cela peut former des micelles qui empêchent l'association d’HA 
aux NPL. Cependant, la plus grande partie de l'HA est liée aux NPL et ces résultats suggèrent 
qu’à un rapport de 1/5 (m/m), 3 antigènes différents ont été associés avec succès aux NPL. Ces 
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formulations ont été testées par nos partenaires du consortium UniVacFlu pour une analyse in 
vivo d’une vaccination intranasale contre le virus de la grippe.  
Après immunisations intranasales de souris avec CTA1-3M2e-DD ou CTA1-3M2e-DD / NPL, 
les souris immunisées avec CTA1-3M2e-DD / NPL démontraient l'efficacité protectrice de 
cette formulation contre la souche peu virulente X47 du virus de la grippe (H3N2), comparées 
aux souris ayant CTA1-3M2e-DD. De plus, les souris immunisées par voie intranasale avec le 
HA + CTA1-M2e-DD / NPL ont été entièrement protégées contre une infection provoquée par 
le virus agressif PR8 (A / Puerto Rico / 8/34 (H1N1), alors que la formulation HA / NPL, 
CTA1-M2e-DD / NPL ou CTA1-M2e-DD seule n’a pas protégé les souris. Dans ce projet, 
nous avons montré que la co-intégration de deux antigènes cibles spécifiques de la grippe, le 
CTA1-3M2e-DD et l’HA dans les NPL était plus efficace contre les infections par le virus de 
la grippe que l'un ou l'autre des composants utilisés seuls, le vecteur combiné HA + CTA1-
3M2e-DD / NPL présente une immunogénicité améliorée et une meilleure protection virale 
après immunisations intranasales.  
Ensuite, nous avons appliqué ces NPL comme nanosystème de délivrance d’antigène pour 
développer un vaccin intranasal contre le virus de la grippe Udorn (H3N2). Dans cette étude, 
nous avons évalué l'immunogénicité, l'efficacité protectrice et la transmission du virus en 
utilisant des formulations vaccinales composées de Udorn split virus seul ou en mélange avec 
les nanoparticules NPL et / ou CTA1-DD et administrées par voie nasale.  
Les charges et l’hydrophobie des NPL facilitent les interactions électrostatiques avec les 
antigènes chargés négativement. De plus, leur structure poreuse permet aux NPL d'être 
chargées avec une grande quantité d'antigènes. Les antigènes provenant du virus Udorn 
inactivé et éclaté (split Udorn) et le CTA1-DD utilisé dans notre étude s’associent aux NPL 
comme le démontre nos PAGE natifs. Fait important, les NPL peuvent très efficacement 
délivrer split Udorn dans les 3 lignées cellulaires de la muqueuse nasale. L'amélioration de la 
délivrance des antigènes dans les cellules présentatrices d’antigènes font des NPL un système 
idéal de délivrance.  
L’étude in vivo a montré que l'administration intranasale de split Udorn / NPL augmente 
légèrement la réponse des anticorps IgG spécifiques d' Udorn par rapport aux souris ayant reçu 
Udorn seul. L'ajout du CTA1-DD améliore encore le niveau d' IgG spécifiques produits.  
Dans le cas d'infection par des virus respiratoires tels que la grippe, une attention particulière 
devrait être accordée au nez et aux poumons en tant qu’organes de transmission et de points 
d'entrée de ces virus respiratoires (Kohlmeier and Woodland 2009). Dans cette étude, nous 
avons comparé nos vaccins antigrippaux en termes d'inhibition virale dans le museau et les 
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poumons des souris infectées. Corrélées à la sécrétion d'IgG spécifiques d' Udorn, les souris 
recevant split Udorn / NPL ont montré une diminution de la réplication du virus dans le museau 
et les poumons des souris, alors que celles vaccinées par Udorn n’étaient pas protégées contre 
l'infection virale. L'effet additionnel du CTA1-DD a été retrouvé. Nos données ont démontré 
que l'utilisation d'un adjuvant et d’un nanosystème d'administration (CTA1-DD + NPL) a un 
fort effet sur la clairance du virus dans le museau et les poumons des souris infectées. Alors 
que les souris immunisées avec split Udorn fragmenté ne pouvaient pas complètement inhiber 
la propagation (transmission) du virus, par contre les souris recevant split Udorn / NPL n’ont 
montré aucune transmission du virus. Il n'est pas surprenant d'observer que les souris vaccinées 
avec  split Udorn / CTA1-DD / NPL ont aussi complètement bloqué la transmission du virus 
Udorn. Ces résultats ont démontré que même si le nanovecteur peut améliorer l'efficacité du 
vaccin, il n'est pas suffisant pour induire une réponse immunitaire complètement protectrice.  
Il a été démontré qu’un vaccin antigrippal recombinant à base de nanoparticules et d’HA 
nécessitait un adjuvant à base de saponine afin d'induire des réponses protectrices contre les 
souches de la grippe A (H3N2) (Smith et al. 2017). De même, des liposomes modifiés au PEG 
contenant l'adjuvant CRX-601 et du méthylglycol chitosan amélioraient la réponse immunitaire 
sublinguale des souris vaccinées contre la grippe (Oberoi et al. 2016). Ces études ont démontré 
l'intérêt de la combinaison d'un nanosystème de delivrance, du choix des antigènes et d'un 
adjuvant pour améliorer l'efficacité d’un vaccin antigrippal.  
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Conclusion  
  
Les nanoparticules sont des outils prometteurs pour la vaccinantion intranasale grâce à leurs 
capacités de la délivrance de protéines dans la muqueuse, de stabilisation des protéines et 
d’augmentation du temps de contact (résidence) avec les épithéliums. Le développement d'un 
vaccin muqueux à base de nanoparticules a nécessité la présence de nanovecteurs capables 
d’associer des antigènes, de pénétrer dans les cellules et de les libérer dans les cellules. Parmi 
les 5 types de nanoparticules étudiés dans cette comparaison, nous démontrons que les NPL 
sont le meilleur candidat potentiel pour l'application du vaccin muqueux. De plus, des données 
in vivo ont montré que les NPL administrées par voie intranasale amélioraient l'efficacité du 
vaccin universel contre la grippe testé. Ce travail de thèse a démontré l'intérêt de l'utilisation 
de nanoparticules cationiques à base de maltodextrine et lipidées. 
La vaccination muqueuse présente des avantages significatifs par rapport à la vaccination 
parentérale, y compris l'absence d'aiguille, l'induction d'une immunité systémique et muqueuse 
et un faible coût. Malgré ces avantages, actuellement, seuls un vaccin nasal et huit vaccins 
oraux sont homologués pour une administration à l'homme, ciblant les cinq agents pathogènes 
suivants: la grippe, le poliovirus, le choléra, salmonella typhi et le rotavirus. De plus, la plupart 
des vaccins homologués pour l'administration par voie muqueuse sont à base de virus vivants 
atténués qui présentent le risque de retrouver leur pouvoir pathogène. Il n'y a toujours pas de 
vaccins muqueux (oral, intranasal…) contre de nombreuses autres maladies infectieuses telles 
que le paludisme, le VIH, la leishmaniose, l'hépatite B et C. Cette étude de thèse contribue à 
l’amélioration des nanosystèmes de délivrance pour le vaccin muqueux. Basés sur cette étude, 
d'autres vaccins muqueux à base de nanoparticules pourraient être développés à l' avenir.  
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1.$ Nanoparticle based drug delivery system 
The application of nanotechnology in drug delivery has gained increasing interest over the past 
few decades. Nanoparticles (NPs) are made of organic or inorganic materials to deliver drugs 
into the body for the treatment of various diseases. NPs such as polymeric micelles, quantum 
dots, liposomes, polymer-drug conjugates, dendrimers, biodegradable nanoparticles, silica, etc. 
are few examples of nanoparticulate materials undergoing preclinical development, or already 
used in clinic (Kabanov and Alakhov 2002; Duncan 2003; Farokhzad and Langer 2006; Davis, 
Chen, and Shin 2008; Peer et al. 2007; Tasciotti et al. 2008). These nanomaterials can deliver 
low molecular weight compounds, proteins and nucleotides to target disease cells or tumors to 
maximize clinical benefit while limiting untoward side effects. Such NPs are also expected to 
drastically improve drug delivery for treatment diseases. 
 
Figure 1: Representation of several types of nanoparticles used in biomedical applications 
Nanoparticles require site-specific cellular entry to deliver their cargo to subcellular position. 
NPs can employ multiple pathways for cellular entry. 
1.1. Endocytosis of nanoparticles 
Macromolecules and particles can be taken up by eukaryotic cells from the surrounding 
medium by an active process called endocytosis. Endocytosis involves multiple stages. First, 
the material is enclosed in an area of plasma membrane, which then buds off inside the cell to 
form a vesicle named as endosomes (or phagosomes in case of phagocytosis). Second, the 
endosomes deliver the cargo to various specialized cellular compartment, which enables 
sorting of materials towards different destinations. Finally, the cargo is delivered to 
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intracellular compartments, recycled to the extracellular milieu or delivered across cells (a 
process known as “transcytosis” in polarized cells). Depending on the cell type, as well as the 
proteins, lipids, and other molecules involved in the process, endocytosis can be classified into 
several types (Doherty and McMahon 2009; Kumari, Mg, and Mayor 2010). Five main 
different mechanisms of endocytosis are: phagocytosis, clathrin-mediated endocytosis (CME), 
caveolin-mediated endocytosis (CavE), clathrin/caveolae-independent endocytosis, and 
macropinocytosis. Some authors may consider the last four mechanisms subtypes as process 
of pinocytosis. Compared to phagocytosis, which takes place mainly in professional 
phagocytes, pinocytotic mechanisms are more common and occur in many cell types (Fig 2) 
(Salatin and Yari Khosroushahi 2017; Sahay, Alakhova, and Kabanov 2010). 
 
Figure 2: Schematic presentation of endocytosis mechanisms 
1.2. Parameters affecting endocytosis 
1.2.1. Surface chemistry of nanoparticle 
The very first requisite for an optimal surface chemistry is that the NPs stay dispersed in 
biological media. Proteins tend to bind to NPs surface (Lynch, Dawson, and Linse 2006). 
Proteins can form a corona that can quickly cover the entire NPs surface, even at low 
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concentrations (Lundqvist et al. 2011; Monopoli et al. 2011). An effective approach to limit 
protein fouling is to coat the surface with a polymer brush layer that generates repulsive steric 
forces (Leckband and Israelachvili 2001). The modification of NPs by non-ionic polymers 
helps to particle stability through steric stabilization and limits the direct interaction between 
cells and phagocytic system (Storm et al. 1995). Polyethylene glycol (PEG) is a neutral and 
hydrophilic material that can be grafted on the surface of particles leading to high blood 
circulation time due to low opsonization and escape from capture by the phagocytic system 
(Gref et al. 1995). PEGylated NPs are often referred as “stealth” nanoparticles (Vasir and 
Labhasetwar 2008). The modification of surface of NPs by PEG avoids the adsorption of 
proteins and recognition of them by macrophages. Therefore, these modified NPs can easily 
escape the blood stream and can accumulate in tumours  (Czeczuga 1975). In another study, 
bovine serum albumin (BSA) loaded inside porous cationic polysaccharide NPs or lipids inhibit 
the complement activation of these nanoparticles. This study demonstrated that protein binding 
in/on NP was able to generate stealth NPs and may represent an alternative to the use of PEG 
(Paillard et al. 2010). The modification of NPs with neutral polysaccharides is also another 
strategy to create stealthness as the polysaccharides can interact with particular receptors on 
the cell membrane and tissue surface thus caused active targeting (Lemarchand, Gref, and 
Couvreur 2004).  
Nanoparticle with targeting 
Nanoparticle’s targeting is normally achieved by decorating the particles with moieties that 
bind preferentially to specific receptors on cells surface. Nevertheless, this is strongly 
dependent on the identification of cellular/tissue-specific markers. Cellular specificity 
combined with endocytosis ensures that once the NPs reach their target, they are readily 
internalized. For this reason, as the receptor of transferrin (Tf) is highly present on cell surface, 
receptor mediated endocytosis of transferrin NP is widely used to deliver drugs within cells 
(Tanaka, Fujishima, and Kaneo 2001; Iinuma et al. 2002). For example, poly(lactic-co-glycolic 
acid) (PLGA) nanoparticles covered by Tf were shown to be selectively uptaken by tumors 
cells in vitro and in vivo (Chang et al. 2012). Furthermore, the coating of these NP by Tf highly 
increased their plasma retention in mice and rats.  At the cellular level, the increased uptake by 
F98 glioma cells of Tf-PLGA suggests interaction between Tf and the overexpressed Tf-
receptor at the surface of F98 cell plasma membranes. These studies open a new concept: Tf is 
used to cover NP in order to get stealth and targeted NP. Other receptors have been widely used 
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to improve endocytosis such as epidermal growth factor (EGF) receptors (Kirpotin et al. 2006; 
Zeng, Lee, and Allen 2006; Lee et al. 2007; Mi, Zhao, and Feng 2013), albumin receptors 
(Schmid et al. 2007; Kratz 2008), folate receptors (Pan et al. 2002; Zhang, Huey Lee, and Feng 
2007; Han et al. 2009), and low-density lipoprotein (LDL) receptors (Chnari et al. 2006).  
 
Figure 3: Schematic representation of surface modified liposomes. 
1.2.2. Size of the nanoparticle
Some entry mechanisms are very specific when it comes to acceptable cargo size, whereas 
others are less. For example, phagocytosis has been believed for quite some time to be 
associated uniquely with the uptake of large particles (>1 µm). However, there are several 
reports that show the phagocytosis of nanometer-sized particles such as viruses (Clement et al. 
2006; Ghigo et al. 2008), and polymer NPs (Lunov et al. 2011), as well as quantum dots 
(Fischer et al. 2010). Nevertheless, it is worth noting that this endocytic mechanism is strongly 
linked to protein opsonization, which can induce aggregation and hence a loss in size control. 
Similarly, macropinocytosis can be exploited for the uptake of large particles (up to 1 mm) 
(Swanson 2008). However, because macropinocytosis is a cargo-unspecific uptake mechanism, 
it can accommodate a range of cargo sizes and types of materials and often operates in 
conjunction with other entry mechanisms (Reynwar et al. 2007; Nam et al. 2009; Thurn et al. 
2011). Eukaryotic cells can use clathrin-mediated entry to internalize particles with sizes 
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ranging from 10 nm to 300 nm (Ehrlich et al. 2004). For caveolae mediated endocytosis formed 
caveosomes have diameters 50–80 nm with a neck 20–40 nm (Kurzchalia and Parton 1999; 
Pelkmans and Helenius 2002). Even though this would suggest a tight limit for cargo size 
(Wang et al. 2009). They observed that this route can facilitate the entry of NPs up to 100 nm 
in diameter. For clathrin-independent the uptake of particles is observed for NP larger than 100 
nm (Mayor and Pagano 2007).  
1.2.3. Effect of nanoparticle’s charge  
The modification of NPs with positively charged functional groups facilitates electrostatic 
interaction with negatively cell membrane (He et al. 2010; Lankoff et al. 2013). Hence, 
generally cationic NPs have higher uptake than negatively charged (Harush-Frenkel et al. 
2007). The internalization of NPs with negative charge surface decreases by increasing the 
surface charge, while an increase of uptake of cationic NPs is observed while increasing the 
charge density (He et al. 2009). The permeability of positively charged drug carriers to 
gastrointestinal mucous barrier is higher than neutral and negatively charged NPs because of 
the presence of negatively charged proteins in outer surface of gastrointestinal epithelial cells 
(El-Shabouri 2002). The cationic nature of chitosan-based NPs facilitates the electrostatic 
interaction with cell membrane and subsequently cellular internalization (Tahara et al. 2009; 
Duceppe and Tabrizian 2010; Amidi et al. 2010). However, in some cases, surface modified 
by negative charge can enhance the uptake of nanoparticles. By increasing the negative surface 
charge of carboxymethyl dextran-modified iron oxide NPs, these particles are highly taken via 
non- specific pathways (Ayala et al. 2013). Super paramagnetic iron oxide NPs coated with 
anionic silica have a cellular uptake 3-fold higher than cationic one (Prijic et al. 2010). Citrate 
groups grafted on NP giving a negative surface charge of NPs, increases the stability on NPs 
in serum-free culture medium and subsequently their cellular internalization (Kolosnjaj-Tabi 
et al. 2013).  
1.3. Examples of nanoparticle as drug delivery system in clinics 
Nanotechnology has provided the possibility of delivering drugs to specific cells using NPs 
(Ranganathan et al. 2012). Targeted drug delivery is intended to reduce the side effects of drugs 
with concomitant decrease in dose and treatment expenses (Tiwari et al. 2012). Nanoscale 
particles/molecules are developed to improve the bioavailability and pharmacokinetics of 
therapeutics. Currently, there are several commercialized drug products such as liposomes (and 
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virosomes), polymer NPs, protein–drug conjugates, antibodies or metal-based 
nanoformulations… 
Liposomes are used as drug carriers or drug-delivery systems based on their ability to 
encapsulate hydrophilic molecules in their aqueous inner space as well as hydrophobic 
molecules in their phospholipid bilayer membranes. There are many products in the market 
employing liposomes as drug delivery systems. Doxil®, a liposome formulation containing 
doxorobucin hydrochloride (DOX), is the first FDA-approved nano drug delivery system based 
on PEGylated liposome technology. DOX is located within the hydrophilic core of the 
liposomes in the form of DOX–sulphate complex (Veronese and Harris 2002). Sequus 
Pharmaceuticals, USA originally developed Doxil® in 1995 as an intravascular injection for 
the treatment of advanced ovarian cancer, multiple myeloma and HIV-associated Kaposi’s 
sarcoma. Ambisome® liposome contain Amphotericin B for injection is a sterile, non-
pyrogenic freeze-dried product for intravascular infusion. Ambisome® liposomes (100 nm) 
provides prolonged circulation in the plasma, along with in vivo stabilization. It is a product of 
Astellas Pharma USA approved in 1997. Ambisome® is approved for the treatment of serious, 
life-threatening fungal infections including leishmaniasis, aspergillosis, blastomycosis, 
coccidioidomycosis in febrile, neutropenic patients. Ambisome® is also prescribed for the 
treatment of invasive systemic infections caused by Aspergillus, Candida, or Cryptococcus in 
patients those cannot tolerate conventional Amphotericin B therapy (Bulbake et al. 2017). 
Polymer-based nanoformulations such as Genexol®, Paclitaxel in 20–50 nm micelles 
(Oerlemans et al. 2010) composed of block copolymer poly(ethylene glycol)- poly(D,L-
lactide). Genexol® are used for metastatic breast cancer treatment.  
Protein–drug conjugates such as Abraxane®, the NPs (130 nm) formed by albumin with 
conjugated paclitaxel (Saif 2013). Abraxane® is used for metastatic breast cancer, non-small-
cell lung cancer treatment. 
Metal-based nanoformulations such as Feraheme™ (Ferumoxytol), superparamagnetic iron 
oxide NPs coated with dextran with hydrodynamic diameter 50 nm. Feraheme™ are used for 
treatment of iron deficiency anemia in adults with chronic kidney disease (Weissig, Pettinger, 
and Murdock 2014). 
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1.4. Conclusion 
Currently, nanomedicine is undergoing of attention led by using NPs to deliver drugs to cells. 
Such NPs are engineered so that they target specifically diseased cells, improving efficacy, 
decreasing side effects, and overall improving human health. This technique reduces the side 
effects of drugs in the body. However, despite many advantages of nanomedicine, there are a 
number of potential drawbacks for using these nanodrug delivery vehicles. The disadvantages 
of NPs as drug delivery system are, for example: immunogenicity induction, poor site-specific 
accumulation, production cost… (Blanco, Shen, and Ferrari 2015). By successively addressing 
each of these barriers, nanoparticle based drug delivery system could revolutionize the way we 
treat disease of humans in the future. 
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REVIEW 
 
 
Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, 
gastrointestinal tract and reproductive tract. To fight these pathogens, scientists are developing 
vaccines that can create the efficient defense at mucosal surfaces. Vaccines can be delivered 
via mucosal role but they are quickly cleared away before it can provoke an immune response. 
To overcome that, many strategies have developed to protect the antigens and to target immune 
cells to generate a strong immune response in mucosal surfaces. Some current approaches for 
mucosal vaccine are presented in the review herein. 
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Abstract 
The vast majority of human pathogens infect at the mucosal surfaces. Preventing infection at 
these sites by mucosal vaccines is a promising approach for vaccine development. However, 
to date only a few vaccines have applied for mucosal use. It has also been difficult to induce a 
mucosal response consistently after the immunization of vaccine antigen by the mucosal route 
because of their rapid elimination by mucus turn over or inactivation by mucosal enzymes. 
Other potential limitations include lack of interaction of antigen with M cells and other mucosal 
cells that are responsible for antigen uptake or processing. It is necessary to investigate the 
specific immunization strategies to improve their efficacy. Application of nanotechnology to 
create mucoadhesive particle that can prolong mucosal residence time, target the mucosal 
immune system and incorporate mucosal adjuvants maximizing immune response is key 
strategy to improve the effectiveness of mucosal vaccines. This review summary new 
nanotechnology approaches to mucosal immunization have now been proposed to address these 
issues. 
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1. Introduction 
Due to the vast surface area, the mucosal surfaces of the gastrointestinal tract, urogenital, 
respiratory tracts and the ocular cavities are major routes of entry into the body for the 
pathogens [1, 2]. The majority of current vaccination methods target the systemic immune 
system and elicit only a weak or no mucosal immune response [3, 4]. In contrast, mucosal 
immunization with an appropriate vaccine delivery vehicle induces both protective mucosal 
and systemic immune responses, leading to a dual layer of protection against pathogens [5]. In 
addition, compared to parenteral routes, mucosal vaccine offers advantages such as ease of 
administration, decreased costs, avoidance of needle-stick injuries and reduced risk of 
transmission of blood-borne diseases. Moreover, this needle- and syringe-free delivery helps 
to reduce medical waste [6]. Therefore, mucosal vaccines are highly desirable. 
Despite these numerous advantages, the development of mucosal vaccines has been slow. Only 
a handful of mucosal vaccines have been approved for clinical use in humans, the best-known 
example being the Sabin polio vaccine, which is given orally and absorbed in the digestive 
tract [6]. Others include oral vaccines against Salmonella typhi, Vibrio cholera, and rotavirus 
and a nasal vaccine against influenza virus [7-9]. Challenges for mucosal immunization are: 
dilution of mucosal vaccine in the mucosal fluids, proteolytic degradation and fast mucosal 
clearance that might limit effective capture by the mucosal immune system [7].  
Different strategies can improve mucosal vaccines such as the use of an efficient antigen 
delivery system associated or not to an adjuvant. Nano-delivery system may protect antigen 
from degradation, overcome the mucus barrier and potentially target the mucosal inductive 
sites. These nanocarriers can further be functionalized with targeting moieties to deliver the 
vaccine to microfold cells (M-cells) or antigen presenting cells (APCs). We will focus this 
review on the interest of using different nanocarriers to improve the efficacy of vaccines.  
2. Mucosal immune system 
Mucosal immune responses that occur at mucosal membranes of the intestines, the urogenital 
tract and the respiratory system, i.e., surfaces that are in contact with the external environment. 
The mucosal immune system can be divided into two general compartments known as 
inductive and effector sites. Inductive sites are areas where antigen sampling leads to initial 
activation of immune cells, while at effector sites, T and B cells are activated (Figure 1) [10]. 
The main inductive sites consist of specific lymphoid tissues, known as mucosa-associated 
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lymphoid tissue (MALT) as well as their surrounding regional lymph nodes [10, 11]. The 
MALT contains T-cell zones, B cell-enriched areas containing a high frequency of surface IgA-
positive (sIgA+) B cells and a subepithelial area with APCs for the initiation of specific 
immune responses. The MALT is covered by a follicle-associated epithelium (FAE) that 
consists of M-cells, columnar epithelial cells which play a central role in the initiation of 
mucosal immune responses. These cells are specialized in the transport of 
antigens/microorganisms from the lumen to underlying dendritic cells (DCs) located in the 
subepithelial dome region (SED) [12, 13]. DCs present antigens to CD4+ T cells in the 
interfollicular regions (IFRs). Activated CD4+ T cells can subsequently support class-switch 
recombination and somatichypermutation in naïve B cells in the germinal center, resulting in 
the generation of IgA-expressing B cells or IgA+ B cells. Retinoic acid plays a key role 
allowing IgA+ B cells to traffic to mucosal effector sites. At these sites, IgA+ B cells mature 
into IgA producing plasma cells [14]. In addition to T-cell dependent IgA responses, T-cell 
independent IgA class switching can also take place by a direct action of DCs on B cells [15]. 
Finally, upon binding to the polymeric immunoglobulin receptor (pIgR) expressed on epithelial 
cells, IgA is translocated from the lamina propria into the lumen as secretory IgA (sIgA) [16, 
17]. Mucosal vaccines can also induce systemic IgG. Due to dual protection, mucosal 
vaccination could be a promising strategy against pathogens infection. An optimum mucosal 
vaccination strategy should aim to protect mucosal surface against pathogen infection (e.g., 
sIgA, sIgG), cytolytic T lymphocytes (e.g., CD8+) and T-helper lymphocytes (e.g., CD4+, 
Th17) and a protective systemic response [18]. 
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Figure 1: Induction of mucosal immune responses. At inductive site, M cells sample 
antigens and transfer them to dendritic cells (DCs). DCs take up antigen, present processed 
antigen to T cells. Activated T cells stimulate B cells to become of IgA-expressing B cells in 
germinal center. IgA-expressing B cells enter systemic circulate to traffic to mucosal effector 
sites and become plasma cells. Plasma cells produce polymeric IgA molecules that are 
translocated as sIgA following binding to the polymeric Ig receptor (pIgR). 
3. Strategies for mucosal vaccines 
To enter into contact with mucosa cells, nanovaccines must cross the mucosa barrier mainly 
composed of mucous. 
3.1. Mucin and mucoadhesive properties  
Mucus membranes are the moist surfaces largely covering the mucosal surface such as the 
gastrointestinal and respiratory tracts. The main components of all mucus gels are mucin 
glycoproteins, lipids, inorganic salts and water [19]. Mucins are large molecules (0.5–40 MDa 
in size, 3–10 nm in diameter), formed by mucin monomers linked together via disulfide bonds 
[20]. These mucin fibers reversibly crosslink and entangle with each other, forming the mucus 
layer with shear-thinning properties [21]. In addition, mucins are proteins glycosylated with a 
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dense glycan coverage [22, 23]. Most mucin glycoproteins have a high sialic acid and sulfate 
content, resulting in a strongly negative surface. Thus, the charge repulsion greatly increases 
the rigidity of mucin fibers [20]. Meanwhile, the mobility of positively charged particles in 
mucus decreases due to electrostatic interaction and thus they are easily to be trapped in mucus. 
Glycosylated regions of mucins are separated by “naked” protein regions, which are internal 
cysteine-rich domains along the peptide backbone [24]. Similar with the electrostatic 
interaction, the hydrophobic interaction increases the mucoadhesion of hydrophobic particles 
and macromolecules (Figure 2) [25]. 
The most common mucoadhesive materials include chitosan (CS), maltodextrin, alginate, 
hyaluronic acid, carboxymethyl cellulose, hydroxyethyl cellulose, pectin, etc [26-28] (Figure 
3). Mucoadhesion has been commonly applied to improve the residence time of particles at the 
mucosal surface and, hence, the uptake of particulate vaccines when administered by the nasal 
or pulmonary routes [29]. Mucoadhesive particles have been widely explored as promising 
strategy for mucosal vaccine.   
 
Figure 2: Mucin and mucoadhesive interaction. A: Structure of mucin and their potential 
mucoadhesive components. B: Examples mucin and nanoparticle interaction: 1- nanoparticle 
interact with mucin via electrostatic interaction. 2- nanoparticle interact with mucin via 
hydrophobic interaction. 3-nanoparticle interact with mucin via both electrostatic and 
hydrophobic interactions. 
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Figure 3: Mucoadhesive materials 
 
3.1.1. Mucoadhesive nanoparticles  
Chitosan is a cationic polymer obtained by deacetylation of chitin [30]. Its mucoadhesive 
property can overcome the mucociliary clearance, thus increasing the residence time of the 
formulation. CS also promotes para-cellular transportation through the nasal mucosa [31]. 
Therefore, CS is used as an adjuvant for mucosal vaccination [32-38]. To induce specific 
mucosal immunity, CS was employed as a mucosal gene carrier. The previously constructed 
multi-epitope gene vaccine against mycobacterium bovis bacillus Calmette-Guérin (BCG) was 
combined to CS. The gene vaccine delivered in a CS formulation via mucosal route remarkably 
enhances specific sIgA level and mucosal IFN-"(+) T cell response [39]. The adsorption of 
negatively charged human serum albumin (HSA) onto the surface of the CS nanoparticles has 
been shown to enhance transfection efficacy. A strong systemic and mucosal immune response 
was observed after vaccination using HSA-loaded CS-DNA (HSA-CS-DNA) complexes [40]. 
A drawback of CS, however, is its limited aqueous solubility at neutral and basic pH. CS 
derivatives with improved solubility over a wide pH range have been developed. Among them, 
trimethyl chitosan (TMC) is widely used for nasal vaccines [41, 42]. Niels Hagenaars and 
colleagues synthesized different TMC NPs with varying degrees of quaternization (DQ, 22–
86%), O-methylation (DOM, 0–76%) and acetylation (DAc 9–54%). These TMC NPs were 
formulated with whole inactivated influenza virus (WIV). Increase degree of quaternization 
strongly enhances the immunogenicity and induces protection against viral challenge after 
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intranasal vaccination [43]. The adjuvant effect of TMC NPs is also significantly reduced by 
reacetylation of TMC, whereas the DQ and DOM lightly influence the adjuvanticity of TMC 
[43].  
Glycol chitosan (GC) is a CS derivative conjugated with ethylene glycol branches, water 
soluble at a neutral/acidic pH values [44]. GC NPs showed the lowest nasal clearance rate and 
better mucosal cellular uptake as compared to CS NPs [45]. Moreover, GC NPs induced 
stronger immune response as compared to CS NPs.  
Other polysaccharides such as maltodextrin, alginates and hyaluronic acid have been 
considered as potential mucosal vaccine deliver carriers.  
Porous maltodextrin-based nanoparticles (NPL) are composed of a cationic maltodextrin 
matrix enclosing lipid in their core (Figure. 4). NPL are highly endocytosed by airway 
epithelial cells and significantly improve protein delivery in cells. Moreover, its mucoadhesive 
properties can promote after nasal administration protein delivery in airway mucosa cells [46]. 
Furthermore, NPL-Toxoplasma gondii formulations after nasal administration protect animals 
against chronic and congenital Toxoplasmosis [47, 48]. These studies provide evidence of the 
potential of NPL for the development of new vaccines against a wide range of pathogens. 
 
Figure 4: Representation of porous maltodextrin-based nanoparticles (NPL). 
 
Alginates are safe and inexpensive natural polymers with high mucoadhesive properties [49]. 
It consists of varying proportions of 1, 4-linked β-D-mannuronic acid (M), α-L-glucuronic acid 
(G). They are known to have a wide variety of uses, particularly as thickeners or emulsion 
stabilizers in manufacturing of processed foods and pharmaceutical formulations. They have a 
unique property of forming gel in the presence of divalent cations such as calcium [50]. Vaccine 
enclosed alginate microparticles have been demonstrated to be effective for oral immunization 
in several animal species [51]. Sodium alginate microparticles were tested as a delivery system 
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for oral vaccines. The oral or subcutaneous administration of ovalbumin encapsulated in 
alginate microspheres were equally effective in stimulating the systemic immune response in 
mice. These studies suggest that alginate microparticles could be used as mucosal delivery 
systems [52].  
Hyaluronic acid is a naturally polysaccharide made of D-glucuronic acid and N-acetyl-D-
glucosamine. O'Hagan et al., have described a composition which contains a selected antigen 
in combination with a hyaluronic acid polymer. It was concluded that the vaccine composition 
may display enhanced immunogenicity as compared to antigen alone [53]. Singh et al. studied 
hyaluronic microspheres as a delivery system for flu antigen and observed an adjuvant effect 
after nasal administration [54]. 
3.1.2. Improvement of the mucoadhesivity of NP  
Poly(lactic-co-glycolic) acid (PLGA), a biocompatible and biodegradable polymer with 
sustained release property, is extensively used for the therapeutic delivery of proteins and 
peptides including vaccines. However, due to its poor mucoadhesiveness, PLGA has limited 
use in mucosal vaccination. The half time of clearance of non- mucoadhesive formulations 
from the human nasal cavity is only about 20 min [40]. Such a rapid clearance time may not 
allow sufficient retention for antigen to be taken up by APCs in the nasal-associated lymphoid 
tissue (NALT). Incorporation of mucoadhesive polymers such as CS to the delivery system can 
overcome such limitations and increases absorption of protein and peptides across the mucosal 
barrier [55, 56]. Moreover, these particular polymers can prolong their residence time in the 
nasal cavity [57-59].  
HBsAg loaded PLGA microparticles were prepared and coated with CS and TMC. It was 
showed that surface coated particles greatly induced anti-HBsAg titer as compared to plain 
PLGA microparticles and the outcome as higher with TMC-coated PLGA microparticles [60]. 
In another study, Dilip Pawar et al., demonstrated that surface coating of PLGA NP with GC 
could induce significantly higher systemic and mucosal immune response compared to PLGA 
and CS-PLGA NPs [61].  
To enhance mucoadhesive properity, poly(lactic acid) (PLA) nanospheres was modified by GC 
or alginate. Systemic and mucosal immune responses were investigated after the intranasal 
administration of Streptococcus equi (S. equi) antigens associated by adsorption or 
encapsulation to PLA nanospheres coated by GC or alginate. The modified nanoparticles 
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induced a mixed Th1 and Th2 response, being therefore potential carriers for the delivery of S. 
equi antigens [62]. 
Coating liposomes with CS to improve mucoadhesive property has also been studied. Anionic 
liposomes (AL) associated to CS-DNA complexes was developed [63]. It was showed that AL-
CS-DNA NPs can enhance the delivery of the anti-caries DNA vaccine pGJA-P/VAX into 
nasal mucosa and induced a significantly higher level of sIgA than the CS/DNA.  
Nasally delivered mucoadhesive liposome using an inactivated H5N3 virus as a model antigen 
was conducted [64]. Mucoadhesive liposomes were developed using 2 polysaccharides: 
tremella (T) or xanthan gum (XG). XG is derived from Xanthomonas campestris, and T is 
extracted from Tremella fuciformis (TreE). These mucoadhesive liposomes are more suitable 
for nasal delivery which elicited higher sIgA and serum IgG after two vaccinations in chicken.  
3.2. MALT targeting  
Nanovaccine must reach the immune cells of the MALT. The main targets are M cells, DCs 
and macrophages 
3.2.1. M- cells targeting 
Although M cells are the natural antigen sampling cells, they compose less than 1% of all 
intestinal epithelial cells and are difficult to reach in the NALT [65]. In order to improve 
vaccine uptake, M cells can be specifically targeted, which may provide an opportunity to 
enhance activation of the mucosal immune system by increasing vaccine delivery across the 
intestinal epithelial layer to the inductive MALT underneath [66].  
The M cells express a wide range of carbohydrate markers with diverse glycoconjugate profiles 
[67], which perhaps allows M cells to interact with a broad range of microbes [68]. For 
example, while Ulex europaeus agglutinin-1 (UEA-1), the α-L-fucose residue- specific lectin, 
recognizes M cells and goblet cells lining the mouse Peyer's patch [69, 70]. Particle mediated 
delivery vehicles can be targeted to M-cells by surface modifications with lectins that naturally 
bind to M cell surfaces through α-L-fucose residue (Figure 5) [66, 71]. Orally delivered 
polystyrene microspheres covalently coupled to Ulex europaeus agglutinin-1 (UEA-1) lectin 
resulted in selective binding and rapid uptake by Peyer’s patch M-cells, in comparison with 
other non-M cell specific lectins [72]. In another study, LTA (Lotus tetragonolobus from 
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Winged or Asparagus pea) was explored as the potential of $-l-fucose targeting. LTA grafted 
PLGA nanoparticles loaded with HBsAg elicited strong mucosal and systemic response against 
Hepatitis B [73].  
Secretory immunoglobulin-A but not IgG or IgM adheres to the apical membrane of M cells 
promoting its uptake by M cells [74-76]. In addition, sIgA has favourable properties for the 
development as a vaccine formulation component due to its endogenous nature, non-
pathogenic origin and the lack of interspecies variation in its interaction with M cells. Dectin-
1 has been described as a small type II transmembrane protein of the C-type lectin family. Its 
presence on M cells was shown to play a role in sIgA capture and internalisation (Figure 5) 
[77]. According to these findings, chitosan dextran sulphate (CS-DS) NPs loaded with pertussis 
toxin (PTX) and sIgA was developed for the intranasal delivery of proteins. The in vivo uptake 
of sIgA-loaded CS-DS NPs showed a preferential uptake of NPs probably by M-cells. The 
results of this study indicated the potential application of sIgA for improving a nasal vaccine 
delivery system [78]. 
 
Figure 5: M cell targeting. 1- Nanoparticle conjugated UEA-1 or LTA for $-l-fucose on M 
cell recognition. 2- Nanoparticle conjugated sIgA for Dectin-1 on M cell recognition.  
3.2.2. Dendritic cells or macrophages targeting  
Given the essential role of APCs, and especially DCs, in the initiation of adaptive immune 
responses, the potential to directly target has been considered. However, most bioconjugate 
vaccines have been tested through parenteral routes of administration. DEC-205 receptor 
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belongs to C-type lectin receptors (CLRs) which expressed primarily by DCs was conjugated 
to CS NPs to deliver antigen to DCs (Figure 6a) [79]. The plasmid DNA encoding N protein 
(highly conserved part from SARS-CoV) was selected antigen for this delivery system. 
Intranasal administration this formulation led to the detection of augmented levels of N protein 
specific systemic IgG and nasal IgA antibodies.  
The mannose receptor is also one kind of CLRs primarily present on the surface 
of macrophages and immature dendritic cells [80, 81]. The receptor recognizes 
terminal mannose, N-acetyl-glucosamine and fucose residues on glycans attached to 
proteins [82] found on the surface of some microorganisms. Grafting a manose motif to CS 
could improve receptor-mediated endocytosis of the carrier (Figure 6b) [83-85]. Mannosylated 
chitosan (MCS) as a delivery system had been employed to deliver genes into APCs [86-89]. 
A vaccine delivery system based on mannosylated chitosan microspheres (MCMs) was studied. 
The dermonecrotoxin (BBD) collected from Bordetella bronchiseptica antigens were loaded in 
MCMs or chitosan microspheres (CMs). The results showed that mannose moieties in the 
MCMs induced immune-stimulating effects through mucosal delivery. These outcomes were 
probably the result of specific interaction between mannose groups in the MCMs and mannose 
receptors on the macrophages [90]. Wenjun Yao et al., used a mannose ligand to modify CS, 
which enhanced the delivery efficiency of CS via mannose receptor-mediated endocytosis 
[91]. A DNA vaccine was condensed with mannosylated CS (MCS) or CS NP to form the 
vaccines against prostate tumor. These vaccine formulations were intranasally administered 
in a mice prostate carcinoma model to evaluate the efficacy on inhibition of the growth of 
tumor cells. Immunization with DNA formulated MCS showed significant higher level of IgG 
than DNA conjugated formulations lead to efficiently suppress the growth of tumor cells.  
A water soluble, linear copolymer of D-mannose and D-glucose, namely glucomannan (GM), 
was explored as a ligand for mannose receptors [92]. Glucomannosylated CS NP entrapped 
bovine serum albumin (BSA) were found to uptake RAW 264.7 via both mannose and glucose 
transporter-mediated endocytosis. GM modification nanoparticle resulted in significantly 
higher systemic (serum IgG titer), mucosal (sIgA) and cell-mediated immune responses in 
comparison with non-modified CS NPs in BALB/c mice. In another study, glucomannosylated 
bilosomes (GM- bilosomes) was studied for oral vaccine. Thin film hydration method was used 
for the preparation of BSA loaded GM-bilosomes [93]. The immune response observed for 
GM-bilosomes was similar to alum adsorbed BSA (BSA-AL) administered through 
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intramuscular route. More importantly, GM-bilosomes induced mucosal and cell mediated 
immune response which was failed via intramuscular administration. GM-bilosomes could be 
considered as promising carrier and adjuvant system for oral mucosal immunization and 
efficiently exploited for oral delivery of other candidate antigens.  
 
Figure 6: Dendritic cells or macrophage targeting. A) Nanoparticle conjugated DEC 205 
ligand for DC recognition. B) Nanoparticle conjugated mannose ligand for mannose receptor 
on DC recognition. 
3.3. Mucosal adjuvant  
Mucosal adjuvants improve the immunogenicity of an antigen by binding to a receptor or target 
immune cell [94].  
Cholera toxin (CT) and the E. coli heat-labile enterotoxin (LT) bind to ganglioside receptors 
present on enterocytes, DCs, macrophages as well as B and T-lymphocytes [94, 95]. 
Furthermore, they are immunogens that induce antigen-specific sIgA and serum IgG antibody 
responses; and when co-administered with a protein antigen they can potentially enhance the 
mucosal and serum antibody response to induce long-term memory to the antigen [94]. The 
adjuvant activity of these toxins may result from improved antigen uptake as well as inducing 
the secretion of various cytokines [94]. Due to their high degree of toxicity these toxins are not 
considered as useful adjuvant although efforts have been made to detoxify them [96]. 
Toll-like receptors (TLRs) are a type of pattern recognition receptor (PRR). They recognize 
molecules that are generally shared by pathogens but distinct from host molecules or pathogen-
associated molecular patterns (PAMPs). TLRs are expressed on the membranes of leukocytes 
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including dendritic cells, macrophages, natural killer cells, cells of the adaptive immunity (T 
and B lymphocytes) and non immune cells (epithelial and endothelial cells, and fibroblasts) 
[97- 98]. Our current knowledge in the area of the TLRs and their ligands, should also be 
applied to the development of safe and effective mucosal adjuvants [99].  
Lipopolysaccharides (LPS) are large molecules found in the outer membrane of gram-negative 
bacteria. It binds the TLR4 receptor which expressed in many cell types, but especially in 
monocytes, dendritic cells, macrophages and B cells, which promotes the secretion of pro-
inflammatory cytokines and nitric oxide [100]. Since LPS is too toxic to be used as an adjuvant, 
the nontoxic derivative of the lipopolysaccharide (LPS) from Salmonella minnesota known as 
monophosphoryl lipid A (MPLA) was developed (Figure 7a). MPLA has been used as a 
vaccine adjuvant most effectively when incorporated into liposomes [101]. Ovalbumin (OVA) 
and MPLA were incorporated in PLGA NPs induced a stronger IgG and IgA immune response 
than that induced by OVA in PBS solution or OVA incorporated into PLGA NPs. These 
findings demonstrated that co-delivery of OVA and MPLA in PLGA NPs induced both 
systemic and mucosal immune responses. This system therefore could be a suitable strategy 
for oral vaccination [102]. 
Imiquimod (TLR7 agonist) combined to CS NPs to help antigens overcome mucosal barriers 
(Figure 7b). [103]. The study used of a multifunctional nanocarrier consisting of a lipophilic 
immunostimulants in the core, and a polymeric corona made of CS, intended to associate 
antigens and facilitate their transport across the nasal mucosa. The recombinant hepatitis B 
surface antigen (HB), was selected as antigen for the validation of the concept. The 
nanocapsules containing imiquimod elicited a protective immune response characterized by 
increasing IgG levels over time and specific immunological memory. This study suggested the 
capacity of the nanocapsules to modulate the systemic immune response upon nasal 
vaccination. 
Cytidine-phosphate– Guanosine (CpG) motifs are unmethylated dinucleotides commonly 
found in bacterial DNA but not in mammalian genomes that have been found to be 
immunostimulatory. CpG motifs are considered PAMPs due to their abundance in microbial 
genomes but their rarity in vertebrate genomes [94, 95, 104]. The CpG is recognized by TLR9, 
which is expressed only in B cells and plasmacytoid dendritic cells (pDCs) in humans (Figure 
7c).  [105]. Strong adjuvant effect on cellular and humoral immunity was observed [95, 104, 
106]. Alignani D et al., demonstrated that orally administered OVA/CpG induces a specific 
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immune response against OVA in mice [106].  
Five potential immunopotentiators including LPS, PAM3CSK4, CpG, the NOD-like receptor 2 
ligand - muramyldipeptide (MDP) and the non-toxic beta subunit of cholera toxin (CTB) were 
conducted their adjuvant effect after nasal administration [107]. Results showed that co-
encapsulation of an additional immune-modulator with the antigen into TMC NPs can further 
improve the immunogenicity of the vaccine. However, the strength and quality of the response 
depends on the immunopotentiator as well as the route of administration.  
 
Figure 7: Mucosal adjuvants. A) Nanoparticle associated LPS or MLPA for TLR4 on DC 
recognition. B) Nanoparticle associated imiquimod for TLR7 on DC recognition. C) 
Nanoparticle associated CpG for TLR9 on DC recognition. 
4. Conclusion 
Different strategies exist for the delivery and presentation of vaccine antigen to the mucosal 
immune system. Effective mucosal immunization will require (a) overcoming physiological 
barriers at mucosal routes, (b) targeting and delivering antigen into mucosal epithelium for 
appropriate processing of antigens that lead to specific T and B cell activation. Mucoadhesive 
NPs associated with mucosal targeting or adjuvant aim to bypass the mucus layer and present 
antigens to the target cells could be optimistic solutions for mucosal vaccine. This review gives 
evidences of the interest of applying nanotechnologies as both delivery system of antigens and 
targeting immune cells in mucosa. 
ABBREVIATIONS 
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Antigen presenting cell (APC), microfold or membranous cells (M-cells), polylactic-co-
glycolic acid (PLGA), polylactic acid (PLA), an adjuvant that uses squalene (MF59), Adjuvant 
System 03 (AS03), gut-associated lymphoid tissue (GALT), bronchus-associated lymphoid 
tissue (BALT), larynx-associated lymphoid tissue (LALT), secretory immunoglobulin A 
(sIgA), dendritic cells (DCs), subepithelial dome region (SED), cluster of differentiation 40 
(CD40), cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), transforming 
growth factor beta (TGF-β), interleukin (IL), lymphocyte B (B cells), lymphocyte T (T cells), 
T helper (Th), polymeric immunoglobulin receptor (pIgR), chitosan (CS), Bacillus Calmette–
Guérin (BCG), chitosan DNA (CS-DNA), human serum albumin (HSA), HSA-loaded chitosan 
DNA (HSA-CS-DNA), N-trimethyl chitosan (TMC), degrees of quaternization (DQ), degrees 
of O-methylation (DOM), degree of acetylation (DAc), inactivated influenza virus (WIV), 
glycol chitsan (GC), hepatitis B virus antigen (HBsAg), chitosan PLGA (CS PLGA), anionic-
chitosan-liposome DNA (AL-CS-DNA), fusion DNA vaccine against PAc and 
glucosyltransferase I of Streptococcus mutans (pGJA-P/VAX), Zwitterionic porous 
maltodextrin-based nanoparticles (NPL),  maltodextrin nanoparticles (NP+), Ulex europaeus 
agglutinin-1 (UEA-1), α-L-fucose (LTA), Cholera toxin (CT), chitosan dextran sulphate (CS-
DS), pertussis toxin (PTX), mannosylated chitosan (MCS), mannosylated chitosan 
microspheres (MCMs), Bordetella bronchiseptica dermonecrotoxin (BBD), chitosan 
microspheres (CMs), plasmid Gastrin-releasing peptide (pGRP), Glucomannan (GM), bovine 
serum albumin (BSA), murine macrophage cell line (RAW 264.7), cholera toxin (CT), heat-
labile enterotoxin (LT), toll like receptors (TLRs), pattern recognition receptors (PRR), 
lipopolysaccharide (LPS), cluster differentiation 14 (CD14), lymphocyte antigen 96 (MD2), 
monophosphoryl lipid (MPLA), ovalbumin (OVA), CpG oligodeoxynucleotides (CpG ODN), 
toll-like receptor 2 agonist (Pam3CSK4), muramyldipeptide (MDP), cholera toxin B subunit 
(CTB). 
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2. Influenza and vaccination 
2.1. Influenza virus 
2.1.1. Influenza virology 
Influenza viruses belong to the family Orthomyxoviridae and they are categorized into four 
types: A, B, C and D (Palese 2004). Influenza A viruses, together with influenza B viruses, are 
responsible for human seasonal epidemics and pre-pandemic outbreaks. Moreover, they cause 
respiratory illness in humans with the potential for severe issues. Annual outbreaks cause 3–5 
million severe cases and between 250,000 and 500,000 deaths (Horimoto and Kawaoka 2005). 
Each influenza A virus is further classified based on the surface glycoproteins hemagglutinin 
(HA) and neuraminidase (NA), into subtypes. At present, 18 HA and 11 NA subtypes have 
been described infecting in birds and mammals. In addition to influenza A viruses, two 
evolutionary diverging influenza B virus lineages have been reported: the Yamagata and the 
Victoria lineages (Rota et al. 1990). Influenza A viruses responsible for seasonal influenza 
epidemics belong to the H1N1 and H3N2 subtypes and, together with influenza B viruses, are 
responsible for millions of infections each year (Freidl et al. 2014).  
Influenza viruses A, B and C are very similar in overall structure. The virus particle is around 
100 nm in diameter and usually spherical. The viral particles of all influenza viruses are similar 
in composition (Bouvier and Palese 2008). These are made of a viral envelope containing 
surface glycoproteins HA and NA. The central core contains the viral RNA genome (vRNA) 
and other viral proteins that package and protect this RNA. There are seven or eight pieces of 
segmented negative-sense RNA, each piece of RNA containing either one or two genes, which 
code for a protein (Bouvier and Palese 2008) such as: hemagglutinin (HA), neuraminidase 
(NA), nucleoprotein (NP), M1, M2, nuclear export protein (NEP), RNA polymerase (PA, PB1 
and PB2) (Ghedin et al. 2005).  
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Figure 4: Schematic presentation of Influenza A virus. Hemagglutinin (HA), neuraminidase 
(NA), matrix protein 2 (M2), matrix protein 1 (M1), nucleoprotein (NP) and others 
ribonucleoproteins (PB1, PB2 and PA). Eight native-senses RNA lay in the capsid. Nulear 
export protein (NEP). 
 
2.1.2. Mechanism of replication 
Influenza viruses can replicate only in living cells. Influenza infection and replication is a multi-
step process: first, the virus bind to the cell, then deliver its genome (Smith and Helenius 2004). 
HA bind to sialic acid sugars on the surfaces of epithelial cells facilitate the endocytosis of 
virus (step 1) (Wagner, Matrosovich, and Klenk 2002). After internalization into the host cells, 
the virus localize in the early endosome and eventually reaches the late endosome. Because of 
the acidic pH, HA changes conformation and the viral envelope fuses with the endosomal 
membrane (Edinger, Pohl, and Stertz 2014; Lakadamyali, Rust, and Zhuang 2004; Rust et al. 
2004). In the endosome the M2 ion channel let the protons flow into the virus. As a result of 
the acidification, M1 is disrupted and consequently ribonucleoproteins and viral RNA (vRNAs) 
are delivered in the cytoplasm (Jing et al. 2008) (step 2). The M2 ion channel is blocked by 
amantadine drugs, preventing infection (Pinto and Lamb 2006).  
In the nucleus, the vRNAs serve as templates for the production of two forms of positive-sense 
RNA: viral mRNA (messenger RNA) and cRNA (complementary RNA). The synthesis of 
mRNA is catalyzed by the viral RNA-dependent RNA polymerase (comprising the three 
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subunits PA, PB1 and PB2) (step 3a). These mRNA then are exported into the cytoplasm for 
viral proteins translation (step 4). The cRNAs remain in the nucleus and are the template for 
synthesis of further negative-sense genomic vRNA segments for packaging into progeny 
virions (step 3b) (Cros and Palese 2003). The new proteins are either secreted through the Golgi 
apparatus to reach the cell surface (in the case of HA and NA, step 5b) or moved back into the 
nucleus to bind vRNA (step 5a). The vRNA and viral core proteins leave the nucleus and reach 
the cell surface at HA and NA location (step 6). The mature virus collect HA and NA in the 
new virus surface then buds off from the cell (step 7) (Nayak, Hui, and Barman 2004). After 
the release of new influenza viruses, the host cell dies. 
 
Figure 5: Influenza virus replication mechanism  
2.2. Influenza vaccines 
2.2.1. Conventional vaccine against influenza 
Vaccination is one of the most effective means for public health control of infectious diseases 
such as influenza. Currently, there are two types of the influenza vaccine: the inactivated 
influenza vaccine (IIV) and the live attenuated influenza vaccine (LAIV).  
Inactivated influenza vaccines 
PART I: INTRODUCTION 
 64 
Inactivated influenza vaccines are the most commonly products for influenza vaccination due 
to relatively low production costs, safety, and effectiveness. There are four types of inactivated 
vaccines: whole inactivated virus vaccines (WIV), split virus vaccines, subunit vaccines, and 
virosomal influenza vaccines (Soema et al. 2015). Typically, whole-virus killed vaccines are 
produced in 9-11-day-old pathogen-free embryonated chicken eggs, chemically inactivated 
with formaldehyde or β- propiolactone, concentrated and purified. In split virus vaccines, the 
virus envelope is disrupted by detergent treatment to exhibit all viral proteins (Neurath et al. 
1971). Concerning subunit vaccines, it is required the purification steps to separate the 
nucleocapsid and lipids from the surface proteins HA and NA (Laver and Webster 1976). 
Virosomal vaccines are lipid based vaccines made of phospholipids and antigens to build a 
viral nanoparticle. Split virus and subunit vaccines are more frequently used as seasonal 
influenza vaccines in human due to their less reactogenicity as compared to the whole-virus 
products (Beyer et al. 2011).  
Most human seasonal trivalent inactivated vaccine/quadrivalent inactivated vaccine (TIV/QIV) 
are available as single dose vaccines for people ≥9 years of age administered via an intra 
muscular (i.m.) injection. Current guidelines recommend that children 6 months old to <9 years 
old receive an extra dose administered 4 weeks after the first vaccination. Efficacy of existing 
vaccines is highly dependent on the age group, with much lower efficacy in children, the 
elderly, and adults with underlying conditions (Swayne et al. 2011; Sandbulte et al. 2015).  
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Figure 6: Schematic presentation of composition and spatial organization of WIV, split, 
subunit and virosome vaccines (Hagenaars et al. 2008) 
Live-Attenuated influenza Vaccines 
Live-attenuated influenza vaccines are available in several countries for use in human and 
horses. LAIVs for human use were independently obtained after serial passage in eggs resulting 
in viruses with cold-adapted, temperature-sensitive mutations that prevented their growth at 
temperatures higher than 35 0C and thus restricting virus replication to the nasal cavity 
(Maassab, Heilman, and Herlocher 1990). LAIVs have an advantage over inactivated products 
because they mimic a natural route of infection but with very low rate of adverse reactions. In 
contrast to inactivated products, vaccination with live products provides both humoral and cell-
mediated immunity. They can induce mucosal IgA responses in the upper respiratory tract, 
hence providing more comprehensive cross-reactive and longer-lasting immune responses 
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(Loving et al. 2013; Hoft et al. 2017). These vaccines are not recommended for use in 
immunocompromised people because of their inherent risk of developing disease. Other 
perceived risks associated with the use of LAIVs are vaccine strain reversion and 
recombination with circulating field strains. However, the different LAIV systems have been 
consistently safe and stable. An intranasal cold-adapted LAIV produced by MedImmune (FluMist) 
was licensed in the U.S. in 2003. A quadrivalent version of FluMist received approval in 2012. 
2.2.2. Strategies for influenza vaccines  
The greatest problem for vaccine manufacturing for both animal and human influenza is the 
high variability and rapid evolution of the virus. Another obstacle is the timeline for influenza 
vaccine manufacture. From strain selection to vaccine distribution it takes at least 6 months 
and in some instances, the distribution and antigenic make up of circulating viruses at the end 
of the season differs from the selected vaccine strain, which could result in a mismatch. 
Moreover, high-risk groups, such as the elderly or immunocompromised people may not 
respond optimally to vaccination due to declined immune function (Kunisaki and Janoff 2009; 
Lambert et al. 2012).  
The limitations discussed above require the need for new strategies that could improve vaccine 
efficiency and induce long-lasting broadly protective immunity. Alternative routes of delivery 
and different vaccination approaches could improve immune response to traditional vaccines. 
Moreover, vaccines that target conserved regions of the virus lead to broader, longer-lasting 
immune response, termed “universal” vaccines, are also studied these days.  
2.2.2.1. Adjuvants for influenza vaccine  
The role of adjuvant 
Fundamentally, adjuvants improve the ability of the host immune system to recognize the 
administered antigen as foreign and respond to it. Adjuvants are used to boost responses in 
populations with poor immune responses. Another advantage is that adjuvants can accelerate 
responses to the vaccine, for example during a pandemic. The inclusion of adjuvants can enable 
dose sparing, both for routine and pandemic vaccines. A final use is to enable mucosal delivery 
of vaccines. Mucosal surfaces are much harder to vaccinate for a number of reasons such as 
mucus and proteolytic enzymes barriers to antigen. Specific adjuvants may be required to 
protect the antigen in this environment and to induce a local immune response. One adjuvant 
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that was licensed for this purpose was the heat labile enterotoxin of Escherichia coli, which 
was included in Nasalflu, but this has been withdrawn (Gluck, Gebbers, and Gluck 1999). 
Adjuvants in licensed influenza vaccines  
Alum is the oldest and most widely used adjuvant. Though it should be noted that the 
description alum, which strictly refers to potassium alum KAl(SO4)2 only, often covers a broad 
range of aluminium salts, including sodium, potassium and ammonium alum.  
MF59 is an oil-in-water adjuvant which contains squalene, polysorbate 80 and sorbitan 
trioleate. Squalene was chosen as the oil component is a naturally oil found in large quantities 
in human tissues.  
AS03 is an oil-in-water adjuvant, developed by GSK as part of a broader Adjuvant System 
which has multiple members (Garcon and Di Pasquale 2017). AS03 contains squalene, DL-α-
tocopherol and polysorbate 80. Variants of AS03 have been produced, based on the amounts 
of these contents.  
AF03 is an oil-in-water adjuvant developed by Sanofi Pasteur. AF03 contains squalene, 
montane 80 PH and eumulgin B1- PH. The manufacture of AF03 is slightly different to MF59 
and AS03, using phase inversion temperature emulsification process (Klucker et al. 2012).  
In general, adjuvanted influenza vaccines have a good safety profile and improve the immune 
response to vaccine antigens. The addition of an adjuvant may not address the problems with 
the current generation of influenza vaccines. However, novel adjuvants may also help in the 
drive for a universal influenza vaccine by stabilizing antigens, boosting responses to 
recombinant antigens, or redirecting the immune response towards either a local or a cellular 
response (Tregoning, Russell, and Kinnear 2018). 
2.2.2.2. Nucleic acid influenza vaccines 
Nucleic acid vaccines were studied decades ago but have already been widely used for 
infectious diseases. Nucleic acid vaccination is a technique for protecting against disease by 
injection with antigenic DNA (as a plasmid) or RNA (as mRNA). In contrast to recombinant 
bacteria or virus vaccines, nucleic acid vaccines consist only of DNA or RNA, uptaken by cells 
and delivered to the cytoplasm or nucleus and transformed into protein antigen. There are 
several reasons why nucleic acids are attractive candidate vectors for the development of 
vaccines for infectious diseases. Firstly, nucleic vaccines are relatively inexpensive and easy 
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to manufacture. In contrast to recombinant bacteria or viruses, the vaccine composition is 
simple and has immunological advantages. Unlike live-attenuated viruses, which can revert in 
to their pathogenic form, nucleic acid vaccines cannot replicate inside the body. Moreover, 
many target proteins can be produced in one time leading to the induction of a wider range of 
immune response types (Khalid et al. 2017).   
To produce a DNA vaccine, a DNA copy is made from the viral RNA segment coding for the 
antigen of interest (i.e. an influenza protein), which is then inserted into a plasmid. The plasmid 
is administered into the host allowing antigen production in cells of the host, which results in 
an immune response against the antigen. An influenza DNA plasmid encoding for H5N1 HA, 
NP and M2 proteins loaded into cationic liposome induced antibody and T cell responses after 
intramuscular injections in a clinical study (Smith LR et al. 2010). The vaccine has showed to 
induce HA antibody titers comparable to titers induced by a subunit vaccine. While influenza 
DNA vaccines are a promising concept, several issues regarding safety have to be considered 
such as concern for genome integration, or the high doses and devices needed (e.g., 
electroporation) (Soema et al. 2015). 
The mRNA vaccine technology overcomes the challenges of DNA approach (Schlake et al. 
2012). It offers advantages in speed and precision of antigen design which is particularly 
important for emerging infections, such as potential pandemic influenza (Partridge et al. 2010). 
Moreover, mRNA vaccines induce both cellular and humoral response (Midoux et al. 2015). 
At 105–106 Da in size, mRNA requires a delivery system to be taken up by the host cells. This 
can be accomplished by nanoparticulate vehicles that encapsulate mRNA and then deliver 
mRNA to the cytoplasm of the target cells. Many synthetic materials have been discovered as 
a nano-delivery system for mRNA vaccine such as lipid nanoparticle or polymer based 
nanoparticle (Table 1). 
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Materials 
 
Application 
 
mRNA delivered 
 
Route of 
administer 
 
Ref 
 
Ionizable LNP 
 
Zika vaccine 
 
prM-E 
 
Intradermal 
 
Pardi N et al. 
2017 
 
Ionizable LNP 
 
Influenza vaccines 
 
H7 and H10 
haemagglutinins 
 
Intramuscular or 
intradermal 
 
Bahl K et al. 
2017  
 
Ionizable LNP 
 
HIV therapy 
 
VRC01 light and heavy 
chain 
 
Intravenous 
 
Pardi N et al. 
2017 
 
PSA 
nanomicelle 
 
HIV vaccine 
 
HIV-1 gag 
 
Subcutaneous 
 
Zhao M et al. 
2016 
 
CP 2k 
conjugate 
 
HIV vaccine 
 
HIV gp120 
 
Intranasal 
 
Li M et al. 
2016 
 
Modified 
dendrimer 
nanoparticle 
 
Influenza, Ebola or 
Toxoplasma gondii 
vaccine 
 
Haemagglutinin, Ebola 
glycoprotein and six T. 
gondiispecific antigens 
 
Intramuscular 
 
Chahal JS et 
al. 2016 
 
Table 1: Selected synthetic materials for mRNA vaccines  
CP 2k, cyclodextrinpolyethyleneimine 2k; gag, group-specific antigen; gp120, envelope 
glycoprotein gp120; HIV, human immunodeficiency virus; LNP, lipid nanoparticle; PLGA, 
poly(lactic-co-glycolic acid);  PSA, polyethyleneimine-stearic acid. 
 
Reports of mRNA based vaccination described the use of mRNA encoding the influenza virus 
nucleoprotein these vaccines generated a cytotoxic T cell response in mice (Khalid et al. 2017). 
There are ongoing clinical trials for mRNA vaccines for influenza, Zika and HIV (Khalid et al. 
2017). Recently, lipid nanoparticles (LNP)-formulated, with mRNA vaccines, encoding HA 
proteins of H10N8 or H7N9 induced strong immune responses in mice, ferrets, and nonhuman 
primates. Furthermore, a single dose of H7N9 mRNA loaded into LNP protected mice from a 
lethal challenge and decreased lung viral titers in ferrets. The study showed that LNP-
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formulated mRNA vaccines can induce protective immunogenicity against influenza infection 
(Bahl K et al. 2017). 
For infectious diseases with high mutation rates such as influenza, mRNA vaccine can be 
produced reliably allowing rapid response to emergence of pandemic strains. Therefore, 
mRNA vaccines are of great strategies for the prevention of influenza virus infection (Petsch 
et al. 2012). 
 
2.2.2.3. Universal influenza vaccines  
The “universal” influenza vaccine approaches attempt to overcome the problem of the highly 
changing nature of influenza viruses. The objective of these vaccines is to induce cross-
protection, which depends on stimulating both humoral and cell-mediated arms of the immune 
system. These “universal” vaccines are based on the concept of developing broadly protective 
effect against conserved viral epitopes. The primary goal of these strategies is to avoid annual 
vaccine updates and decreasing the need for re-vaccination. To develop universal influenza 
vaccine, researchers try to target either the highly conserved epitopes of the HA (the HA stalk 
domain) or the extracellular domain of the M2 protein (M2e), or target internal proteins like 
the nucleoprotein (NP) and the matrix protein (M1) to induce cross-protective T-cell response 
(Rajao and Perez 2018). 
2.3. Intranasal universal influenza vaccine – UniVac Flu Project 
Influenza vaccines are administered mostly by intramuscular route which has some limitations. 
Poor T cell response and no mucosal response is induced. Intranasal route for influenza vaccine 
administration, on the contrary, offers several advantages. Firstly, this route use is needle-free 
and painless. The vaccine activates the immune cells in the nasal-associated lymphoid tissue 
(NALT) effector sites including larynx- and bronchus-associated lymphoid tissues (Davis 
2001). Hence, intranasal route can also exert defensive activities at the prime sites of influenza 
virus infection. Moreover, the vaccine applied intranasally may also reach the blood circulation 
and the systemic immune response is stimulated in spleen and peripheral lymph nodes (Neutra 
and Kozlowski 2006). Thus, both mucosal and systemic immune responses can be expected 
after the intranasal immunization of appropriate vaccine formulation (Svindland et al. 2012). 
Currently available influenza vaccines are made of either inactivated whole viruses or virus 
subunit or split products (Wong and Webby 2013). However, while these vaccines are less 
reactogenic they confer limited immunogenicity and require either high antigenic dose or a 
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booster dose or adjuvants (Centers for Disease and Prevention 2012; Neuzil et al. 2006). One 
approach to improve influenza vaccines is to include adjuvants that boost the immune response. 
Cholera toxin (CT) has been known as the potential adjuvant for mucosal vaccine. Cholera 
toxin is protein complex secreted by the bacterium vibrio cholera (Yusuf 2015; Faruque and 
Nair 2002). CT is a complex made of six protein subunits: a single copy of the A subunit (part 
A, enzymatic), and five copies of the B subunit (part B, receptor binding), expressed as AB5. 
The five B subunits form a five-membered ring. The A subunit has two important segments. 
The A1 portion of the chain (CTA1) payload that ADP-ribosylates G proteins, while the A2 
chain (CTA2) links the CTA1 subunit to the pentameric CTB subunits (De Haan and Hirst 
2004).  
 
Figure 7: Crystal structure of cholera toxin. The heterodimeric CTA protein subunit (blue) is 
composed of CTA1 and CTA2. The cholera toxin B subunit is composed of five identical 
polypeptide subunit chains (yellow, purple, red, orange, and turquoise), each with membrane 
receptor GM1ganglioside binding capacity (Odumosu et al. 2010). 
However, CT can induce toxicity. To circumvent the problem with toxicity of CT, a non!toxic 
derivative of CT, termed CTA1 was developed (Agren et al. 1997). The CTA1 has strong ADP-
ribosyl transferase activity and is thought to act on several G proteins. Lacking the B subunit, 
the cholera toxin does not bind to the GM1-ganglioside receptor that is present in almost all of 
mammalian cells (Lycke 2004a, 2004b). CTA1 has been linked to the c-terminal region of a 
dimer of the D-fragment of the protein A from Staphylococcus aureus (DD). DD binds the Fc 
and Fab fragments of immunoglobulin present on B cells, thereby allowing binding of the 
complex CTA1-DD (Agren et al. 1997; Lycke 2004a; Eriksson, Schon, and Lycke 2004). 
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CTA1-DD does not show any systemic toxicity and gave promising results in mouse model. 
This adjuvant shows strong class I and class II MHC restricted T cell immunity after intranasal 
or systemic administration (Eriksson, Schon, and Lycke 2004; Simmons et al. 1999). Nasally 
administered CTA1-DD does not induce inflammatory events in the nasal mucosa and does not 
accumulate in the olfactory bulb, confirming the safety of this adjuvant (Eriksson, Schon, and 
Lycke 2004).  
 
 
Figure 8. Adjuvanted antigen CTA1-3M2e-DD. The fusion protein is composed by three 
parts: the adjuvant CTA1, subunit A1 of the cholera toxin; the antigen M2e, extracellular 
domain of the conserved porous channel of influenza A and a targeting portion DD, dimer of 
the D fragment of the staphylococcal protein A. 
To overcome weak immunogenicity of the M2e-based universal vaccine, this innovative 
adjuvant- CTA1-DD, has been therefore fused to 3M2e, to give CTA1-3M2e-DD (Figure 5). 
Mucoadhesive nanocarrier systems created from starch, hyaluronic acid and chitosan offer a 
promising approach for the development of mucosal vaccines (Illum et al. 2001; Singh, 
Briones, and O'Hagan 2001). Such carriers can be designed to prolong their residence time in 
the nasal cavity, to protect entrapped antigens against degradation, to enhance uptake by M-
cells, and to target the antigens more specifically to APC (Soane et al. 1999; Soane et al. 2001; 
Bernocchi et al. 2016; Dimier-Poisson et al. 2015). According to this idea, cationic porous 
maltodextrin based-NPs (NPL) were applied as vaccine delivery system to deliver CTA1-
3M2e-DD + HA into nasal mucosa. This vaccine formulation was challenged with H3N2 and 
H1N1 influenza virus strains to investigate the protective effect. Recently, we observed that 
this vaccine was able to protect against live flu viruses infection. This study demonstrated that 
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CTA1-3M2e-DD + HA loaded NPL could be potential universal influenza vaccine (Bernasconi 
et al., Journal Frontiers in Immunology, submitted). 
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Several strategies have been explored using nanoparticles for the mucosal delivery of antigen 
such as: protection to the antigen, enhanced antigen absorption, extended residence time in the 
mucosa. Hence, a better understanding of the interaction of nanoparticles with mucosal cells is 
essential for drug delivery as well as vaccine applications. Therefore, investigating how the 
physicochemical characteristics of nanomaterials influence their interactions with cells is a 
critical issue to obtain effective clinical applications.  
In this study, we investigated the effect of nanoparticles’ surface charge and inner composition 
on their interactions with nasal mucosa cells, by comparing anionic and cationic liposomes, 
anionic and cationic Poly-Lactic co-Glycolic Acid nanoparticles (PLGA NP) and cationic NPL 
(cationic porous maltodextrin-based nanoparticles with an anionic lipid core). 
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ABSTRACT 
Different types of biodegradable nanoparticles (NP) have been studied as nasal mucosa cell 
delivery systems. These nanoparticles need to strongly interact with mucosa cells to deliver 
their payload. However, while many studies are promising, few simultaneous comparisons with 
other systems have been made and it is therefore difficult to determine the best candidate. Here 
we compared 5 types of nanoparticles with different surface charge (anionic or cationic) and 
various inner compositions as potential vectors: cationic and anionic liposomes, cationic and 
anionic PLGA (Poly Lactic co-Glycolic Acid) NP and zwitterionic maltodextrin NP (cationic 
on their surface with an anionic lipid core: NPL). We first quantified their nasal residence time 
after nasal administration in mice using in vivo live imaging and NPL showed the longest 
residence time. In vitro endocytosis studies on mucosal cells (airway epithelial cells, 
macrophages and dendritic cells) using labeled nanoparticles were performed by flow 
PART II: RESULTS 
 78 
cytometry and confocal microscopy. Among the 5 nanoparticles, NPL were taken up to the 
greatest extent by the 3 different cell lines and the endocytosis mechanisms were characterized. 
Taken together, we observed that the nanoparticles’ cationic surface charge is insufficient to 
improve mucosal residence time and cellular uptake and that the zwitterionic NPL are the best 
candidates to interact with airway mucosal cells. 
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1. Introduction 
Many recent studies have shown that nanoparticles significantly improve the delivery of drugs 
and vaccines into the nasal mucosa [1]. The advantages of using nanoparticles as a delivery 
system include their ability to protect drugs or antigens against enzymatic degradation. 
Moreover, these nanosystems also improve intracellular delivery by transporting an 
encapsulated drug (or vaccine) across the membrane barrier, while they may also extend 
residence time in the nasal cavity [2, 3]. Hence, a better understanding of the interaction of 
nanoparticles with mucosal cells is essential for drug delivery as well as vaccine applications. 
Therefore, investigating how the physicochemical characteristics of nanomaterials influence 
their interactions with cells is key to achieving effective clinical applications. Nanoparticle 
interactions with cells may depend on nanoparticle material [4], size [5], shape [6], surface 
charge [7] and surface chemistry [8]. However cell physiology (differentiation state, 
proliferation rate, morphology…) and cell type, together with their interactions with 
physiological media (salts, proteins, agglomerates…), make the understanding of the 
mechanisms of the nanoparticle interactions with cells very challenging. This much is evident 
from the relatively small number of publications about the interactions of nanoparticles with 
the airway epithelium [9-11].  
 
In this study, we investigated the effect of nanoparticles’ surface charge and inner composition 
on their interactions with nasal mucosa cells, by comparing anionic and cationic liposomes, 
anionic and cationic Poly-Lactic co-Glycolic Acid nanoparticles (PLGA NP) and zwitterionic 
NPL (cationic porous maltodextrin-based nanoparticles with an anionic lipid core). 
Firstly, nano-liposomes are spherical, self-closed structures formed by a single lipid bilayer 
with an aqueous phase inside and may be either anionic or cationic. Liposomes are able to 
deliver material into cells or even inside particular cellular compartments [12]. Liposomes 
modified with sterylglucoside have been shown to be useful as vectors of nasally administered 
insulin [13].  Liposomes as nasal vaccine delivery systems have been well studied [14, 15].  
Secondly, PLGA is one of the most successful biodegradable polymers used widely as a 
nanoparticle based drug delivery system [7]. PLGA coated with chitosan improved tetanus 
protein delivery in the blood via the intranasal route [16].  
Finally, zwitterionic porous maltodextrin-based nanoparticles (NPL) have been shown to be a 
promising adjuvant for intranasal vaccination [17, 18].  
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In this study, we determined the influence of the charge and inner composition of these 5 types 
of nanoparticles on the in vivo nasal residence time and their in vitro uptake by airway mucosal 
cells. 
2. Results  
2.1. Nanoparticle synthesis and characterization  
The size and zeta potential of the 5 types of nanoparticles were characterized (Table 1 and 
Figure 1). Three cationic nanoparticles were prepared: liposomes, PLGA NP and NPL, all 
exhibited a zeta potential of between +31 mV and +37 mV. NPL are porous zwitterionic 
nanoparticles as they have a cationic surface but an anionic core, they therefore are cationic 
nanoparticles. Anionic nanoparticles were also prepared, with anionic liposomes having the 
greater negative charge of about -65mV, while anionic PLGA NP exhibited a negative charge 
of -32 mV. The nanoparticles all possessed a size ranging from 75 to 110 nm, and all types had 
a low polydispersity index (PDI) demonstrating that the size of nanoparticles was homogenous 
in solution. In addition, all these nanoparticles were spherical in shape [17, 19, 20]. 
 
Figure 1. Representation of the 5 types of nanoparticles. Cut view showing the surface and the core 
of the nanoparticles. Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-
): anionic PLGA nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: 
zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle with anionic lipid core). 
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 Size (z-average) (nm) PDI Zeta-potential (mV) 
Lipo(-) 75.91 0.290 -65.9 ± 7.86 
Lipo(+) 77.85 0.174 +31.0 ± 13.2 
PLGA(-) NP 88.66 0.233 -32.6 ± 7.77 
PLGA(+) NP 110.70 0.146 +32.7 ± 12.2 
NPL 102.50 0.181 +37.7 ± 7.87 
Table 1. Size and zeta potential of the 5 types of nanoparticles. The size and the zeta potential of the 
5 types of nanoparticles were measured by dynamic light scattering and by electrophoretic mobility, 
respectively. The PDI (polydispersity index) represents the homogeneity of the size of nanoparticles. 
Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-): anionic PLGA 
nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: zwitterionic nanoparticle 
(cationic maltodextrin-based porous nanoparticle with anionic lipid core). 
2.2. Nasal residence of the nanoparticles 
Labeled batches of NP (20 &g) having the same fluorescence were used (Supplemental Figure 
1). Mice were imaged at different time points (Figure 2) and the kinetics of the nasal residence 
time is presented in Figure 3.  
Cationic and anionic liposomes and anionic PLGA NP were quickly eliminated from the nose 
(30 min), while cationic PLGA NP and NPL had the longer residence times in the nose of 6h 
after administration. Comparing the area under curve data showed that NPL remained in the 
nose at higher doses compared to cationic PLGA NP (612 vs 359 a.u.') while the residence 
times of these two nanoparticle types were similar.  
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Figure 2. Biodistribution of the 5 types of nanoparticles. Mice were treated with PBS (-) or one of the 5 
types of nanoparticles labeled with DiI. The mice were imaged at different time points with the In Vivo 
Imaging System IVIS® Spectrum (n = 3 per group). Images are representative of 3 independent experiments. 
-: vehicle control, Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-): anionic 
PLGA nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: zwitterionic 
nanoparticle (cationic maltodextrin-based porous nanoparticle with anionic lipid core). 
 
Figure 3. Evaluation of the nasal residence time of the 5 types of nanoparticles. The nasal fluorescence 
of nanoparticles from the images of the figure 2 were quantified and the mean fluorescence intensity +/-SD 
is reported on the graph for each nanoparticle. -: vehicle control, Lipo(-): anionic liposome, Lipo(+): cationic 
(chitosan-coated) liposome, PLGA(-): anionic PLGA nanoparticle, PLGA(+): cationic (chitosan-coated) 
PLGA nanoparticle, NPL: zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle with 
anionic lipid core). 
2.3. Endocytosis of nanoparticles in H292 airway epithelial cells 
Epithelial cells are arranged in tightly packed layers that line the surfaces and cavities of tissues 
and organs throughout the body. The first barriers that nanoparticles face once nasally instilled 
are mainly the epithelial cells and some specialised cells such as M cells [21, 22]. We evaluated 
the uptake of the nanoparticles in H292 airway epithelial cells producing mucus using flow 
cytometry and confocal microscopy [23]. The uptake of all 5 nanoparticles increased over time 
meaning that nanoparticles accumulated in the cells, without reaching a steady-state under the 
conditions tested. After 24h of treatment with the 5 types of nanoparticles, the anionic and 
cationic liposomes were slowly taken up by epithelial cells and only 1% of cells were positive. 
PLGA NP were endocytosed 5 to 8 times more than liposomes, respectively, with 17% of 
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positive cells for anionic PLGA and 36% of positive cells for cationic PLGA. Finally, we 
observed that NPL were strongly taken up (46-fold more than liposomes) with more than 90% 
of positive cells. Indeed, NPL were quickly endocytosed since after only 30min 40% of cells 
were positive (Figure 4a). These results were confirmed by confocal microscopy (Figure 4b) 
and corroborated using a different fluorescent probe (Supplemental Figure 3). 
 
Figure 4. Uptake of the 5 types of nanoparticles in H292 airway epithelial cells. A) Kinetics of the NP 
uptake by flow cytometry. The NPs were labeled with DiI then incubated with cells for 30 min, 2h, 6h and 
24h, then analyzed by flow cytometry. Nanoparticle uptake (left) and percentage of positive cells for labeled-
NP(right). B) Confocal microscopy images of cellular uptake. The cells were incubated for 2h with NP 
labeled with DiI (red) then cells were processed for confocal imagery with a staining of the nuclei by Hoescht 
33342 (blue). Original magnification: 40x. Representative graphs and images of three independent 
experiments. Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-): anionic 
PLGA nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: zwitterionic 
nanoparticle (cationic maltodextrin-based porous nanoparticle with anionic lipid core). 
2.4. Endocytosis of nanoparticles in SRDC dendritic cells 
Different subsets of antigen presenting cells (APC) are present in the nose-associated lymphoid 
tissue (NALT). Dendritic cells have a key role in nanoparticle uptake [5, 24]. After 24h of 
treatment, the uptake of liposomes by SRDC was low, but nevertheless higher than in the 
airway epithelial cells. The endocytosis of PLGA NP was faster than liposomes with a better 
uptake of cationic PLGA NP (25% of positive cells) compared to the anionic PLGA NP (11% 
of positive cells). Again, NPL showed remarkable endocytosis with 57% of positive cells after 
6h incubation. Interestingly, we found that the uptake of NPL at 30 min was very high (16 
PART II: RESULTS 
84 
times better than cationic liposomes) (Figure 5a). These results were confirmed by confocal 
microscopy (Figure 5b) and corroborated using another fluorescent probe (Supplemental 
Figure 3). 
 
Figure 5. Uptake of the 5 types of nanoparticles in SRDC dendritic cells. A) Kinetics of the NP uptake 
by flow cytometry. The NPs were labeled with DiI then incubated with cells for 30 min, 2h, 6h and 24h, then 
analyzed by flow cytometry. Nanoparticle uptake (left) and percentage of positive cells for labeled-NP 
(right). B) Confocal microscopy images of cellular uptake. The cells were incubated for 2h with NP labeled 
with DiI (red) then cells were processed for confocal imagery with a staining of the nuclei by Hoescht 33342 
(blue). Original magnification: 40x. Representative graphs and images of three independent experiments. 
Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-): anionic PLGA 
nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: zwitterionic nanoparticle 
(cationic maltodextrin-based porous nanoparticle with anionic lipid core). 
2.5. Endocytosis of nanoparticles in THP-1 macrophages  
As the presence of macrophages in the airways is highly documented we evaluated the ability 
of macrophages to uptake the NP [25]. Once again, kinetics were comparable and NPL showed 
the highest endocytosis rates (98% of positive cells at 24h), with a 65-fold increase vs. 
liposomes and a 5-fold increase vs. PLGA (+). The endocytosis rates were constant, except for 
NPL that showed rapid initial uptake (93% of cells were positive after 2h) that continued more 
slowly thereafter (Figure 6a). These results were confirmed by confocal microscopy studies 
(Figure 6b) and corroborated using another fluorescent label (Supplemental Figure 3). 
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Figure 6. Uptake of the 5 types of nanoparticles in THP-1 macrophages. A) Kinetics of the NP uptake 
by flow cytometry. The NPs were labeled with DiI then incubated with cells for 30 min, 2h, 6h and 24h, then 
analyzed by flow cytometry. Nanoparticle uptake (left) and percentage of positive cells for labeled-NP 
(right). B) Confocal microscopy images of cellular uptake. The cells were incubated for 2h with NP labeled 
with DiI (red) then cells were processed for confocal imagery with a staining of the nuclei by Hoescht 33342 
(blue). Original magnification: 40x. Representative graphs and images of three independent experiments. 
Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-): anionic PLGA 
nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: zwitterionic nanoparticle 
(cationic maltodextrin-based porous nanoparticle with anionic lipid core). 
 
2.6. Endocytosis mechanism of NPL 
Owing to their higher uptake, we focused the study of the endocytosis mechanisms on the 
zwitterionic NPL in order to understand why this nanoparticle is so effectively endocytosed. 
Cells were pretreated with known inhibitors of specific pathways of endocytosis (Table 2). As 
shown in Figure 7, the inhibition of the caveolae pathway gave approximately a 24% decrease 
in the uptake of NPL by H292 cells and a decrease of about 33% and 52% in SRDC and THP-
1 cells, respectively. Clathrin inhibition had a significant effect on NPL internalization in 
SRDC (60-71% of inhibition) and in THP-1 cells (about 53% of inhibition), but had a more 
moderate effect in H292 cells (32% of inhibition). Dynamin was likely one of the main actors 
in NPL endocytosis by H292 and THP-1 as dynasore inhibited 53% and 58%, respectively, of 
the nanoparticle uptake by these cell lines. However, dynasore had a lesser effect on SRDC 
with 29% of inhibition. Macrophagocytosis may also be a vital pathway of NPL entry into 
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SRDC and THP-1, since amiloride exhibited inhibition of 54% and 44 %, respectively. As 
expected, amiloride impaired only 36% of the nanoparticle uptake by the non-phagocytic H292 
epithelial cells. Lastly, ATP depletion by NaN3 pretreatment resulted in an ca. 45% decrease 
in NPL uptake by H292 and THP-1 cells, while it showed stronger inhibition in SRDC with a 
60% decrease, confirming the energy-dependent nature of the endocytosis mechanisms. Taken 
together, these data clearly showed that the cellular uptake pathways of NPL is mediated by a 
combination of several cellular endocytosis mechanisms. 
 
Inhibitors Final concentration Endocytosis pathways 
Nystatin,  
Filipin  
20 µg/ml 
10 µg/ml 
Caveolae  
Chlopromazine (CPZ),  
Phenylarsine oxide (PAO)  
10 µg/ml 
1 µg/ml 
Clathrin 
Dynasore  26 µg/ml Dynamin 
Amiloride  23 µg/ml Macropinocytosis 
Sodium azide (NaN3) 600 µg/ml ATP inhibitor 
Table 2. Inhibitors of endocytosis. The final concentration and the targeted endocytosis pathways of the 
endocytosis inhibitors used in the study. 
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Figure 7. Mechanism of endocytosis of NPL in H292, SRDC and THP-1 cells. The cells were pre-treated 
with different endocytosis inhibitors following the table2 then DiI-labeled NPL were added to cells for 30 
min at 37°C. Cells were then washed and immediately anaylsed by flow cytometry. Data represent the mean 
fluorescence intensity +/- SEM (n = 3) and untreated cells were set to 100% of NPL uptake. Representative 
graphs of three independent experiments performed in triplicates. - : untreated cells, CPZ: chlorpromazin, 
PAO: Phenyl Arsine Oxide. 
3. Discussion  
An increasingly large number of studies have examined nasal delivery of drugs and vaccines 
using nano-carriers such as micelles, polysaccharide nanoparticles [2], liposomes or PLGA 
nanoparticles, but little is known of their ability to interact with mucosal cells in the airway. In 
this study, we compared 5 types of nanoparticles commonly used as nano-carriers for intra-
nasal administration: they were either anionic or cationic (liposomes and PLGA NP), while 
NPL are zwitterionic (a cationic surface with an anionic core). The aim of this study was to 
correlate the characteristics of the nanoparticles with their ability to be efficiently endocytosed 
by airway epithelial cells. Many studies have described the potential of different types of NP 
for mucosal delivery, but they were generally administered at very high doses: while positive 
results were obtained, no comparison was made with other delivery systems. This comparative 
study was set up with the same dose of each of the nanoparticle types (1&g/cm'), and each had 
the same fluorescence. In the literature, due to their poor endocytosis, liposomes and PLGA 
NP have generally been studied at higher doses, up to 100 fold more than used in this study 
[26-28].  
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Our study of in vivo nasal residence time of these 5 nanoparticle types showed that cationic 
PLGA NP and NPL had the longer residence times (Figure 2). This is in accordance with 
previous experiments that described a stronger interaction between cationic compounds and 
the airway mucosa than anionic or neutral compounds [2, 5, 29]. Indeed, increased residence 
times might be attributed to the strong electrostatic interactions between cationic nanoparticles 
with anionic sialic and acidic moieties of glycosaminoglycan contained in the mucin and on 
the surface of airway cells [30]. Unexpectedly, the cationic liposome nanoparticles showed 
completely different behavior, even though they possessed the same positive charge density as 
cationic PLGA NP and NPL.  
In this study the longer nasal residence time of NPL compared to the 4 other nanoparticles 
(Figure 3) might be due to the presence of anionic lipids inside the core of these nanoparticles 
[31].  In another study we found that NPL increased the nasal residence time of an encapsulated 
protein and that these NPL were observed in the first layer of the nasal mucosa cells after nasal 
administration [32]. According to this finding, we hypothesized that NPL could be more 
efficiently taken up by the cells underlying the mucus layer. In order to confirm this, we studied 
the cellular uptake of the 5 nanoparticle types by cell lines representative of the airway mucosa 
[24, 33].   
Flow cytometry and confocal studies showed that the endocytosis was consistent among the 3 
cell lines for the 5 types of nanoparticles. Interestingly, while NPL showed a rapid initial 
endocytosis (in the first 2 hours), the other types of nanoparticles were more slowly and 
continuously taken up over the 24h experiment. As expected, anionic nanoparticles were taken 
up to a lesser extent than the cationic ones [34, 35] (Figures 4, 5 and 6; Supplemental Figure 
3). 
Despite their common use in nanomedicine (DOXIL®), we observed that liposomes are poorly 
taken up by the cells compared to the other types of nanoparticles. These results were confirmed 
in the 3 cells lines using another fluorescent probe: Rhodamine DHPE (Dihexadecanoyl-sn-
Glycero-3-Phosphoethanolamine) (Supplemental Figure 2). The relatively poor endocytosis 
efficiency of liposomes compared to PLGA NP and NPL could be attributable to their stability 
in vitro and in vivo. However, we confirmed that the colloidal properties and the fluorescent 
labeling of the liposomes were both stable (Supplemental Figure 3).  
Cell membranes have many negatively charged groups on the surface. It is expected that 
positively charged nanoparticles will thus be better associated via ionic interactions and that 
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their subsequent endocytosis is thus facilitated [6, 36, 37]. In our study, we found that the 
uptakes of the cationic liposomes and cationic PLGA NP were clearly lower than that of the 
cationic NPL in all 3 cell lines representing the nasal mucosa. These in vitro data confirmed 
the in vivo results and supported our hypothesis. The greater residence time of NPL might be 
due to their muco-adhesive property (acting as a zwitterion) that may increase subsequent 
cellular uptake. Furthermore, it has been shown that polysaccharides have a high attraction 
towards mucosal surfaces covering the nasal, pulmonary and gastrointestinal tract [38].  
Cell membranes are impermeable to macromolecules [39, 40]. Nanoparticles, like viruses, are 
taken up via endocytosis [41-45]. Understanding the endocytosis mechanisms of nanoparticles 
is thus vital for developing efficient therapeutic applications. Practically, the endocytosis 
pathways of the 5 nanoparticles might be mediated via non-phagocytic mechanisms since the 
size of all nanoparticles is less than 1 µm. According to the relatively poor uptake of liposomes 
and PLGA NP compared with NPL, we focused our investigation of the cellular uptake 
mechanisms on NPL. We observed a similar profile for all the cell lines: inhibition of clathrin, 
caveolae and micropinocytosis pathways inhibited the uptake of NPL (Figure 7). Dynamin is 
involved in many endocytosis pathways, including clathrin and caveolae pathways [46], and 
promotes the scission and release of intracellular endocytic vesicles. Inhibiting dynamin-
dependent mechanisms provided confirmation that clathrin and caveolae were indeed involved 
in the endocytosis of NPL. Interestingly, depleting ATP by NaN3 did not completely block the 
uptake of NPL in the 3 cell lines tested, though the dose of inhibitor used was sub-optimal to 
protect cells from mortality.  
Our results demonstrate that NPL endocytosis was significantly inhibited by all the inhibitors 
tested, suggesting that NPL enter these 3 cell lines by a combination of all the pathways. The 
clathrin pathway has been shown to be the major route for cellular uptake of chitosan 
nanoparticles in Caco-2 cells [47]. Other experiments suggested that clathrin-mediated 
endocytosis and macropinocytosis were involved in the uptake of cholesteryl pullulan (CHP) 
nanoparticles [48]. Interestingly, we found that zwitterionic NPL entered epithelial cells, 
macrophages and dendritic cells via a combination of several pathways. This behavior might 
be due to the composition and the porous structure of these nanoparticles, which allows the 
NPL to expose both cationic (polysaccharide) and anionic (lipid) charges together with the 
lipophilic core, thus enabling strong interactions with cell membrane components.  
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4. Conclusion 
Taken together, this comparison of 5 types of nanoparticle has demonstrated that zwitterionic 
NPL is the best candidate for delivering drugs into airway epithelial cells owing to their long 
residence time and efficient endocytosis. Further studies are needed to confirm the utility of 
zwitterionic nano-carriers for improving the uptake of drugs administered via the nasal mucosa. 
 
5. Material and Methods 
5.1. Material 
Maltodextrin was purchased from Roquette (France), DPPG (1,2-dipalmitoyl-snglycero-3-
phosphatidylglycerol) and DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) came from 
Lipoid (Germany), while PLGA (Resomer RG503H) was from Evonik (Germany). Non-
essential amino acids, RPMI 1640, Iscove's Modified Dulbecco's Medium (IMDM), fetal calf 
serum (FCS), phosphate buffered saline (PBS), Hoescht 33342, DiI (1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindocarbocyanine Perchlorate), trypsin, NaOH, L-glutamine and absolute ethanol 
were purchased from ThermoFisher Scientific (France). Epichlorhydrin (1-chloro-2,3-
epoxypropane), NaBH4, GTMA (glycidyl-trimethyl-ammonium chloride), deacetylated 
chitosan (50-190kDa), PD-10 Sephadex G25 desalting column, nystatin, filipin (caveolae-
mediated endocytosis inhibitors), chlorpromazine (CPZ) and phenylarsine oxide (PAO) 
(clathrin-mediated endocytosis inhibitor), amiloride (macropinocytosis endocytosis inhibitor), 
dynasore (dynamin endocytosis inhibitors) and NaN3 (mitochondrial inhibitor) were from 
Sigma Aldrich (France). 
The human muco-epidermoid bronchiolar carcinoma cell line NCI-H292 (H292) was 
generously donated by Dr J.M. Lo-Guidice (Lille, France). The human monocytic cell line 
THP-1 was provided by Dr. F. Nesslany (Lille, France). The CD4–CD8α+CD205+CD11b– 
immortalized murine spleen dendritic cell line SRDC was obtained from Pr. I. Dimier-Poisson 
(Tours, France)[49]. 
5.2. Methods 
5.2.1. Cell culture 
The H292 and THP-1 cells were maintained in RPMI supplemented with 10 % (v/v) heat-
inactivated FCS, 100 U/mL penicillin, 100 µg/mL streptomycin and 2mM L-glutamine at 37oC 
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in a humidified, 5% CO2 atmosphere. The SRDC were cultured in IMDM supplemented with 
5% (v/v) heat-inactivated FCS, 100 U/mL penicillin, 100 µg/mL streptomycin and 2mM L-
glutamine at 37°C in a humidified, 5% CO2 atmosphere.  Cells were seeded 3 days before 
treatment at a density of 1.5 x 105 cells per well in 8-well glass chamber slides (LabTekII, 
Thermo Scientific Nunc Lab) or 5 x 105 cells per well in 6-well plates. 
5.2.2. Nanoparticle synthesis 
Anionic and cationic liposome synthesis 
For anionic liposomes, 35 mg of lipids (DPPC 80% and DPPG 20%) were dissolved in 2 ml of 
ethanol. Dissolution was performed for 5 minutes under stirring at 150 rpm. Dissolved lipids 
were then injected into ultrapure water (aqueous phase) under stirring at 150 rpm. For cationic 
liposome, 35 mg of DPPC dissolved in ethanol was injected into ultrapure water (aqueous 
phase) under stirring at 150 rpm following by the addition of 10% chitosan (w/w of lipid) at 
80oC. No surfactant was added at any step of the synthesis. Residual organic solvents were 
eliminated under vacuum evaporation. 
Anionic and cationic PLGA NP synthesis 
Anionic PLGA NP were produced by nanoprecipitation at room temperature [50]. The PLGA 
polymer was dissolved at 10 mg/mL in an acetone/ethanol mixture (85:15) comprising the 
organic phase. Dissolution was performed for 5 minutes under stirring at 150 rpm. Dissolved 
PLGA were then injected into ultrapure water (aqueous phase) under stirring at 150 rpm. No 
surfactant was added at any step of the synthesis. Residual organic solvents were eliminated 
under vacuum evaporation. For cationic PLGA NP, the dissolved PLGA was injected into 
ultrapure water containing 10% chitosan (w/w of PLGA) under stirring at 150 rpm. Chitosan 
(10 mg/ml) was prepared in water containing 5% acid acetic (v/v). 
NPL synthesis 
The NPL were prepared as described previously [31]. Briefly, maltodextrin was dissolved in 
2 N sodium hydroxide with magnetic stirring at room temperature. They were reticulated and 
cationised using epichlorhydrin and GTMA to obtain hydrogels that were neutralized with 
acetic acid and sheared using a high pressure homogenizer. The nanoparticles thus obtained 
were purified by tangential flow ultra-filtration (Centramate Minim II, PALL, France) using a 
300 kDa membrane (PALL, France) and mixed with DPPG above the gel-to-liquid phase 
transition temperature to produce NPL. 
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5.2.3. Characterization of nanoparticles  
The size (Z-average) and zeta potential of the nanoparticles were measured with the zetasizer 
nanoZS (Malvern Instruments, France) by dynamic light scattering and by electrophoretic 
mobility analysis, respectively. The nanoparticles were measured in triplicate at a concentration 
of 100 µg/ml in ultrapure water. 
5.2.4. Labeling of nanoparticles 
The 5 types of nanoparticles were labeled with the DiI (NP/DiI) previously diluted in ethanol 
at 1mg/ml. For the labeling of the cationic and anionic liposomes, DiI was added in ethanol 
together with the lipids to a final concentration of 0.1% (w/w of lipid). For the labeling of the 
cationic and anionic PLGA NP, DiI was added during nanoparticle synthesis in the organic 
phase with a final concentration of 0.1% (w/w of PLGA) [34]. The labeling of NPL was 
performed by mixing the ethanol solution of DiI with premade NPL nanoparticles at a final 
concentration of 0.5% (w/w of DPPG) [32]. The DiI loading was confirmed by gel permeation 
studies on a PD-10 Sephadex G25 desalting column. The nanoparticles were kept in the dark 
at 4 °C before use. Batches having the same fluorescence intensity at the same concentration 
of nanoparticles were used for the studies. 
5.2.5. Nanoparticle endocytosis  
Cells were plated for 3 days in 6-well plates and treated for different exposure times (0.5, 2, 6, 
and 24h) with 10 µg of NP/DiI. The cells were then analyzed by flow cytometry with a BD 
Accuri™ C6 CFlow Sampler flow cytometer (BD Bioscience, USA). For confocal microscopy, 
the cells were plated for 3 days in 8-chamber slides. After three washes with PBS, cells were 
treated for 2h with 1 µg of different NP/DiI and washed again with PBS. After that, cells were 
fixed for 10 min with 4% (v/v) paraformaldehyde at 4°C and nuclei were stained with Hoescht 
33342. Cells were viewed with a LSM710 Zeiss confocal microscope (Zeiss). 
5.2.6. Treatment with endocytosis inhibitors 
Cells were pre-incubated for 15 min at 37°C with various endocytosis inhibitors: nystatin (20 
µg/ml), filipin (10 µg/ml), chlorpromazine (CPZ 10 µg/ml), phenylarsine oxide (PAO 1 µg/ml), 
amiloride (0.023 mg/ml), dynasore (26 µg/ml), NaN3 (600 µg/ml). NPL/DiI were added for 30 
min then cells were collected by trypsin and nanoparticle endocytosis was measured by flow 
cytometry. 
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5.2.7. In vivo nasal residence studies after nasal administration 
Non-anesthetized mice (n=3) received intra-nasally 20 µg (11µl per nostril) of fluorescently-
labeled nanoparticles. The five groups of mice were maintained in separate boxes with water 
and diet ad libitum. Longitudinal studies in individual animals were performed using the In 
Vivo Imaging System IVIS® Spectrum (PerkinElmer, Waltman, USA). Mice groups were 
successively imaged at 0.5, 1, 1.5, 2, 2.5, 3, 6, 24 and 48h following administration, and one 
control mice was also imaged with each treatment group at each time point. Acquisitions and 
analyses of images thus obtained were performed with the PerkinElmer Living Image software 
(version 4.2). Mice were maintained under pathogen-free conditions in our animal house. 
Experiments were carried out in accordance with the guideline for animal experimentation (EU 
Directive 2010/63/EU) and the protocol was approved by the local ethics committee at Tours 
University (CEEA VdL). 
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Supplemental data : 
Residence time and uptake of zwitterionic nanoparticles in the nasal mucosa: 
comparison with anionic and cationic nanoparticles  
by Le MQ. et al. 
 
1. Supplemental Material and Methods 
1.1. Supplemental material 
Rhodamine-DHPE (1,2-Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine), hereafter 
abbreviated as Rhod, was from Life Technologies, France. 
 
1.2. Supplemental Methods 
1.2.a. Control of the fluorescence of the DiI-labeled nanoparticles for in vivo experiments 
Batches of nanoparticles having the same fluorescence intensity at the same concentration were 
used as described in the material and methods. Additionally, for in vivo experiments, drops of 
10µL containing serial dilutions of DiI-labeled nanoparticles (from 9µg to 0µg) were loaded 
onto a glass slide. The fluorescence of the nanoparticles was determined with the In Vivo 
Imaging System IVIS® Spectrum (PerkinElmer, Waltman, USA). 
1.2.b. Stability study of the anionic and cationic DiI-labeled liposomes 
DiI-labeled liposomes were synthesized in water and the size, the zeta potential and the 
fluorescence of anionic and cationic liposomes were analyzed as described in the material and 
methods section. Immediately after the synthesis batches of liposomes were divided into 2 
groups, each receiving an extra volume of 11.11% of either water or 10xPBS followed by 
homogenization. Each batch were divided again into 2 groups stored either at 4°C or 37°C. The 
size, the zeta potentials and the fluorescence were analyzed at the specified time points from 
0.5 to 24 hours.  
1.2.c Labeling and characterization of the Rhod-labeled nanoparticles  
The labeling of the 5 types of nanoparticles with Rhod was performed following the same 
protocol as for DiI-labeling: the 5 types of nanoparticles were labeled with the Rhod previously 
diluted in ethanol at 1mg/ml. For the labeling of the cationic and anionic liposomes, Rhod was 
added in ethanol together with the lipids to a final concentration of 0.1% (w/w of lipid). For 
the labeling of the cationic and anionic PLGA NP, Rhod was added during nanoparticle 
synthesis in the organic phase with a final concentration of 0.1% (w/w of PLGA). The labeling 
of NPL was performed by mixing the ethanol solution of Rhod with premade NPL 
PART II: RESULTS 
 98 
nanoparticles at a final concentration of 0.5% (w/w of DPPG). The Rhod loading was 
confirmed by gel permeation studies on a PD-10 Sephadex G25 desalting column. The 
nanoparticles were kept in the dark at 4 °C before use. The size and the zeta potential of all 
nanoparticles were measured with the zetasizer nanoZS (Malvern Instruments, France) as 
described in the material and methods. Batches having the same fluorescence intensity at the 
same concentration of nanoparticles were used for the studies. 
1.2.d. Endocytosis of the Rhod-labeled nanoparticles 
Cells were plated for 3 days in 6-well plates, as described in the material and methods, and 
treated for different exposure times (0.5, 2, 6, and 24h) with 10 µg of Rhod-labeled 
nanoparticles. The cells were then analyzed by flow cytometry with a BD Accuri™ C6 CFlow 
Sampler flow cytometer (BD Bioscience, USA).  
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Supplemental Figure 1 : Control of the fluorescence of the DiI-labeled nanoparticles for 
in vivo experiments. Before the in vivo experiment, the fluorescence of nanoparticles was 
analyzed with the In Vivo Imaging System IVIS® Spectrum. The fluorescence of each of the 
5 types of nanoparticles were very similar, as shown above. Representative data of 4 
experiments. Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-
): anionic PLGA nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: 
zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle with anionic lipid 
core). 
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Supplemental Figure 2 : Stability of the liposomes. Liposomes were synthesized in water 
then water or PBS (final concentration 1x) was added and they were stored either at 4°C or at 
37°C for 24h. The size (A-B), the zeta potentials (C-D) and the relative fluorescence (E-F) of 
anionic (A, C, E) and cationic (B, D, F) liposomes were analyzed. No shrinkage (meaning a 
size decrease) nor destabilization was observed (A-B). The zeta potential remained consistent 
with the original charge of the liposomes (C-D) and the fluorescence intensities were constant 
throughout the experiment (E-F), demonstrating the stability of the liposomes in buffer at 37°c. 
Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-): anionic 
PLGA nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: 
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zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle with anionic lipid 
core).  
 
Supplemental Figure 3 : Endocytosis of Rhod-labeled nanoparticles. The endocytosis of 
the 5 types of Rhod-labeled nanoparticles were analyzed by flow cytometry in NCI-H292 
airway epithelial cells (A), in SRDC dendritic cells (B) and in macrophage-derived THP-1 cells 
(C). Consistently with the DiI-labeled nanoparticles, liposomes were slowly taken over the 24h 
experiment, PLGA NP exhibited an intermediary endocytosis profile, while NPL were quickly 
endocytosed. Lipo(-): anionic liposome, Lipo(+): cationic (chitosan-coated) liposome, PLGA(-
): anionic PLGA nanoparticle, PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, NPL: 
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zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle with anionic lipid 
core). Rhod: Rhodamine-DHPE (1,2-Dihexadecanoyl-s 
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Conclusion 
 
This study demonstrated that among the 5 different nanoparticles, NPL is the best candidate 
that owns longer nasal residence time and efficiently deliver drugs into airway epithelial cells. 
Nanocarriers administered intra-nasally may improve the delivery of antigens to immune cells 
while limiting their mucosal clearance. Other advantages include their ability to protect 
antigens against enzymatic degradation and the transport across the mucous barrier. In order to 
select the appropriate antigen delivery systems for intranasal vaccine, different properties such 
as antigen loading and cell delivery must be evaluated. In the next study, we compared the 
loading and delivery of antigens with airway mucosa cells (airway epithelial cells, 
macrophages and dendritic cells). The study was performed on anionic and cationic liposomes, 
anionic and cationic PLGA and NPL (cationic on their surface and anionic in their porous core).  
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ABSTRACT 
Different types of biodegradable nanoparticles (NP) have been studied as delivery systems for 
proteins into nasal mucosal cells, especially for vaccine applications. Such a nanocarrier must 
have the ability to be loaded with proteins and to transport this payload into mucosal cells. 
However, comparative data on nanoparticles’ capacity for protein loading, efficiency of 
subsequent endocytosis and the quantity of nanocarriers used are either lacking or 
contradictory, making comparisons and the choice of a best candidate difficult. Here we 
compared 5 types of nanoparticles with different surface charge (anionic or cationic) and 
various inner compositions as potential vectors: the zwitterionic NPL (cationic maltodextrin 
NP with an anionic lipid core), cationic and anionic PLGA (Poly Lactic co-Glycolic Acid) NP, 
and cationic and anionic liposomes. We first quantified the protein association efficiency and 
NPL associated the largest amount of ovalbumin, used as a model protein. In vitro, the delivery 
of fluorescently-labeled ovalbumin into mucosal cells (airway epithelial cells, dendritic cells 
and macrophages) was assessed by flow cytometry and revealed that the NPL delivered protein 
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to the greatest extent in all 3 different cell lines. Taken together, these data underlined the 
potential of the zwitterionic NPL as efficient protein delivery systems to mucosal cells. 
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1. Introduction  
Nasal vaccination is an attractive strategy for the induction of mucosal and systemic immunity 
[1, 2]. Indeed, most pathogenic infections start at a mucosal surface and the induction of both 
local and distal mucosal immunity offers the possibility of neutralizing them at their point of 
entry. However, despite this clear advantage, as well as the practicality of needle-free 
administration, intranasal vaccination remains challenging owing largely to inefficient uptake 
and rapid clearance of the antigen.   
Nanoparticles (NP) have been tested as delivery systems for nasal vaccines and shown to 
improve the delivery of antigens to immune cells while limiting their mucosal clearance. Other 
advantages include their ability to protect antigens against enzymatic degradation and their 
ability to transport antigens across the mucous barrier [3, 4]. However, while many 
nanoparticulate delivery systems are described, no direct comparison between available types 
has so far been published, making it difficult to choose the ideal nanocarrier for this application.  
Natural and synthetic biodegradable materials are generally used as components of 
nanoparticles. Polyester derivatives such as poly lactic-co-glycolic acid (PLGA), lipid-based 
nanoparticles such as liposomes, and polysaccharides such as chitosan, starch, alginate or 
dextran are the main candidates under evaluation [4, 5]. Maltodextrin-based nanoparticles 
(NPL) have been studied as delivery systems of antigens and drugs administered via the nasal 
route [6]. These zwitterionic NP are made from cationic maltodextrin with an anionic 
phospholipid core. NPL can deliver antigens to the mucosal cells [7]. After intranasal 
administration of a NPL-based vaccine, an immune protection was observed after an oral 
challenge [8, 9]. NPL also increase the nasal residence time of proteins [10]. These studies 
strongly support the potential for NPL to be an excellent vaccine delivery system. PLGA is 
composed of two polymers: lactic acid and glycolic acid, linked by ester bonds easily 
metabolized by the body and auto-degradable. PLGA has been approved by the American Food 
and Drug Administration and European Medicine Agency (EMA) for human applications [11] 
and it has been demonstrated that PLGA nanoparticles (PLGA NP) are of interest for vaccines 
[12-16]. Liposomes are spherical, self-closed structures consisting of one or several 
phospholipid bi-layers enclosing an aqueous phase [17]. Due to their lipid structure, they are 
bioavailable and able to entrap both hydrophilic and hydrophobic drugs – in addition, 
liposomes could have an adjuvant effect [18].  
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In order to compare different antigen delivery systems, different properties such as antigen 
loading capacity and cell delivery must be evaluated [19]. In this study, we compared the 
loading and delivery of antigens using three types of airway mucosal cells (airway epithelial 
cells, macrophages and dendritic cells). The study was performed on NPL (cationic on their 
surface and anionic in their porous core), on anionic and cationic PLGA and on anionic and 
cationic liposomes. 
 
2. Material and methods 
2.1. Materials 
Maltodextrin was purchased from Roquette (France) while DPPG (1,2-dipalmitoyl-snglycero-
3-phosphatidylglycerol) and DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) were from 
Lipoid (Germany). Cell culture media (RPMI 1640 and IMDM), fetal calf serum (FCS), non-
essential amino acids, trypsin, L-glutamine, phosphate buffered saline (PBS), NaOH, ethanol, 
DAPI (4,6-diamidino-2-phenylindole), DiI (1,10-dioctadecyl-3,3,30,30-tetramethylene) and 
Micro BCA Protein Assay Kit were purchased from ThermoFisher Scientific (France). PLGA 
(50:50, Acid copolymer : Resomer RG503H) was from Evonik (Germany). Epichlorhydrin (1-
chloro-2,3-epoxypropane), GTMA (glycidyl-trimethyl-ammonium chloride), NaBH4, 
chitosan, PD-10 Sephadex G25 desalting column, ovalbumin (OVA) and Fluorescein-5-
isothiocyanate (FITC) were all purchased from Sigma-Aldrich (France).  
The human muco-epidermoid bronchiolar carcinoma cell line NCI-H292 (hereafter H292) was 
supplied by Dr J.M. Lo-Guidice (University of Lille, France). The human monocytic cell line 
THP-1 was donated by Dr. F. Nesslany (Pasteur Institute of Lille, France). The CD4–
CD8α+CD205+CD11b– murine spleen dendritic cell line SRDC line was obtained from Pr. I. 
Dimier-Poisson (University François-Rabelais of Tours, France)[20]. 
 
2.2. Cell culture 
The H292 and THP-1 cells were maintained in RPMI supplemented with 10% heat-inactivated 
fetal calf serum (FCS), 100 U/mL Penicillin, 100 mg/mL streptomycin and 2mM L-glutamine 
at 37oC in humidified 5% CO2 atmosphere. SRDC were cultured in IMDM supplemented with 
5% heat-inactivated FCS, 100 U/mL Penicillin, 100 mg/mL streptomycin and 2mM L-
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glutamine at 37°C in humidified 5% CO2 atmosphere.  Cells were seeded 3 days before 
treatment at a density of 1.5 x 105 cells per well in 8-well glass chamber slides (LabTekII, 
Thermo Scientific Nunc Lab), or at 5 x 105 cells per well in 6-well plates. 
 
2.3. Nanoparticles synthesis 
Zwitterionic NPL synthesis 
NPL were prepared as described previously [21]. Maltodextrin was dissolved in 2N sodium 
hydroxide with magnetic stirring at room temperature. To introduce the positive charge, 
epichlorhydrin and GTMA were added to make cationic polysaccharide gels. The gels were 
then neutralized with acetic acid and sheared using a high-pressure homogenizer (LM20, 
Microfluidics, France). The nanoparticles thus obtained were purified by tangential flow ultra-
filtration (AKTA flux 6, GE Healthcare, France) using a 750 kDa membrane (GE Healthcare, 
France) and mixed with DPPG above the gel-to-liquid phase transition temperature to produce 
NPL. 
Cationic and anionic PLGA NP 
Anionic PLGA NP were produced by nanoprecipitation at room temperature [22]. The PLGA 
polymer was dissolved at 10 mg/mL in an acetone/ethanol mixture (85:15) composing the 
organic phase. Dissolution was performed for 5 minutes under stirring at 150 rpm. Dissolved 
PLGA was then injected into ultrapure water (aqueous phase) under stirring at 150 rpm. No 
surfactant was added at any step of the synthesis. Residual organic solvents were eliminated 
under vacuum evaporation. For cationic PLGA NP, dissolved PLGA was then injected into 
ultrapure water with 10% of chitosan (w/w of PLGA) (aqueous phase) under stirring at 150 
rpm. 
Cationic and anionic liposomes 
Anionic liposome: 35 mg of lipid (DPPC 80% and DPPG 20%) were dissolved in 2 ml of 
ethanol. Dissolution was performed for 5 minutes under stirring at 150 rpm. Dissolved lipids 
were then injected into ultrapure water (aqueous phase) at 80°C under stirring at 150 rpm.  
Cationic liposome: 35 mg of DPPC dissolved in ethanol was injected into ultrapure water 
(aqueous phase) at 80oC under stirring at 150 rpm, chitosan (10w/w of lipid) was added after 
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10 minutes. No surfactant was added at any step of the synthesis. Residual organic solvents 
were eliminated under vacuum evaporation. 
 
2.4. Characterization of nanoparticles and formulations 
The size (hydrodynamic diameter in Z-average) of nanoparticles and formulations was 
measured by dynamic light scattering in pure water. The zeta potentials were measured by 
electrophoretic mobility in pure water. Measurements were carried out in triplicate using a 
zetasizer nanoZS (Malvern Instruments, France). 
 
2.5. Labeling of ovalbumin 
Ovalbumin (OVA) was labeled with FITC according to a previously described protocol [8]. 
Briefly, FITC was added to proteins solubilized in 0.1 M bicarbonate buffer (pH 9.5) at a ratio 
of 1/10 (w/w), and the solution was stirred for 6 h in the dark at room temperature. The labeled 
protein was purified by gel filtration on a PD-10 Sephadex desalting column (Sigma–Aldrich).  
 
2.6. Post-loading of protein onto nanoparticles 
The loading of different nanoparticles with OVA was performed by mixing both components 
in solution at room temperature for 1h at an OVA/NP ratio of 1/10 or 3/10 (w/w).  
 
2.7 Characterization of the association of protein with NP 
The protein association of OVA with NP was evaluated using native polyacrylamide gel 
electrophoresis (native PAGE). Formulations were supplemented with a non-denaturing buffer 
(Tris–HCL 125 mm (pH 6.8), 10% glycerol and 0.06% bromophenol blue) and run on a 10% 
acrylamide-bisacrylamide gels stained by the silver nitrate method. Gels were scanned and 
quantify using the ImageJ software. Under these conditions, non-associated protein enters the 
gel while NP-associated protein does not. 
 
PART II: RESULTS 
111 
2.8. Protein delivery by nanoparticles in cells 
Cells were plated for 3 days in 6-well plates and treated for different times (0.5, 2, 6, and 24h) 
with 1µg of OVA-FITC either in a free state, or associated with nanoparticles at a 1/10 (w/w) 
ratio. The cells were then analyzed by flow cytometry with a BD Accuri™ C6 CFlow Sampler 
flow cytometer (BD Bioscience, USA). 
3.  Results 
3.1. Fabrication and protein association characterization 
The five types of nanoparticles were synthesized and their size and zeta potential were 
characterized (Figures 1 and 2). The 2 anionic nanoparticles prepared: anionic PLGA NP 
(PLGA(-)) and anionic liposome (Lipo(-)), exhibited a zeta potential of -23 and -52mV, 
respectively. Cationic nanoparticles were also prepared by covering nanoparticles with 
chitosan. PLGA(+) had a zeta potential of +38mV while Lipo(+) had a zeta potential of 
+25mV. NPL are porous, zwitterionic nanoparticles with a cationic surface and an anionic, 
porous core – they therefore appeared as cationic nanoparticles with a zeta potential of +45mV. 
The nanoparticles all possessed a Z-average size ranging from 57 to 161 nm. In addition, all 
these nanoparticles were spherical in shape [8, 23, 24]. 
 
Figure 1. Representation of the 5 types of nanoparticles. Cross sectional view showing the surface 
and the core of the nanoparticles. NPL: zwitterionic nanoparticle (cationic maltodextrin-based porous 
nanoparticle with anionic lipid core), PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, PLGA(-
) : anionic PLGA nanoparticle, Lipo(+): cationic (chitosan-coated) liposome, Lipo(-): anionic liposome.  
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Figure 2. Size and zeta potential of the 5 types of nanoparticles and their formulations with OVA. The 
nanoparticles’ size (left) and the zeta potential (right) of ovalbumin (OVA), the 5 types of nanoparticles and 
their formulations with OVA at a mass ratio of 1/10 (OVA/NP), were measured by dynamic light scattering 
and electrophoretic mobility, respectively. The graphs represent the mean +/- SD of three independent 
measurements. NPL: zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle with 
anionic lipid core), PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, PLGA(-): anionic PLGA 
nanoparticle, Lipo(+): cationic (chitosan-coated) liposome, Lipo(-): anionic liposome. 
The OVA appeared as a 6nm-protein with a negative surface charge of -15mV. The association 
of OVA to NPL did not change the nanoparticles’ size and only a slight decrease (-8mV) of 
the zeta potential was observed, meaning that proteins were associated inside these porous 
nanoparticles. The formulations OVA/PLGA(+) and OVA/PLGA(-) showed a slight decrease 
of their respective surface charges (+30mV and -18mV) and both PLGA formulations retained 
their size. Finally, the OVA formulations with the liposomes increased their size by around 
20nm and drastically modified the zeta potential : 0mV for Lipo(+) and -10mV for Lipo(-). 
This suggested an association of OVA with the 5 types of nanoparticles and this was confirmed 
by native PAGE (Table 1). At a mass ratio OVA/NP of 1/10, nanoparticles with a positive 
surface charge associated 90% of the OVA, and even 100% for NPL. By contrast anionic 
nanoparticles associated only 10% (Lipo(-)) to 50% (PLGA(-)) of the OVA. To highlight 
differences in the protein loading capacity of the nanoparticles, particularly the cationic NP, a 
mass ratio OVA/NP of 3/10 was also examined. NPL still associated 100% of the OVA. The 
loading reached 70% for PLGA(+) but fell to only 10% for Lipo(+). Regarding the anionic 
nanoparticles, the loading of OVA with the mass ratio 3/10 was null for Lipo(-) and 20% for 
PLGA(-). 
Hence, the ratio of 1/10 (w/w) of the OVA/NP was used in the following formulation 
experiments. 
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Formulations 
OVA/NP ratio (w/w) 
1/10 3/10 
OVA/NPL 100% 100% 
OVA/PLGA(+) 90% 70% 
OVA/PLGA(-) 50% 20% 
OVA/Lipo(+) 90% 10% 
OVA/Lipo(-) 10% 0% 
 
Table 1. Loading efficacy of OVA with the 5 types of nanoparticles. Native PAGE were run with the 
OVA/NP formulations at 1/10 and 3/10 mass ratios and non-associated proteins were determined by gel 
densitometry. The percentages of association with the NP were calculated by comparison with the 100% 
OVA reading and are reported in the table. NPL: zwitterionic nanoparticle (cationic maltodextrin-based 
porous nanoparticle with anionic lipid core), PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, 
PLGA(-): anionic PLGA nanoparticle, Lipo(+): cationic (chitosan-coated) liposome, Lipo(-): anionic 
liposome. 
 
3.2. Comparison of the protein delivery by nanoparticles in H292 airway epithelial cells 
Epithelial tissue covers the outside of the body and lines organs and cavities. The first barriers 
that nanoparticles face once nasally instilled are primarily the airway epithelial cells and some 
specialised cells such as microfold (M) cells [25, 26]. We evaluated the delivery of protein by 
the 5 types of nanoparticles into H292 airway epithelial cells using flow cytometry for 24h 
[27]. The endocytosis of OVA alone increased for 2h then constantly decreased until 24h, 
where intracellular OVA was no longer detectable. Nevertheless, even the maximum amount 
of endocytosed OVA was still low. OVA delivery by NPL was rapid and 14 times more 
efficient than protein alone at 2h, whereupon the delivery reached a steady-state. The kinetics 
of protein delivery by PLGA(+) was comparable to those of the PLGA(-) until 6h then a 
decrease was observed. PLGA(-) showed a similar profile to NPL (an initial and rapid protein 
delivery within 2h followed by a steady-state), but were only 3 times more efficient than OVA 
alone. The delivery of OVA by Lipo(+) was firstly as efficient and quick as PLGA NP then 
decreased after 2h. With Lipo(-), the OVA delivery increased during the first 2h, being roughly 
half as efficient as Lipo(+), then decreased to reach a similar value to the OVA alone. Finally, 
at 24h, NPL had delivered OVA 10 times more efficiently than PLGA(+) and Lipo(+) and 4 
times more than PLGA(-) while OVA alone or associated with Lipo(-) was not detectable 
PART II: RESULTS 
 114 
(Figure 3). Together, all the 5 types of nanoparticles delivered OVA into the cells but major 
differences in the kinetics of the delivery and in its efficiency were highlighted.  
 
Figure 3. Protein delivery by the 5 types of nanoparticles in H292 airway epithelial cells. Ovalbumin 
(OVA) was labeled with fluorescein and cells were treated with OVA (protein, grey line) or OVA/NP 
formulations (1/10 w/w ratio). The kinetics of protein delivery by the 5 types of nanoparticles (or the protein 
endocytosis for non-formulated OVA) were evaluated by flow cytometry. Representative graph of three 
independent experiments. NPL: zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle 
with anionic lipid core), PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, PLGA(-): anionic PLGA 
nanoparticle, Lipo(+): cationic (chitosan-coated) liposome, Lipo(-): anionic liposome, Control : untreated 
cells.  
 
3.3. Comparison of the protein delivery by nanoparticles in SRDCs dendritic cells 
Nasal- or nasopharynx- associated lymphoid tissue (NALT) represents the immune system of 
nasal mucosa and is a part of mucosa-associated lymphoid tissue. The NALT is specifically 
enriched in dendritic cells (DCs) [28-30] that pick up the antigens from M-cells, or directly 
through the epithelial layer, for subsequent antigen presentation and immune response 
triggering [31]. OVA alone was slowly and weakly endocytosed for 2h before reaching a 
steady-state. By comparison, the 5 types of nanoparticles showed a rapid initial delivery of 
OVA into DC during the first 30 min. At 30 min, NPL displayed the most efficient protein 
delivery (235 times more than OVA) followed by Lipo(-) (x90), Lipo(+) (x60), PLGA(-) (x20) 
then PLGA(+) (x15). After 30 min, the 5 types of nanoparticles behaved differently: NPL and 
Lipo(-) reached a steady-state, while protein kept being delivered until 6h for the other NP. At 
24h, NPL had delivered OVA 16 times more efficiently than non-associated protein, while the 
4 other types of nanoparticle showed an increase limited to x4 for PLGA(-) to x7 for PLGA(+), 
while liposomes had only intermediary values (Figure 4). This comparison meant that NPL 
was once more the most efficient nanoparticle-based protein delivery system into DC. 
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Figure 4. Protein delivery by the 5 types of nanoparticles in SRDC dendritic cells. Ovalbumin (OVA) 
was labeled with fluorescein and cells were treated with OVA (protein, grey line) or OVA/NP formulations 
(1/10 w/w ratio). The kinetics of protein delivery by the 5 types of nanoparticles (or the protein endocytosis 
for non-formulated OVA) were evaluated by flow cytometry. Representative graph of three independent 
experiments. NPL: zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle with anionic 
lipid core), PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, PLGA(-): anionic PLGA nanoparticle, 
Lipo(+): cationic (chitosan-coated) liposome, Lipo(-): anionic liposome, Control : untreated cells.  
 
 
3.4. Comparison of the protein delivery by nanoparticles into THP-1 macrophages  
As the presence of macrophages in the airways has been documented [32], we examined the 
ability of the 5 types of nanoparticles to deliver proteins into macrophages. Compared to the 
other cell types in this study, the kinetics of protein delivery (and endocytosis of OVA alone) 
were more homogenous in THP-1, though the rate slightly decreased after 6h. After 30 min, 
the delivery of OVA by the 5 types of nanoparticles was equivalent to the endocytosis of OVA 
alone. After 2h, differences appeared and remained constant until 24h, when NPL were 3 times 
more efficient than OVA alone while the 4 other types of nanoparticles were only by 1.5-1.7 
times better at delivering OVA into THP-1 (Figure 5). This again demonstrated that NPL was 
the most efficient nanoparticle in delivering OVA into macrophages. 
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Figure 5. Protein delivery by the 5 types of nanoparticles into THP-1-derived macrophages. Ovalbumin 
(OVA) was labeled with fluorescein and cells were treated with OVA (protein, grey line) or OVA/NP 
formulations (1/10 w/w ratio). The kinetics of protein delivery by the 5 types of nanoparticles (or the protein 
endocytosis for non-formulated OVA) were evaluated by flow cytometry. Representative graph of three 
independent experiments. NPL: zwitterionic nanoparticle (cationic maltodextrin-based porous nanoparticle 
with anionic lipid core), PLGA(+): cationic (chitosan-coated) PLGA nanoparticle, PLGA(-): anionic PLGA 
nanoparticle, Lipo(+): cationic (chitosan-coated) liposome, Lipo(-): anionic liposome, Control : untreated 
cells.  
 
 
4. Discussion 
The vast majority of pathogens invade at the mucosal surfaces in the body and mucosal 
vaccination is a promising strategy for the induction of protective, mucosal-specific immunity. 
The nasal route is advantageous because of the presence of the relatively accessible nasal 
associated lymphoid tissue (NALT). However, nasally administered antigens are quickly 
cleared from nasal mucosal surfaces and delivery systems that protect antigens from this rapid 
clearance are needed [2, 33]. The challenge is developing a delivery system that protects 
antigens from clearance and degradation, and improves their delivery to cells [34]. An 
increasing number of nanocarriers have been used in nasal vaccine applications such as 
micelles, liposomes, polysaccharide nanoparticles and PLGA nanoparticles [5]. Nonetheless, 
no comparison of the vaccine efficiency of these nanocarriers has yet been published. 
We previously compared the in vivo nasal residence time and the endocytosis of 5 types of 
nanoparticles: the zwitterionic NPL, cationic and anionic PLGA NP, cationic and anionic 
liposomes, and showed that zwitterionic NPL had the longest residence time and were the most 
efficiently endocytosed by the 3 cell lines used in this study (Residence time and uptake of 
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zwitterionic nanoparticles in the nasal mucosa: comparison with anionic and cationic 
nanoparticles. Le et al., submitted publication). Here we compared the antigen loading and the 
cellular delivery efficacy of these 5 types of nanoparticles, using OVA as a model protein.  
Many studies have evaluated the protein loading efficiency of nanocarriers as a priority 
condition for their use as a vaccine delivery system. Accordingly, we compared the protein 
loading efficacy of the 5 types of NP. Only the zwitterionic NPL showed 100% of protein 
loading at mass ratios of 1/10 and 3/10 (OVA/NP). PLGA NP and liposomes did not reach this 
level of protein loading [35-37] (Figure 1 and Table 1). This is likely due to the structure of 
the nanoparticles: NPL are porous and the surface of interaction with protein is larger than non-
porous nanoparticles like PLGA NP and liposomes where protein interactions are limited to 
the nanoparticles’ surface. With liposomes, we observed an increase of the size and a decrease 
of the zeta potential that approached the zeta potential of the free protein, clearly demonstrating 
an association of OVA with these NPs at their surface. This association reached saturation since 
increasing the OVA/NP ratio led to a decrease of efficiency (Table 1). To increase the protein 
loading, OVA should have been entrapped in the liposomes as previously described but the 
loading efficiency remains low [35, 38] and efforts to increase the protein loading efficiency 
lead to size heterogeneity incompatible with pharmaceutical applications [39]. With PLGA NP, 
we did not observe large modifications of the size and the zeta potential when associated with 
proteins. However, PLGA NP are spherical particles [24] and it is likely that the proteins only 
interact with the nanoparticles’ surface. Indeed, the insertion of a protein during the synthesis 
of PLGA NP might denature its native form [40, 41]. Therefore, the post-loading method is the 
preferred process to associate proteins to PLGA NP.  
We then evaluated the protein delivery in 3 cell lines representative of the airway mucosal 
tissue: epithelial cells, dendritic cells and macrophages. To keep consistency, the same amount 
of nanocarriers was used all along the comparison. In these cell lines, all of the 5 types of 
nanoparticles delivered the OVA protein. However, the zwitterionic NPL was much more 
efficient in this regard than the 4 other types of nanoparticles tested. The difference appeared 
in the first 30 minutes for epithelial and dendritic cells and after only 2h in macrophages. This 
implies that using NPL for protein delivery will not require an overly long exposure time of 
the nanocarrier with cells or tissues (Residence time and uptake of zwitterionic nanoparticles 
in the nasal mucosa: comparison with anionic and cationic nanoparticles. Le et al., submitted 
publication)[8, 10]. 
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The kinetics of protein delivery by the 5 types of nanoparticles varied between the cell types, 
and especially in macrophages. In these cells, one cannot preclude that non-specific 
phagocytosis and pinocytosis occurred in combination with endocytosis, leading to a constant, 
non-saturated protein delivery over 24h. This is supported by the protein delivery by PLGA 
NP and the liposomes that were very similar to the protein endocytosis (1.5 time increase). 
To our knowledge, this is the first study to compare several types of nanocarriers currently 
under investigation for the delivery of proteins in airways. We have previously shown that 
intranasal administration of a total extract of Toxoplasma.gondii loaded into NPL afforded 
protection against this parasite by oral challenge in both chronical and congenital contexts [8, 
9], and that NPL also increased the nasal residence time of proteins [10]. Taken together with 
the current study, these data underline the potential for NPL as a nanocarrier for the delivery 
of nasally-administered vaccines. 
 
Conclusion 
The development of a nasally-administered, nanoparticle-based vaccine requires nanocarriers 
capable of being loaded with antigens and that they enter the mucosal cells in order to deliver 
these antigens into cells. Among the 5 types of nanoparticles tested here, our comparison 
demonstrates that zwitterionic, porous NPL nanoparticles are the best candidate for protein 
loading and protein delivery. Studies should now be performed in vivo, taking appropriate 
account of the specific biological environment.  
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Comments 
Cationic porous maltodextrin based-NPs (NPL) have received particular interest for the 
delivery of macromolecules via nasal route. In previous studies, we have already demonstrated 
that amongst the 5 nanoparticles tested, NPL owns the longest nasal residence time, higher 
capacity of cellular uptake and protein delivery so this delivery system was used as nano 
delivery system to develop an intranasal influenza vaccine.  
 
In the next study, we evaluated the ability of nanoparticle-base influenza vaccine to protect 
animals from transmission of the virus to naïve animals. 
The immunogenicity of intranasal vaccine formulations made of split Udorn virus alone or 
admixed with the nanoparticles NPL and/or CTA1-DD (a demonstrated mucosal adjuvant) was 
evaluated in mice. The viral antigen loading and delivery by NPL were performed in nasal 
mucosal cell models. Moreover, the immunogenicity and the inhibition of the virus 
transmission protective efficacy were examined. 
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Abstract 
 
Influenza vaccines administered intramuscularly exhibit poor mucosal immune responses at 
the respiratory mucosa which is the prime site of the infection. Intranasal vaccination is a 
potential another route for vaccine delivery which has been demonstrated as effectively 
inducing protective immune responses in both systemic and mucosal compartments.  The major 
influenza vaccines are based on subunit/split influenza vaccines which is relatively low 
immunogenicity and thus required proper adjuvant and/or delivery vehicle for immunogenicity 
enhancement. Herein we demonstrated a stronger protection against influenza virus by split 
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Udorn virus co-delivered intranasally with zwitterionic nanoparticles (NPL) carrying the 
mucosal adjuvant, CTA1-DD. NPL were firstly evaluated for their ability to load and deliver 
antigens into nasal mucosa cells. Data showed that at mass ratio 1:5, all the antigens were 
loaded into NPL. Moreover, NPL significantly enhanced virus delivery into three different cell 
lines, airway epithelial cells, macrophages and dendritic cells. Compared to the flu virus 
vaccination, intranasal vaccination with NPL associated split Udorn was slightly enhanced the 
specific humoral immune response thus decreased the virus infection and the addition of 
CTA1-DD greatly improve this effect. Furthermore, mice received NPL carrying split Udorn 
and/or CTA1-DD did not spread virus to naïve mice. These results demonstrate an efficient 
intranasal vaccine delivery system utilizing a combination of a porous NPL and mucosal 
adjuvant CTA1-DD to achieve a robust influenza virus protection. 
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1. Introduction 
Influenza is a highly contagious devastating respiratory disease which causes public health and 
socio-economic problems worldwide [1]. Intranasal route for influenza vaccine administration 
has become promising strategy. This route is needle-free and painless. Moreover, antigens 
activated the immune cells at the nasal-associated lymphoid tissue homing at the respiratory 
immune effector sites including larynx- and bronchus-associated lymphoid tissues [2] that exert 
their defensive activities at the prime sites of influenza virus infection. Furthermore, the 
vaccine antigens applied intranasally may also reach the blood circulation and the systemic 
immune response is stimulated in spleen and peripheral lymph nodes [3]. Thus, both mucosal 
and systemic immune responses can be expected after the intranasal immunization of 
appropriate vaccine formulation [4].  
Currently available influenza vaccines are made of either inactivated whole viruses or the virus 
subunit/split products [5]. The inactivated vaccine is highly immunogenic but often cause 
adverse reactions particularly in infants and children [6] while the subunit/split vaccines confer 
limited immunogenicity and require either high antigenic dose or a booster dose [7, 8]. Cholera 
toxin (CT) bind to ganglioside receptors present on enterocytes, DCs, macrophages as well as 
B and T-lymphocytes [9, 10]. It can induce antigen-specific sIgA and serum IgG antibody 
responses and when co-administered with a protein antigen it can potentially enhance the 
mucosal and serum antibody response to induce long-term memory to the antigen. Due to its 
high degree of toxicity, CT is not considered as a useful adjuvant although efforts have been to 
limit its toxicity [11]. Consequently, non-toxic derivative of CT, termed CTA1 was developed 
[12] and to improve its adjuvant property, CTA1 has been linked to the c-terminal region of a 
dimer of the D-fragment of the protein A from Staphylococcus aureus (DD). DD binds the Fc 
and Fab fragments of immunoglobulin present on B cells, thereby allowing binding of the 
complex CTA1-DD to the B-cell receptors [12-14]. CTA1-DD has adjuvant effects comparable 
to those of CT, and it enhances a wide range of immune responses following intranasal 
immunizations, including antibody, CD4+ T cell and cytotoxic CD8+ T cell responses [15]. 
Candidate vaccines containing CTA1-DD have been shown to enhance immunity to HIV-1, 
Chlamydia trachomatis, H. pylori, M. tuberculosis, rotavirus and influenza A virus [16].  
Mucoadhesive nanodelivery systems created from starch, hyaluronic acid and chitosan offer a 
significant potential for the development of mucosally administered antigens [17-19]. Such 
carriers can be designed to prolong their residence time in the nasal cavity [20-22] to protect 
PART II: RESULTS 
 127 
entrapped antigens against degradation, to enhance uptake by M-cells, and to target the antigens 
more specifically to antigen presenting cells (APCs). Zwitterionic porous maltodextrin based-
NPs (NPL) have received particular interest for the delivery of macromolecules via nasal route. 
Data showed that NPL increased the nasal residence time of a carried protein in the first layer 
of the nasal mucosa cells after nasal administration [22]. Furthermore, zwitterionic NPL has 
been successfully used as a nanocarrier for mucosal vaccines [19, 23].  
In this study, we evaluated immunogenicity of intranasal vaccine formulations comprised of 
split Udorn virus alone or admixed with the nanoparticles NPL and/or CTA1-DD (a 
demonstrated mucosal adjuvant) [24]. The viral antigen loading and delivery by NPL were 
performed in nasal mucosal cell models. Moreover, the immunogenicity and the inhibition of 
the virus transmission protective efficacy in a mouse model were examined. 
2. Materials and Methods 
2.1. Animals  
Six to eight weeks old BALB/c and DBA/2J mice were purchased from Janvier Laboratories 
(Strasbourg, France). Mice were kept under specific-pathogen-free conditions in the local 
animal facility. All experiments were performed in accordance with the guidelines of the 
Federation for Laboratory Animal Science Associations (FELASA) and the national animal 
welfare body. Experiments were in compliance with the German animal protection law and 
were approved by the local animal welfare committee.    
2.2. NPL synthesis  
NPL were prepared as described previously [25]. Maltodextrin was dissolved in 2N sodium 
hydroxide with magnetic stirring at room temperature. To introduce the positive charge, 
epichlorhydrin and GTMA were added to make cationic polysaccharide gels. The gels were 
then neutralized with acetic acid and sheared with a high-pressure homogenisor (LM 20, 
Microfluidics, France). The nanoparticles thus obtained were purified by tangential flow ultra-
filtration (AKTA flux 6, GE Healthcare, France) using a 750 kDa membrane (GE Healthcare, 
France) and mixed with DPPG above the gel-to-liquid phase transition temperature to produce 
NPL. 
2.3. Virus preparation 
Udorn virus were inactivated following incubating with β-propiolactone (β-BPL) for 16 hours 
at 4 ℃, then subsequently incubated at 37℃ for 2 hours to facilitate hydrolysis of β-BPL. 
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Inactivated virus were stored at -80℃. To split Udorn virus, the virus was incubated with 10% 
Trixton X-100. 
2.4. Protein labeling and loading into nanoparticles 
The split Udorn virus was covalently labeled with FITC according to the following protocol: 
FITC was added to split Udorn virus, solubilized in 0.1 M bicarbonate buffer (pH 8.3), and the 
solution was mixed for 6 h in the dark at room temperature. The labeled virus was purified by 
gel filtration on a PD-10 Sephadex column. The concentration of the labeled protein was then 
evaluated using the Micro BCA Protein Assay Kit following the supplier's instructions. 
Proteins were post-loaded with pre-made sterile NPL by mixing both components at RT for 1 
h obtaining 1:5 (w/w) protein:NPL formulations. 
2.5. Characterization of the nanoparticle and formulations  
The hydrodynamic diameter (Z-average) of nanoparticles was measured by dynamic light 
scattering in pure water. The zeta potential was measured by electrophoretic mobility in pure 
water. Measurements were carried out in triplicate using a zetasizer nanoZS (Malvern 
Instruments, France). 
2.6. Characterization of the association of proteins/split virus to NPL  
The protein association of split Udorn virud to NP was evaluated using native polyacrylamide 
gel electrophoresis (native PAGE). Formulations were supplemented with a non-denaturing 
buffer (Tris–HCL 125 mm (pH 6.8), 10% glycerol and 0.06% bromophenol blue) and run on a 
10% acrylamide-bisacrylamide gels stained by the silver nitrate method. Gels were scanned 
and quantify using the ImageJ software. In these conditions non-associated proteins enter the 
gel while NP-associated proteins do not.  
2.7. Split Udorn delivery by NPL 
H292 and THP-1 cells were maintained in RPMI supplemented with 10 % heat inactivated 
foetal calf serum (FCS), 100 U/mL Penicillin, 100 mg/mL streptomycine and 1% L-glutamine 
at 37oC in humidified 5% CO2 atmosphere. SRDC were cultured in IMDM supplemented with 
5% heat inactivated FCS, penicillin (100 U/ml)/streptomycin (100 mg/ml), L-glutamine 
(2 mM) at 37°C in humidified 5% CO2 atmosphere.  Cells were seeded 3 days before treatment 
at a density of 1.5 x 105 cells per well in 8-well glass chamber slides (LabTekII, Thermo 
Scientific Nunc Lab) or 5 x 105 cells per well in 6-well plates. 
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Cells were plated for 3 days in 6-well plates and treated for 3 h with 1µg of split Udorn-FITC 
either free or associated to nanoparticles at a 1/5 ratio (w/w). The cells were then collected by 
trypsin analyzed with flow cytometry with a BD Accuri™ C6 CFlow Sampler flow cytometer 
(BD Bioscience, USA). 
2.8. Vaccination of mice 
Six to eight weeks old female BALB/c mice (purchased from Janvier Labs) were immunized 
with 10 µl (5 µl per nostril) containg 1 µg of split Udorn alone or admixed with the 
nanoparticles NPL and/or CTA1-DD by intranasal route (i.n.) for three times, 10 days apart. 
Ten days after the first and the second boost immunizations, serum samples were collected for 
measuring the levels of anti-HA specific antibody by ELISA. 
2.9. Detection of anti-Udorn antibodies in serum 
To determine Udorn-specific antibody titers, microtiter plates (MaxiSorp, Nunc) were coated 
with split Udorn virus, and incubated overnight at 4°C. After washing, the plates were blocked 
for 2h with 5% BSA in PBS. After blocking, a series of 1/3 dilutions of the different serum 
samples were loaded on the peptide-coated plates. The bound antibodies were measured with 
a horseradish peroxidase-labeled antibody directed against mouse IgG diluted 1/2000 (Thermo 
Fisher Scientific, USA). After washing, the microtiter plates were incubated for 20 min with 
TMB substrate (Tetramethylbenzidine, Life technologies). The reaction was stopped by adding 
0.5M H2SO4 and absorbance was measured at 450 nm. The endpoint titers are defined as the 
highest dilution resulting in an O.D. value two-fold that of background (pre-immune serum). 
2.10. Virus transmission study 
Six to eight weeks old female BALB/c mice were immunized with 10µl containing 1 µg of split 
Udorn, split Udorn/NPL, split Udorn/CTA1-DD/NPL and OVA/NPL by intranasal route for 
three times 10 days apart. Five weeks after the second immunization all immunized BALB/c 
mice were infected intranasally with 20 µl of 3x104 PFU H3N2 Udorn virus 
(A/Udorn/307/1972 (H3N2)) and mice were used as index animals. At 24 h post infection index 
mice were one to one co-housed with uninfected 6-weeks-old DBA/2 mice as contact mice in 
a clean cage. The snouts and the lungs of the index and contact mice were collected on day 4 
post co-housing and viral loads were determined by viral titration assay. 
2.11. Viral titration  
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MDCK cells were maintained in DMEM (Sigma Aldrich), 10% FCS (Biochrom KG, Germany) 
medium, kept at 37 °C in 5% CO2 and passaged twice weekly using trypsin (Sigma Aldrich, 
Sweden). MDCK cells were grown to a confluent cell layer in 12-well plates for plaque assay. 
Snouts and lungs were homogenized in 800 µl cold PBS using FastPrep® spheres, tubes and 
homogenizer for 3 times at 6.5 m/s for 20s. Afterwards samples were centrifuged for 10 min at 
9,000 rpm at 4°C and supernatants were performed a 10-fold dilution in OptiMEM (Thermo 
Fisher Scientific) supplemented with 0.3% BSA. A volume of 450 µl diluted samples were 
added on confluent MDCK cells for 2h at RT. After removing the inoculum, cells were overlaid 
with 1.5% Avicel (FMC BioPolymer) in DMEM supplemented with 10% BSA for 72h. Cells 
were then fixed with 3.7 % formaldehyde and stained with 1% crystal violet solution for 15 
min. Plaques were used to calculate virus titers which is measured in plaque-forming units 
(pfu) per ml. 
2.12. Statistics 
Data were analyzed by one-way and two-way ANOVA using GraphPad Prism version 6.01 for 
Windows (GraphPad Software, San Diego, CA).  
 
RESULTS 
1. Characterization of NPL and formulations  
NPL is about 38 nm in size while split Udorn is 111 nm. The combination of the split Udorn 
with NPL at mass ratio 1:5 created the formulation with the size as the NPL alone. The binding 
of protein antigen was further confirmed by zeta potential. NPL carried positive charge, about 
38 mV and split Udorn owned the negative charged (-20 mV). Interestingly, the antigen 
associated with nanoparticles exhibited a positive charge implying that split Udorn was 
sucessfully absorbed inside the NPL (Figure 1).  
We also loaded NPL with the split Udorn and CTA1-DD. The split Udorn/CTA1-DD/NPL 
(mass ratio 1:5) showed a size as small as NLP. Lower or decreasing PDI after incorporation 
protein antigen with NPL emphasized the homogenous of the formulation solutions due to 
absorbance protein antigen inside NPL. Moreover, the zeta potential remianed positive after 
combined antigens into NPL confirmed the sucessful loading (Figure 1). 
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In addition to size and zeta study, native PAGE was performed to verify the loading of protein 
antigens into NPL. Split Udorn was completely associated into NPL as no free protein was 
observed while the combination of two different protein antigens into NPL resulted in 90% of 
loading efficacy. Data strongly demonstrated that all protein antigens were associated into NPL 
at mass ratio 1:5 of the formulation (Figure 2 and Table 1). 
Figure 1: Size, PDI and zeta potential of NPL, split Udorn, CTA1-DD and the related 
formulations. The size (left), PDI (middle) and the zeta potential (right) of NPL, split Udorn, CTA1-
DD, split Udorn/NPL, split Udorn/CTA1-DD/NPL were measured by dynamic light scattering and 
electrophoretic mobility, respectively. The graphs represent the mean +/- SD of three independent 
measurements.  
 
Figure 2: Characterization of the split Udorn/NPL and split Udorn/CTA1-DD/NPL. The 
association of antigens into NPL was characterized by native polyacrylamide gel (PAGE) 
electrophoresis using formulation at 1:5 (w:w) ratios. Unbound proteins were revealed by silver nitrate 
staining. 
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Formulations Percentage of loading 
Split Udorn /NPL 100% 
Split Udorn + CTA1-DD/NPL 90% 
Table 1: Loading efficacy of split Udorn and split Udorn/CTA1-DD with NPL. The percentages 
of association to the NP were calculated over the 100% protein alone input and reported on the table. 
 
3. Cellular delivery split Udorn by NPL 
We investigated the delivery of split Udorn by NPL into 3 different cell lines that dominated 
in nasal mucosa: airway epithelial cells, macrophage and dendritic cells. Data showed that 
associated split Udorn virus into NPL significantly increased the uptake of split Udorn by H292 
airway epithelial cells, THP-1 macrophage and SRDC dendritic cells. The deliverywas 
increased 4 times in H292 and SRDC while it was 5 times in the case of THP-1 macrophages 
(Figure 3).  
 
Figure 3: Split Udorn delivery by NPL in H292 airway epithelial cells, SRDC dendritic 
cell and THP-1 macrophage. Split Udorn was labeled with fluorescein and cells were treated 
with split Udorn or split Udorn/NPL (1/5 mass ratio). The protein delivery by NPL were 
evaluated by flow cytometry after 3 h of incubation. Statistical analysis: Two-way ANOVA; 
asterisks indicate p-values: p < 0.0001 (****) and p<0.001 (***). 
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4. Udorn-specific antibody titers after intranasal vaccination 
To investigate the suitability of vaccines for intranasal vaccination, we compared the serum 
responses of mice after intranasal vaccination. Mice were immunized intranasally with split 
Udorn alone, split Udorn loaded NPL, or split Udorn loaded NPL conjugated with CTA1-DD. 
The levels of HA-specific serum IgG of mice vaccinated with different formulations were 
shown in Figure 4. The Udorn-specific IgG antibody titers in sera of immunized mice with 
were significantly increased after 2 booster immunizations except the negative control 
OVA/NPL. A mixture of split Udorn and NPL greatly enhanced the Udorn-specific IgG 
antibody titers in sera of mice as compared to the OVA/NPL group of control. Moreover, split 
Udorn/NPL have a trend to enhance the secretion of IgG levels as compared to mice vaccinated 
with split Udorn. Importantly, the second booster induced a further raise in the IgG levels of 
mice vaccinated with split Udorn/CTA1-DD/NPL than those achieved split Udorn. Altogether, 
these results underlined the immunostimulating effect of NPL and CTA1-DD upon intranasal 
administration. 
 
Figure 4: Serum Udorn specific IgG titers from vaccinated immunized mice.  Udorn specific IgG 
titers were measured by ELISA assay in serum from mice immunized i.n. with split Udorn or split 
Udorn/NPL or OVA/NPL or split Udorn/CTA1-DD/NPL. Statistical analysis: Two-way ANOVA; 
asterisks indicate p-values: p<0.05 (*). The hash indicate difference between OVA/NPL to other 
groups; p-values: p<0.0001 (####). 
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The snout and lung are the local microenvironment in which primary immune protection 
against respiratory pathogens such as influenza virus takes place. For this reason, we 
determined whether intranasal administration of all vaccines was sufficient to induce mucosal 
immunity and protection against influenza virus infection. We challenged immunized mice 
intranasally with 3*104 PFU/animal of H3N2 Udorn virus 2 weeks after the last of three 
immunizations. Snout and lung viral titers were determined 4 days after challenge. Virus 
transmission was assessed by monitoring the influenza virus titres in the snouts and lungs of 
both index and contact mice. 
Mice immunized with split Udorn/NPL or split Udorn/CTA1-DD/NPL exhibited significantly 
lower viral titers in the snout as compared to OVA/NP group. We also found more reduced 
viral titer in the snouts of the contact mice co-housed with index mice immunized with split 
Udorn/NPL. However, protection against infection in the index mice was not significant 
different between split Udorn alone and split Udorn/NPL. Association of CTA1-DD to the 
formulation split Udorn/NPL significantly enhanced the virus clearance in both snouts and 
lungs of index mice. In contrast, immunization with split Udorn was not likely to block virus 
infection (Figure. 5a). 
To determine whether the reduction of viral titer in index mice by split Udorn/NPL with or 
without CTA1-DD could limit virus transmission, index mice were co-housed with contact or 
naïve mice. Though mice vaccinated with split Udorn were poorly protected from virus 
infection, they were protected from virus transmission. Importantly, mice receiving split 
Udorn/NPL with or without CTA1-DD showed 100% of virus transmission prevention 
(Figure. 5b).  
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Figure 5: Viral transmission from vaccinated immunized index mice. A) The viral titers in index 
mice’s snout and lungs B) The viral titers in contact mice’s snout. Statistical analysis: One-way or 
two-way ANOVA; asterisks indicate p-values: p<000.1 (****), p<0.001, p < 0.01 (**) and p<0.05 
(*).  
Discussion 
Zwitterionic nanoparticles (NPL) are composed of a cationic maltodextrin matrix enclosing 
lipid in their core. NPL are highly endocytosed by airway epithelial cells and significantly 
improve protein delivery in cells [22]. Furthermore, NPL based vaccine protects animals 
against chronic & congenital infection [19, 23]. Providing evidence of the potential for NPL to 
be excellent nanoparticle-associated vaccines against a wide range of pathogens. CTA1-DD 
has been used for mucosal vaccines [16]. CTA1"DD was originally developed to target the B 
cell receptor, but its adjuvant effect also depends on DCs and can enhance the priming of CD4+ 
T cells in a complement-independent manner [24, 26]. This study aimed to evaluate the 
combined effect of NPL and CTA1-DD as vaccine delivery system and mucosal adjuvant for 
influenza vaccine respectively. 
The positive charged and hydrophobic of NPL facilitate electrostatic interactions between NPL 
and the negatively charged antigen. Moreover, their porous structure allow NPL to be loaded 
with high amount of antigens [19]. The antigen of split Udorn and CTA1-DD used in our study 
were shown to remain largely associated with the NPL showing through Native PAGE (Fig 1 
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and 2, Table 1). Importantly, NPL can very efficiently delivered split Udorn in 3 main cell lines 
of the nasal mucosa (Fig 3). The improving uptake and processing of the encapsulated antigen 
by APCs make NPL an ideal nano delivery systems.  
In vivo study showed that intranasal administration of a split Udorn/NPL slightly enhance 
Udorn specific IgG antibody response as compared to the mice received split Udorn alone. 
Adding CTA1-DD into the split Udorn/NP formulation significantly improve the level of 
Udorn specific IgG to level greater than those achieved with split Udorn alone.  
In the case of infections with respiratory viruses such as influenza, particular attention should 
be paid to the snout and lung as the targets for mucosal immunization because they are the 
entry points for respiratory viruses [27]. In this study, we compared our influenza vaccines in 
term of virus inhibition through viral titer in snout and lungs of infected mice. Correlated with 
the secretion of Udorn specific IgG, mice receiving split Udorn/NPL showed a trend to 
decrease virus replication in snouts and lungs of index mice while those achieved split Udorn 
seem could not be exhibited the protection from virus infection. Additional effect was found 
when CTA1-DD was employed. Our data demonstrated that the using an adjuvanted nano 
delivery system (CTA1-DD + NPL) evoked strong effect in virus clearance in snout and lungs 
of infected mice. While mice immunized with split Udorn could not completely inhibit virus 
spread, mice receiving split Udorn/NPL showed 100% block virus transmission. It is not 
surprising to observe mice achieved split Udorn/CTA1-DD/NPL completely blocked the 
transmission of Udorn virus to contact mice. These results demonstrated that even though the 
nanocarrier can enhance the vaccine efficacy, it is not sufficient to induce strongest immune 
response. Using an adjuvant is necessary to create significant protection against the influenza 
virus. It was demonstrated that recombinant HA nanoparticle-based influenza vaccine required 
a saponin-based adjuvant in order to induce protective responses of intranasal vaccine against 
influenza A(H3N2) strains [28]. Polyethylene glycol (PEG) modified liposomes containing 
CRX-601 adjuvant and methylglycol chitosan increased the murine sublingual immune 
response to influenza vaccination [29]. These studies demonstrated the interest of combination 
of a nanodelivery system and an adjuvant in order to improve influenza vaccine efficacy.  
Conclusion 
Intranasal administration NPL and/or CTA1-DD co-delivery with split Udorn enhanced 
immune response and virus inhibition capacity, compared to intranasal administration of 
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soluble (conventional) influenza vaccine. Taken together, our study that NPL carrying CTA1-
DD and split Udorn could be a promising intranasal influenza vaccine.  
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Nasal vaccination is an attractive strategy for the induction of mucosal-specific immunity 
(Ogra, Faden, and Welliver 2001; Zaman, Chandrudu, and Toth 2013). Nanoparticles have 
been proposed as delivery systems for vaccine applications (Bernocchi, Carpentier, and 
Betbeder 2017; Zhao et al. 2014). Natural and synthetic biodegradable materials are used as 
carriers of proteins, peptides and nucleotides based vaccines. The nanomaterials used in nasal 
vaccine delivery are mainly polyesters derivatives such as poly (lactic-co-glycolic acid; 
PLGA), polysaccharides such as chitosan, starch, alginate and dextran, lipid based 
nanoparticles such as liposome (Bernocchi, Carpentier, and Betbeder 2017; Marasini, 
Skwarczynski, and Toth 2017). 
Influenza virus owns the ability to seasonally shift. Therefore every year, vaccine should be 
adapted to the new emerging strains. Hence it raises a question of the development of a 
universal flu vaccine: it could ideally protect from the changes due to the drift and shift of 
influenza virus and also confer long-lasting protection. Nanoparticles increasingly play a 
substantial role in vaccine design, thanks to their ability to improve antigens stability and to 
enhance their delivery. According to that idea, the aim of this thesis work is the selection of an 
appropriate nanocarrier for intranasal vaccines. We tested 5 nanoparticles widely used for nasal 
vaccine including: NPL, cationic/anionic PLGA, cationic/anionic liposome nanoparticles. 
These 5 different nanoparticles were successfully synthesized and characterized. An ideal 
nanoparticulate vaccine should be able to load efficiently the antigens in a stable manner, to 
cross the mucus barrier and to deliver the antigen to the mucosal immune cells. In this thesis 
we evaluated every barrier that have to cross the nanovaccines to understand the physico-
chemical characteristics necessary for such application. 
1. Interaction of nanoparticles with nasal mucosa 
1.1. Nasal residence time 
Several approaches have been explored using nanoparticles for the mucosal delivery of antigen 
such as: protection to the antigen, enhanced antigen absorption, extended residence time in the 
mucosa. Despite the excellence of mucosal delivery, limitations compared with injection still 
restricts its application and development (Gonzalez-Paredes, Torres, and Alonso 2017; Niu et 
al. 2016; Niu et al. 2017). The relatively low delivery efficiency is resulted from complex and 
strong physiological barriers present in mucosal routes (Ensign, Cone, and Hanes 2012). These 
obstacles include the environment with varying pH and numerous enzymes, which challenges 
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the bioactivity of agents. Moreover, the sticky mucus layer and intact epithelium act as 
permeation and absorption barrier, respectively.  
Since the protective mucus strongly hinders the accessibility of drugs or vaccines to epithelia, 
mucoadhesive nanoparticles were applied to overcome the mucus layer and deliver drug or 
vaccine into mucosal cells or to improve their uptake by macrophages and dendritic cells. 
Therefore polymers (e.g. chitosan and TMC) have been employed in literature to extend the 
nasal residence of antigens. Even the simple conjugation of OVA with chitosan can slow the 
protein clearance in the nasal cavity, while the unconjugated antigen is almost completely 
cleared from the nose within 2 hours (Slutter et al. 2010). Hence the use of muco-adhesive 
nanoparticles to attain a sustained antigen release is reasonable. 
According to this idea, we compared 5 different nanoparticles in term of nasal residence time 
aiming to search for the nanocarrier that owns mucoadhesive property and stay longer in the 
nasal mucosa. Our data demonstrated that cationic PLGA and NPL have the higher nasal 
residence time in mice and that NPL were observed in higher quantity. In another study, we 
found that NPL increased the nasal residence time of an encapsulated protein. Moreover, NPL 
were observed in the first layer of the nasal mucosa cells after nasal administration (Bernocchi 
et al. 2016).  
Indeed, increased residence times might be attributed to the strong electrostatic interactions 
between cationic nanoparticles with anionic sialic and acidic moieties of glycosaminoglycan 
contained in mucins and on the surface of airway cells (Plotkowski et al. 2001). To increase 
mucoadhesive property, nanoparticles have been covered by mucoadhesive materials, such as 
chitosan, TMC or glycol chitosan (Asane et al. 2008; Richardson, Kolbe, and Duncan 1999).  
1.2. Uptake by nasal mucosa cells  
Epithelial cells are formed in tightly packed layers that cover the surfaces and cavities of tissues 
and organs throughout the body. The first barriers that nanoparticles face once nasally instilled 
are mainly the epithelial cells and some specialized cells such as M cells (Rivera et al. 2016; 
Weitnauer, Mijosek, and Dalpke 2016). Moreover, different subsets of antigen presenting cells 
(APC) are present in the nose-associated lymphoid tissue (NALT). Dendritic cells have a key 
role in nanoparticle uptake (Kiyono and Fukuyama 2004; Marasini, Skwarczynski, and Toth 
2017). It is important to evaluate the uptake of nanoparticle by nasal mucosa cells as these are 
the cells that will take up nanoparticles after intranasal administration. 
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The nanoparticle NPL was showed to be efficiently taken up by airway epithelial cells 
(Bernocchi et al. 2016). Moreover, following either the polysaccharidic or the lipidic part, 
similar uptake kinetics for both NPL components were observed (Bernocchi et al. 2016).  
Study about the cellular uptake of the 5 nanoparticle types by cell lines representative of the 
airway mucosa showed that the endocytosis was consistent among the 3 cell lines: airway 
epithelial cells, macrophages and dendritic cells. NPL were quickly internalized by the cells 
while the other types of nanoparticles were more slowly and continuously taken up over 24h 
(Publication 2, Le et at.). 
Cell membranes have many negatively charged groups on the surface. It is expected that 
positively charged nanoparticles will thus be better associated via ionic interactions and that 
their subsequent endocytosis is thus facilitated (Blanco, Shen, and Ferrari 2015; Ma et al. 2013; 
Xiao et al. 2011). Unexpectedly, the cationic liposome and PLGA nanoparticles showed 
completely different behavior, even though they possessed the same positive charge density as 
NPL.  
Studies about endocytosis mechanism showed that NPL entered epithelial cells, macrophages 
and dendritic cells via a combination of several pathways.  These results might explain why 
the cellular uptake of NPL was higher.  
2. Nanoparticle as protein delivery system 
2.1. Protein/antigen loading 
Evaluation of the protein loading efficiency of the nanoparticles is critical for an appropriate 
vaccine formulation. 
Ovalbumin, as model of antigen was used to evaluate the loading capacity of NPL (Bernocchi 
et al. 2016). Size and zeta potential analysis as well as Native-PAGE revealed that the 
formulation of OVA:NPL at mass ratios of 1:3 led to the complete association of the OVA to 
the NPL.  
The loading efficacy of OVA into the 5 nanoparticles was conducted. Again amongst the 5 
nanoparticles, NPL show the highest capacity of OVA loading. This is due to the structure of 
NPL, they are cationic on their surface, porous and filled with anionic lipids inside.  They 
possess both cationic and anionic charge so that they can interact with both the cationic and 
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anionic amino acids via electrostatic interaction. These interactions could facilitate the 
association between OVA and NPL (Publication 3, Le et al.). 
The protein loading could depend on the type of antigen. In a study about the loading of 
Toxoplasma gondii extract (TE) into NPL, it was observed that from a 1:1 ratio of NPL/TE 
(w/w), total loading of TE was observed (Dimier-Poisson et al. 2015). Though TE is a complex 
mixture of antigens with heterogeneous molecular weights. 
It is interesting to note that at to our knowledge this percentage of loading (100 mg of proteins 
for 100 mg of nanoparticles) has not been described earlier and is far higher than that observed 
with hollow silica mesoporous nanoparticles (Mahony et al. 2014). These data demonstrate the 
interest of such nanoparticle. 
2.2. Protein delivery 
A good nasal delivery system need to cross the mucus barrier and deliver the antigen to immune 
cells.  Amongst the 5 nanoparticles tested, again NPL was found to be the best delivery system 
in the 3 cell lines (airway epithelial cells, macrophage and dendritic cells) (Publication 3, Le et 
al.).  
These outcomes may come from the ability to higher cellular uptake of the NPL. Indeed, to 
deliver antigens, NPL have to be uptaken by the cells then deliver their payload. Furthermore, 
loading OVA inside the porous structure of NPL lead to minimize the change in size of the 
formulation and influence on endocytosis ability of NPL. In contrary, OVA was bound to the 
surface of PLGA NPs and liposome and eventually that’s might interfere for the internalization. 
That might explain why the uptake of these nanoparticles by cells was not efficient. 
In another study, Toxoplasma gondii extract was successfully delivered into the airway 
epithelial cells by NPL while free TE failed to be really detected in the cells (Dimier-Poisson 
et al. 2015). Interestingly, delivery of TE by NPL did not seem to be influenced by the presence 
of serum (Dimier-Poisson et al. 2015). NPL were also able to efficiently deliver the antigens 
into airway epithelial cells, macrophages and DCs. This delivery induced the activation of these 
cells via the NF-kB pathway, through TLR2 and TLR4 signaling and the production of pro-
inflammatory cytokines (Dimier-Poisson et al. 2015). 
Altogether, due to the high capacity of endocytosis, NPL exhibited efficient cellular protein 
delivery. We demonstrated that amongst the 5 nanoparticles tested, NPL owns the longest nasal 
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residence time, higher capacity of cellular uptake and protein delivery so this delivery system 
was used for the influenza vaccine project. 
Although this study clearly showed the interest of NPL further studies should be conducted. 
For example we observed that NPL can stay up to 6 h in the nasal mucosa (Publication 2, Le 
et al.) however we don’t know what cells really have uptaken NPL. The fate of OVA/NPs 
should be investigated to clarify whether the OVA was delivered into the nasal mucosa cells 
or not. 
Though in vitro data demonstrated that PLGA and liposomes nanoparticles were less efficient 
than NPL in term of nanoparticle uptake and protein delivery, there could be different outcomes 
for in vivo data. Particularly, the cationic PLGA and liposomes nanoparticles were coated by 
chitosan, a well-known molecule that have ability to open tight junction of the epithelia barrier. 
Once they bypass the tight junctions, the cationic PLGA and liposome nanoparticle have more 
chance to deliver antigens into the APCs underlying the epithelium.  
More importantly, to evaluate the vaccine efficacy, the immune response after vaccine 
administration is a critical issue. The humoral and cellular response of these OVA/NPs after 
nasal administration should be tested. Furthermore, elucidation of the mechanism that 
modulate the innate and adaptive immune system by these OVA/NPs is needed. 
3. Nanoparticle as influenza vaccine delivery system 
The flu antigen CTA1-3M2e-DD and HA were formulated with NPL. The construct of antigen 
CTA1-3M2e-DD were prepared by the conjugation of the mucosal adjuvant CTA1-DD and the 
M2e domain, a conserved epitope of influenza. CTA1-3M2e-DD fusion protein consists an 
adjuvant and a conserved region of influenza A virus in a potential candidate for a universal 
anti-influenza vaccine. The current opinion in the flu field is that we would need more than one 
antigen in order to generate a universal flu vaccine and only one antigen is probably not 
sufficient. Yassine H.M. et al. linked HA stabilized-stem region on ferritin nanoparticles and 
showed that these particles elicited complete and partial protection against heterosubtypic 
challenge in mice and ferrets respectively (Yassine et al. 2015). Recently, Deng et al. 
demonstrated that incorporating both the HA stalk domains and M2e induces strong long-
lasting immunogenicity, fully protecting the mice against challenges by different influenza A 
viruses (Deng et al. 2018). Hence, the use of hemagglutinin, a key antigen of influenza 
vaccines, seems to be necessary to develop a universal influenza vaccine. In our project, 
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recombinant HA originated from influenza H1N1 (A/Puerto Rico/8/34 (H1N1)) was together 
with CTA1-3M2e-DD loaded into NPL.  
Different flu antigens were combined to NPL to make the formulation at ratios 1:5 (w/w). 
CTA1-3M2e-DD, hemagglutinin (HA) or adjuvant CTA1-DD. The dynamic light scattering 
analysis showed at ratio 1:5, an increase of the formulation size was observed meaning that 
some NPL-Ag were partially agglomerated. When antigen was incubated with NPL, we 
obtained only a slight decrease of the positive charge of the nanoparticles showing that CTA1-
3M2e-DD was successfully loaded into NPL. Moreover, two different antigens were also 
successfully loaded into NPL (Table 2). In order to assess if some antigen was free, we analyzed 
the formulation by native PAGE (Figure 9). At ratio of the formulation 1:5, the protein CTA1-
3M2e-DD and CTA1-DD was totally bound to NPL while 70 % of HA was associated.  These 
results may be attributed to the use of detergents (Empigen® BB). Indeed, we used a detergent 
to solubilize HA, this can form micelles that prevent the HA association to the NPL. However 
most of the HA is bound to the NPL (Table 3). Taken together these results suggest at ratio 1:5, 
3 different antigens were successfully associated to NPL. 
These formulations were sent to our partners in the consortium for in vivo analysis against viral 
challenge. 
Protein/Formulation Size (nm) PDI Zeta potential (mV) 
NPL 45.6 0.22 +43.3 
HA 1.72 0.65 -11.37 
CTA1-3M2e-DD 238.6 0.37 -11.86 
CTA1-DD 7.36 0.43 -9.35 
HA/NPL 83.67 0.21 +24.46 
CTA1-3M2e-DD/NPL 472.3 0.54 +30.5 
CTA1-3M2e-DD + HA 
/NPL 241.2 0.39 +26 
CTA1-DD+HA/NPL 43.63 0.46 +29.1 
Table	2:	Size	and	zeta	potential	of	protein	antigens,	nanoparticles	and	of	the	formulation	(antigen:NPL).	
Nanoparticles	were	mixed	with	antigens	at	a	ratio	of	the	antigen:NPL	(1:5,	w/w).	Size	and	zeta	potential	
are	measured	in	triplicate	by	dynamic	light	scattering	on	a	zetasizer.	PDI:	Polydispersity	index.	Results	
represented	by	mean	data.	
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Figure 9: Characterization of the formulations by Native-PAGE 
 
Following intranasal immunizations of mice with CTA1-3M2e-DD or CTA1-3M2e-DD /NPL, 
we found that mice immunized with CTA1-3M2e-DD/NPL got an enhanced protective efficacy 
against a challenge with the X47 influenza virus strain (H3N2) as compared to mice received 
CTA1-3M2e-DD. Furthermore, mice immunized intranasally with the combined HA+ CTA1-
3M2e-DD/NPL vector were fully protected against a challenge infection with the aggressive 
PR8 virus (A/Puerto Rico/8/34 (H1N1), whereas non of the HA/NPL, CTA1-3M2e-DD /NPL 
or CTA1-3M2e-DD alone immunized mice were protected (Bernasconi et al., Journal Frontiers 
in Immunology, submitted).  
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However, we failed to show the beneficial function of NPL with adjuvanted antigen, the CTA1-
3M2e-DD or HA+CTA1-3M2e-DD. In fact, this study used high dose of antigen (5 µg per 
dose) and 3 immunizations that leads to maximum immune response so that we could not see 
the additional effect of NPL. Indeed, lower dose of antigen (1 µg per dose) showed increase 
level of T cell proliferation in spleen and mesenteric lymph nodes (mLN) by CTA1-3M2e-DD 
/NPL as compared to CTA1-3M2e-DD alone (data not shown).  
In the end of this project, we found that HA+ CTA1-3M2e-DD/NPL could be a potential 
universal influenza vaccine. However, further studies should be done in future to obtain an 
efficient influenza vaccine with a low dose of flu antigens. The vaccine should be challenged 
with other strains of influenza virus to fulfill the concept of universal influenza vaccine. 
Moreover, instead of using the whole HA from H1N1, the stalk domain, the conserved region 
from HA can be applied as a flu antigen. Other strategies to improve vaccine efficiency should 
be conducted. CTA1-DD contains the c-terminal region of a dimer of the D-fragment of the 
protein A from Staphylococcus aureus (DD) which targets B-cells. However, once the 
adjuvanted antigen CTA1-3M2e-DD was loaded into the porous structure of NPL, it could be 
a question that whether the B-cell targeting still keeps its function or not. Indeed, the CTA1-
DD could be covered by NPL and no longer be recognized by B-cells. Importantly, it has been 
shown that NPL are not able to open tight junctions (Bernocchi et al. 2016) so the main vaccine 
antigen is delivered into nasal mucosa cells, such as epithelial cells, M cells or dendritic cells. 
It could be a potential strategy to improve this vaccine efficiency if the targeting moiety is 
recognized by these cells and constructed to appear in the surface of NPL.  
NPL carrying vaccine antigen can be targeted to M-cells by surface modifications with lectins 
that naturally bind to M-cell surfaces through α-L-fucose residue (Neutra 1999; Mabbott et al. 
2013). Besides, NPL could be covalently coupled with sIgA that has been demonstrated to be 
captured by Dectin-1, a small type II transmembrane protein of the C-type lectin family 
presence on M cells (Rochereau et al. 2013).  
In order to target DCs present in nasal mucosa, NPL can be conjugated with a mannose motif 
that is recognized by mannose receptor of DCs (Raghuwanshi et al. 2012). NPL otherwise can 
be decorated with a cell surface marker such as DEC-205 that is primarily expressed by DCs 
and should facilitate the uptake and delivery vaccine antigen into DCs (Park et al. 2008; 
Diebold et al. 1999; Yeeprae et al. 2006). 
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The nanocarrier can be co-delivered with an adjuvant that can improve the ability of the host 
immune system to recognize the administered antigen as foreign and respond to it. Moreover, 
in our study we found that though the NPL enhanced the vaccine delivery however, it was not 
sufficient to induce stronger immune response and virus protection. Recruitment of an adjuvant 
was necessary to create significant protection effect against influenza virus (Publication 4, Le 
et al.). To induce the vaccine efficiency, NPL can co-deliver the adjuvanted and targeted 
antigen.  Currently, there are several adjuvants licensed for human vaccine such as alum, 
MF59, AS03 AF03. However, these adjuvants are mostly applied for non mucosal vaccine.  
Other adjuvants for nasal vaccine are still under development such as toll like receptors (TLR) 
ligands. Toll-like receptors (TLRs) are a type of pattern recognition receptor (PRR) which are 
expressed on the membranes of leukocytes including DCs, macrophages, natural killer cells, 
cells of the adaptive immunity (T and B lymphocytes) and non immune cells (epithelial and 
endothelial cells, and fibroblasts) (Delneste, Beauvillain, and Jeannin 2007). Many of the other 
TLRs have also been targeted to boost vaccine responses, for example, topical application of 
imiquimod, a TLR7 agonist (Hung et al. 2016), agonists of TLR3 (rintatolimod) (Overton et 
al. 2014) and TLR9 (CpG oligodeoxynucleotides) (Cooper et al. 2004) have also been tried. 
Co-delivery the vaccine formulation with these TLR ligands could be another strategy to 
improve nasal vaccine efficacy. 
Taken together, this thesis study demonstrated that NPL could be a promising nano carrier for 
intranasal influenza vaccine. Other strategies can be applied to improve the vaccine efficiency 
such as targeting the vaccine formulation to nasal mucosa cells or co-delivery with a mucosal 
adjuvant should be investigated in future. 
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Nanoparticles are promising tools for protein delivery in the mucosa, useful for their protein 
stabilization function and more advantageous than other administrations. The development of 
a nanoparticle-based mucosal vaccine requires nanocarriers able to load antigens, to enter the 
cells and to deliver the antigens into cells. Among the 5 types of nanoparticles: cationic/anionic 
PLGA NPs, cationic/anionic liposomes and NPL, we observed that NPL are the best candidate. 
Furthermore, in vivo data showed that NPL improved the efficacy of the universal influenza 
vaccine developed by the consortium. In order to further improve the efficacy of a mucosal 
vaccine, NPL could be modified to target the mucosal cells such as M cells, DCs or co-
delivered with a mucosal adjuvant that can activate the innate immune system, hence 
maximizing the immune response.  
Mucosal vaccination has significant advantages compared with parenteral vaccination 
including needle-free, the induction of systemic and mucosal immunity and low cost. Despite 
these advantages, currently, one nasal and eight oral vaccines are licensed for administration 
to humans, targeting the following five pathogens: influenza, poliovirus, cholera, Salmonella 
typhi and rotavirus. Furthermore, most of the licensed vaccines for mucosal delivery are based 
on live attenuated viruses which carry the risk of recovering their pathogenicity. There are still 
no mucosal vaccines against infectious diseases such as malaria, HIV, leishmaniasis, Hepatitis 
B and C. This thesis study contributes to select the appropriate nano delivery system for 
mucosal vaccine. Based on this study, other mucosal vaccines applying nanoparticle system 
should be developed in future.  
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